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ABSTRACT
The distribution of the granule chymase Sheep Mast Cell Proteinase (SMCP) was determined
in trachea, bronchus, bronchial lymph node, lung, thymus, spleen, liver, flank skin,
abomasum, duodenum, jejunum, ileum, colon and mesenteric lymph node by
immunohistochemistry and by ELISA using a polyclonal, affinity purified anti-SMCP
antibody. The toluidine blue and SMCP-positive cell counts were closely correlated for all
tissues examined (r2= 0.96, P<0.001), with the exception of skin and liver. On the basis of
reactivity to the anti-SMCP antibody, two populations of ovine mast cells were identified.
SMCP-positive cells (analogous to the gastrointestinal or mucosal mast cell [MMC] subset)
were present in all tissues examined whereas SMCP-negative cells were present in skin (the
putative ovine connective tissue mast cell [CTMC] subset) and comprised -98% of the ovine
dermal mast cell population. The functional heterogeneity of the ovine dermal mast cell
population was investigated in cutaneous challenge studies using the secretagogues calcium
ionophore A23187 (A23187), substance P (sP) and compound 48/80 (48/80), which are
known to activate CTMC subsets in other species. Although only A23187 and sP evoked an
immediate weal response (P<0.05; Mann-Whitney U test [MW]), all three agents evoked
dermal neutrophil influx (P<0.05; MW) with extensive mast cell degranulation (P<0.05;
MW), thus identifying these agents as putative ovine dermal mast cell secretagogues. As
SMCP may be released into the dermis following degranulation, its effect in ovine skin in vivo
was investigated. SMCP (36pg - 36ng/50pl) evoked a dose-dependent immediate cutaneous
response characterized by weal formation (maximal by three hours after injection (P<0.05;
MW)) accompanied by dermal neutrophil influx (P<0.05; MW) and concomitant mast cell
degranulation (P<0.05; MW). There was no subsequent delayed component to this response
(24 to 72 hours). Although heat-inactivation of SMCP (64°C for 10 min; -2% residual
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activity) abrogated the weal response (P<0.05-P<0.01; MW), there was no effect on dermal
neutrophil influx. Recombinant ovine interleukin-3 (rOv.IL-3) was shown to consistently
generate a population of rOv.IL-3-dependent bone marrow-derived mast cells (rOv.IL-3
BMMC) in vitro, this cell population being subsequently used to compare functional
heterogeneity in vitro to that previously determined in skin in vivo. These generated cells
contained the granule-associated mediators arylsulfatase, (^-hexosaminidase and SMCP, the
latter finding being consistent with an MMC phenotype. A dose-dependent effect of rOv.IL-3
on cell viability and the maximum percentage of SMCP-positive mast cells obtained was
observed (P<0.05-P<0.01; Student's r-test), the latter being increased by transferring the
non-adherent cell population to fresh wells or flasks at feeding. When harvested optimally at
days 12 to 16 of culture, these rOv.IL-3 BMMC could be activated by sP, 48/80 and A23187
to release arylsulfatase, (3-hexosaminidase and SMCP, indicating that these cells may also
possess CTMC characteristics. Thus, r.Ov.IL-3 BMMC may represent a cell population of
mixed (MMC and CTMC) phenotype. SMCP failed to evoke similar mediator release in
vitro, in contrast to the immediate cutaneous response observed in vivo. One action of SMCP
may therefore be to activate vascular endothelium, thereby promoting increased vascular
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1.1. The Mast Cell And Cutaneous Inflammation
Inflammation can be defined as the "cellular and vascular responses of living tissue to injury"
(Thompson 1978). The mast cell, as one of the participating cells in the skin immune system
(Bos and Kapsenberg 1986), contributes to the development and modulation of cutaneous
inflammation following activation (Walsh, Lavker and Murphy 1990, Harvima et al 1994) as
a consequence of the synthesis and release of preformed or newly synthesized mediators and
cytokines (reviewed in Galli 1993, Marshall and Bienenstock 1994, Schwartz 1994). Mast
cell activation classically occurs when IgE (bound by its Fc portion to FceRI) recognises
specific mutivalent antigen (Galli 1993), but other agents such as neuropeptides (Foreman
1993) and components of the complement cascade (Fiireder et al 1995a) can also evoke
dermal mast cell degranulation (reviewed in Anion et al 1994). Additionally, a potential role
for the mast cell in persistent or chronic inflammatory responses, rather than merely the
classical acute or anaphylactic-type response (e.g. urticaria), has been advocated (Askenase
1977, Dvorak et al 1976, Galli 1993, Torii et al 1993). Cutaneous mast cells differ from mast
cells at other tissue sites with respect to a range of important characteristics (e.g. functional
activity, mediator content, proteinase content; Barrett and Pearce 1993) which can influence
the nature of the inflammatory response in skin compared to other tissues, and which also
defines the heterogeneity of the dermal mast cell population in various species.
Mast cells are believed to contribute to, or be associated with, various dermatoses in both man
and domestic animals (Table 1.1). In routine small animal veterinary practice, about 25% of
all cases seen are dermatological in nature (Grant and Thoday 1991), of which canine atopic
disease alone accounts for between 2% and 8% of all skin cases (Halliwell and Schwartzman
1971, Scott 1981). In sheep, apart from the detrimental effect on health and general welfare,
substantial economic losses can occur due to skin disease. For example, in a single flock
outbreak of Psoroptes ovis infestation ("sheep scab"), the reduction in weight gain alone was
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Veterinary Dermatoses Evidence cited for mast cell involvement
Canine Atopic Disease Halliwell, Schwartzman and Rockey 1972,
Nimmo-Wilkie et al 1990
Canine Flea-Bite Hypersensitivity Kieffer and Kristensen 1979; Gross and
Halliwell 1985; Halliwell and Longino 1985;
Gross, Ihrke and Walder 1992;
Canine demodicosis Copeman 1965
Feline Otodectes cynotis infestation Weisbroth et al 1974; Powell et al 1980
Mast cell neoplasia Bostock 1973, 1986
Ovine cutaneous atopic disease Scott and Campbell 1987
Ovine Culicoides hypersensitivity Connan and Lloyd 1988
Ovine fleece rot and fly strike
CLucilia cuprina)
Colditz etal 1994
Ovine Orf virus infection McEwan Jenkinson, Hutchison and Reid 1992
Human Dermatoses Evidence cited for mast cell involvement
Urtica dioica urticaria Oliver et al 1991
Physical urticaria Hawk et al 1980, Kobza-Black et al 1979
Chronic idiopathic urticaria Elias, Boss and Kaplan 1986; Kaufman and
Rosenstreich 1990; Smith, Soh and Lee 1992;
Jacques et al 1992
Mastocytosis Olafsson, Roupe and Enerback 1986; Irani et al
1990
Scleroderma and fibrosis Nishioka et al 1987; Takeda, Hatamochi and
Ueki 1989; Claman 1989
Acute sunburn response Walsh 1995
Table 1.1. Selected dermatoses in domestic animals and man where an association with mast
cells has been reported.
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equivalent to a £1000 loss (Kirkwood 1980). In addition to a wide range of dermatoses
caused by ectoparasites (e.g. Chorioptic and Psoroptic mange, tick infestation, pediculosis),
bacterial (e.g. Staphylococcal folliculitis), fungal (e.g. mycotic dermatitis) and viral (e.g. Orf
virus infection) dermatoses are common in sheep (reviewed in Martin and Aitken 1991). Mast
cells have been postulated to play a role in immediate hypersensitivty responses to ectoparasite
infestation (Scott 1988), and may also contribute to other ovine hypersensitivity disorders,
given that cutaneous atopic disease has also been demonstrated in the sheep (Scott 1988).
Thus, it is of importance that the contribution of the mast cell to ovine cutaneous
inflammatory responses is elucidated.
Therefore, the focus of this review is the cutaneous mast cell, its heterogeneity and its possible
role in the development and modulation of cutaneous inflammatory responses with particular
emphasis on the mast cell proteinases, tryptase and chymase.
1.2. Historical Aspects Of Cutaneous Mast Cells
Von Recklinghausen (1863) first identified the presence of granular cells at connective tissue
sites during studies on frog mesentery. Using a differential staining technique, Ehrlich (1877)
considered these cells to be a type of "plasma cell". These cells were further characterized as
metachromatic connective tissue cells, and the term "Mastzellen" was coined (Ehrlich 1878,
1879). A role for mast cells in cutaneous pathology was advocated by Unna (1887, 1894),
when increased numbers of mast cells were noted in various dermatoses, including urticaria
pigmentosa. Mast cells have subsequently been demonstrated in the skin of man (Staemmlar
1921, Vallone 1944, Hellstrom and Holmgren 1950, Eady et al 1979), horse (Dozza and
Rampichini 1963, Talukdar, Calhoun and Stinson 1972), cow (Riley 1959, Jenkinson et al
1970), pig (Riley 1959), sheep (Kozlowski and Calhoun 1969), goat (Scott, Smith and
Manning 1984), dog (Riley and West 1956, Emerson and Cross 1965), cat (Riley and West
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1956), rat (Iakovleva 1954), opossum (Santos and Machado 1994), guinea pig (Zimmermann
1908), hamster (Compton 1952), mouse (De Vinals 1931) and also in fish scales (Veil 1957).
Cutaneous mast cells are located in the dermis in most species, in close association with blood
vessels, pilosebaceous units, arrector pili muscles and unmyelinated nerves [i.e. in
perivascular or periadnexal locations](Kozlowski and Calhoun 1969, Van Loeveren, Teppema
and Askenase 1990, Scott, Miller and Griffin 1995). However, both normal (Zelickson 1985)
and diseased (Green, Cordero and Winklemann 1977) human skin is said to contain epidermal
mast cells. Similarly, in a study of various non-neoplastic feline dermatoses (Scott 1990),
11.6% of cases (37 of 338 cats) possessed epidermal mast cells. No epidermal mast cells
have been demonstrated in studies of ovine skin, mast cells being associated predominantly
with wool follicles, capillaries, sweat glands, sebaceous glands and arrector pili muscles in the
dermis (Kozlawski and Calhoun 1969, Vegad 1970). As in other species (e.g. man, Brix
1963; dog, Emerson and Cross 1965) mast cell numbers in sheep skin vary with the
anatomical site, increased numbers of mast cells being detected in one study in periorbital,
interdigital and inguinal areas (Kozlowski and Calhoun 1969). Variations in the vascular
response to a standard injection of histamine in sheep was apparently dependent on whether it
was administered into dorsal or ventral flank skin (Colditz 1988). Care must therefore be
taken when selecting a site on which to perform cutaneous response studies, as such variation
may influence results. This is particularly relevant in studies where large areas of ovine flank
skin are used to assess responses (e.g. Colditz 1988, Yilmaz, Haverson and Morgan 1994).
However, where relatively small areas of flank are used (as in Chapters 4 and 5), this effect is
considered unlikely to affect results (Colditz 1995, personal communication).
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1.3. The Origin OfMast Cells
Mast cells are derived from precursors which originate in bone marrow (Kitamura et al 1977)
and migrate via the bloodstream (Kitamura et al 1979, Sonoda, Ohno and Kitamura 1982) to
complete their differentiation in peripheral sites where their final phenotype is determined
(Kitamura, Matsuda and Hatanaka 1979, Huff et al 1995). However, whether the majority of
mast cell-committed progenitors (unipotential ungranulated colony forming units) reside in
bone marrow or in peripheral tissues is still debatable (Huff et al 1995). Mast cell
development contrasts markedly with that of the basophil, which undergoes its terminal
differentiation in the bone marrow and is subsequently released into the bloodstream as a
mature cell (reviewed in Galli 1990).
1.4. Mast Cells And T Lymphocyte Interactions - Relevance To Mast Cell
Heterogeneity And To The Development Of Hypersensitivity Responses
The T cell dependency of the mucosal mast cell (MMC) population was defined in rodents.
Adoptive transfer studies with T cell-enriched thoracic duct lymphocytes from primed donor
rats results in intestinal mastocytosis in the recipients (Nawa and Miller 1979). Congenitally
athymic (nude) mice do not demonstrate MMC hyperplasia in response to Trichinella spiralis
infection (Ruitenberg and Elgersma 1976) and rats depleted of T cells show a similar lack of
response to Nippostrongylus brasiliensis infection (Mayrhofer 1979, Mayrhofer and Fisher
1979). Also, supernatants from activated T cells (conditioned medium; CM) can support the
growth of rat (Haig et al 1982, Haig et al 1983) and mouse (Schrader et al 1981) bone
marrow-derived mast cells (BMMC). Unlike the MMC population, the connective tissue mast
cell (CTMC) populations in mouse and rat are not considered to be T cell-dependent (Katz,
Stevens and Austen 1985, Stevens and Austen 1989, Galli 1990).
Two types ofmurine CD4+ T helper cell clones (Tm and Tm) were defined, based on their
cytokine-producing phenotype (Mosmann et al 1986, reviewed in Arai et al 1990, Paul and
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Seder 1994), this subsequently being extended to include normal human T cell populations
(Del Prete et al 1991). When activated, both THi and Th2 cells produce interleukin-3 (IL-3),
granulocyte/macrophage colony-stimulating factor (GM-CSF) and tumour necrosis factor-a
(TNF-a). However, additionally, THi cells produce IL-2, interferon-y (IFNy) and TNF-(3 to
enhance cellular immunity, particularly with regard to increased macrophage-induced IL-12
production (Paul and Seder 1994). Tm cells, upon activation, produce IL-4, IL-5, IL-6, IL-9,
IL-10 (Mosmann et al 1991) and IL-13 (Paul and Seder 1994), which (particularly IL-4) acts
to help B cell development to produce antibody-producing cells. IL-4 acts as a co-stimulant
with CD40 ligand (Banchereau et al 1991) on B cell growth, and controls immunoglobulin
class switching of B cells expressing IgM to two isotypes, IgGi and IgE in mouse (Finkelman
et al 1986) and man (in conjunction with IL-13; Punnonen et al 1993).
Cytokine cross-regulation of priming by the THi and Tm subsets occurs (Paul and Seder
1994). Thus, Tm-generated IL-4 inhibits the IL-12 (derived from activated macrophages)
priming of precursor TH (pTH) cells for IFNy production and subsequent development of a Tm
phenotype (Seder et al 1992, Seder et al 1993). Likewise, IFNy inhibits the IL-4 priming of
pTH cells for subsequent generation of a Tm phenotype (Seder et al 1992). Tm cells
themselves need an exogenous pulse of IL-4 to initiate their differentiation and synthesis of
IL-4. Mast cells generate several cytokines upon immunological or non-immunological
activation (Burd et al 1989, reviewed in Gordon, Burd and Galli 1990; discussed below),
including IL-3, IL-4, IL-5 and IL-6, thereby resembling the secretion pattern of Tm cells
(Plaut et al 1989). Importantly, human cutaneous (Bradding et al 1992) and bronchial/nasal
(Bradding et al 1992, 1993) mast cells are a source of IL-4. Additionally, IL-4 is also
detectable in mast cells from lesional and non-lesional skin in human atopic dermatitis
(Horsmanheimo et al 1994). Human lung mast cells also express CD40-ligand, and have been
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shown in vitro to stimulate B cells directly to switch to IgE antibody production (Gauchat et
al 1993). This, in conjunction with mast cell-derived IL-4 and IL-6 (which augments antibody
production, including IgE, by B cells; Vercelli et al 1989), could encourage IgE production
and the development of an atopic state. Thus, mast cells and T cells are closely inter-related
in the initiation and development of immunological responses.
1.5. Proteinases
1.5.1 Serine Proteinases - General Introduction
Proteinases (or proteases; proteolytic enzymes) can be subdivided into exopeptidases (which
cleave bonds near to the ends of polypeptide chains) and endopeptidases (which cleave bonds
distant from the ends of polypeptide chains). Endoproteinases have been classified into four
groups (Hartley 1960) dependent on the nature of the catalytic site of the enzyme into serine-,
cysteine-, aspartic- and metalloproteinases. Serine proteinases, of which mast cell tryptases
and chymases are members, contain a serine residue at the catalytic site and contain a
characteristic "catalytic triad" of histidine, aspartate and serine residues (Springman and
Serafin 1995). The serine residue (in chymotrypsin) sits in a deep cleft which accounts for its
specificity for aromatic and other bulky hydrophobic side chains. Classically, the serine
proteinases can be inhibited by diisopropyl fluorophosphate (DFP).
1.5.2. Mast Cell Tryptases And Chymases
Gomori (1953) first demonstrated that mast cells were the site of unusual hydrolytic
enzymatic activity. Mast cell-derived enzymes were later shown to possess both chymotryptic
(Benditt and Arase 1959, Lagunoff and Benditt 1961, Lagunoff and Benditt 1963) and
tryptic-like activities (Glemier and Cohen 1960, Lagunoff and Benditt 1963), the terms
chymase (originally "chymotrypsin-like esterase ofmast cells; Benditt and Arase 1959,
Glenner and Cohen 1960, Lagunoff and Benditt 1963) and tryptase (Lagunoff and Benditt
1963) being introduced to identify these respective enzymes. Mast cell proteinases have been
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extensively reviewed (Nadel 1991, Walls 1995) with a number of them concentrating on the
role of proteinases in skin and in skin disease (Harvima et al 1994, 1995; Schechter 1995).
Primate and canine mast cells contain large amounts of tryptase, in comparison to mast cells
of the rat (which have little tryptase except in the lung; Chen et al 1993) and rabbit which
contains no tryptase (Chiu and Lagunoff 1972). Although guinea pig mast cells were also
originally considered not to contain tryptase (Chiu and Lagunoff 1972), recently tryptase has
been identified in mast cells from this species (He et al 1995). In the mouse, although two
tryptases are present (MMCP-6 and -7; Stevens et al 1994), these are not expressed by
gastrointestinal MMC (Reynolds, Austen and Serafin 1992) but can be found in CTMC
(Stevens et al 1994). Therefore, chymase is the predominant enzyme in rodent mast cells,
which contrasts with the dog and man.
Tryptase exists in an active form in mast cells (Lagunoff, Benditt and Watts 1962, Lagunoff
and Benditt 1963), a species-specific trypsin-like enzyme having been initially detected by
histochemical methods (Glenner and Cohen 1960), and accounts for between 20% and 50% of
the entire protein content of mast cells (Harvima and Schwartz 1993). Tryptase has been
purified from human lung (Schwartz, Lewis and Austen 1981) and from skin (Harvima et al
1988). Tryptase is a tetrameric endoproteinase of 134kDa, with subunits of 31kDa to 34kDa
(Schwartz 1995). Tryptase, within mast cell granules and after secretion, is associated with
heparin (Caughey et al 1988a), the ionic binding of tryptase to heparin (under physiological
conditions) through a histidine rich sequence (demonstrated with MMCP-7; Matsumoto et al
1995) preventing its dissociation into inactive monomers (Alter et al 1987). Chondroitin
sulphate E can also stabilise tryptase to some extent (Schwartz 1995). (It should be noted
that, in contrast to human tryptase, rat tryptase does not bind heparin (Lagunoff, Rickard and
Marquardt 1991)). Tryptases possess acidic pi values (e.g. MMCP-6 6.50, MMCP-7 5.95)
which contrasts markedly with the basic pi values of chymases (e.g. MMCP-4 9.66), this
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being of relevance to the proteoglycan binding characteristics of tryptase and chymase
(Springman and Serafin 1995). Post-translational modification of proteinases, although not
essential for proteinase function (e.g. Rat Mast Cell Proteinase-I [RMCP-I] and RMCP-II are
non-glycosylated), can account for observed differences in proteinase stability, solubility,
proteoglycan binding/packaging and activity. For example, in the mouse, the activity of
MMCP-1 is dependant upon the particular glycoform (A to E) that is present (Newlands et al
1993). Tryptase hydrolyses proteins on the C-terminal side of the basic/positively charged
residues lysine and arginine (Schwartz 1985) and favours cleavage of tripeptide substrates
with basic amino acids in the SI and S2 positions (Schwartz 1995; biological substrates for
tryptase will be discussed below). Two tryptase cDNA molecules have also been cloned from
a human lung mast cell cDNA library and designated as a-tryptase (Miller, Westin and
Schwartz 1989) and (i-tryptase (Miller, Moxley and Schwartz 1990). Three cDNA molecules
(I, II and III) were also cloned from a human skin mast cell library, the (3-tryptase cDNA
amino acid product being 98% to 100% homologous with that from tryptase I, II and III
cDNA (Vanderslice et al 1990). Tryptase is not inhibited by classical serine proteinase
inhibitors (Harvima et al 1988, Alter et al 1990, Schwartz 1995) such as lima bean, soybean
or ovomucoid trypsin inhibitors which distinguishes it from other serine proteinases, although
it can be inhibited by low molecular weight substances such as leupcptin, DFP and
phenylmethylsulfonyl fluoride and is also rapidly inactivated in low salt conditions (Schwartz
1995). Presently, no specific physiological inhibitor has been found for tryptase (Harvima et
al 1995). Loss of tryptase activity may result from destabilization of the tryptase-heparin
complex in vitro by heparinases (Alter et al 1987) or by heparin binding proteins (Alter et al
1990) in conjunction with divalent cations (Alter and Schwartz 1989). However, the
mechanism by which tryptase is dissociated from heparin in vivo is unknown (Schwartz et al
1995). Certainly, it is stated that active tryptase has a prolonged action following release
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from mast cells in skin, in part due to its interaction with heparin, although no figures are
quoted for the duration of its action (Harvima et al 1995). Given that the proteoglycan
content ofmast cell subpopulations differs between individual anatomical locations (discussed
below), then the nature of the proteoglycan could affect the relative biological activity of
tryptase in different tissues. The possible contribution of heparin to the biological regulation
of proteinase activity should also be addressed when considering experiments in which
purified proteinases are injected in vivo. For example, the intradermal injection of tryptase
plus heparin in ovine skin produces an immediate cutaneous response of greater magnitude
than that due to tryptase alone (Molinari et al in press). This could reflect less rapid
inactivation via destabilization of tryptase-bound heparin and/or persistence at the site of
injection due to the relative size of the tryptase-heparin complex.
Human chymase has been purified from skin (Schechter et al 1983), lung (Wintroub et al
1986) and heart (Urata et al 1990). Chymase is a monomeric serine proteinase of 30kDa by
SDS-PAGE (Wintroub et al 1986) although murine chymases (MMCP-1 to MMCP-5) range
between 26kDa and 36kDa (Springman and Serafin 1995). The gene for human skin chymase
has been cloned (Caughey, Zerwick and Vanderslice 1991). As mentioned above, chymases
possess basic pi values and the characteristic catalytic triad of histidine, aspartate and serine
residues, its endopeptidase activity being measured by cleavage of synthetic p-nitroanilide-
peptide conjugates (Harvima and Schwartz 1993). The strong positive charge associated with
chymase allows it to bind to other cells and to basement membranes following dissociation
from granule proteoglycans (discussed below; Walls 1995). Cleavage of a propeptide in the
initially translated proenzyme allows spontaneous refolding to produce the mature, active site
(Springman and Serafin 1995). Chymotrypsin-like proteinases cleave at large hydrophobic
residues such as tryptophan, tyrosine, phenylalanine, leucine and methionine. For example,
chymases in man, dog and rodents demonstrate an extended substrate binding site with a
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preference for phenylalanine at residue Pi and for hydrophobic residues at P2 and P3 (Powers
et al 1985). Chymase is stored in an active form in mast cells (Huntley et al 1985) in
conjunction with heparin (Harvima and Schwartz 1993). Indeed, chymase and tryptase are
stored in the same mast cell granule (Craig, Schechter and Schwartz 1988), although chymase
is released in a complex along with carboxypeptidase separate from tryptase (Goldstein et al
1992). The chymase complex (with proteoglycan and carboxypeptidase) is between 400kDa
to 560 kDA (tryptase complex is between 200kDa and 250kDa; Walls 1995) and thus there is
a greater relative possibility of chymase retention in comparison to tryptase at sites of release.
This could directly affect the degree of cutaneous response with regard to release of the two
proteinases. However, unlike tryptase, human skin chymase remains active in the absence of
heparin under physiological conditions (Sayama et al 1987). In the same study it was shown
that heparin binding did not affect the cleavage of small peptide substrates but it was
speculated that such binding could reduce the accessibility of the active site to proteins
(Sayama et al 1987). This is supported by data that indicates that only free RMCP-I (i.e. not
granule associated) can hydrolyze larger protein molecules (Le Trong, Neurath and Woodbury
1987). The binding of chymase to heparin within mast cell granules does not block the active
site of the proteinase (Sayama et al 1987) and indeed enhances the activity of chymase by
33% at pH 7.5 (the pH of the extracellular space), in comparison to a depression in activity of
40% at pH 5.5 (pH of the mast cell granule) (McEuen, Sharma andWalls 1995).
Significantly, the presence of heparin was shown to prevent inhibition of RMCP-I activity by
the serpins (serine proteinase inhibitors) ai-proteinase inhibitor (ai-PI) and
ai-antichymotrypsin, and by a2-macroglobulin, soybean trypsin inhibitor and plasma (Pejler
and Berg 1995). Additionally, dissociation of RMCP-I from heparin was shown to result in a
reduced ability of the chymase to inactivate thrombin (Pejler, Soderstrom and Karlstrom
1994). Thus, based on the in vitro evidence above, the glycosaminoglycan-proteinase
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interactions can be speculated to be of functional significance and not merely as a mechanism
to concentrate intracellular molecules (discussed in Sayama et al 1987).
Chymase is inhibited by the classical inhibitors of serine proteinases, including DFP (Harvima
and Schwartz 1993). The interaction of chymase with low molecular weight inhibitors is
reviewed by Schechter (1995). Chymase can be inhibited by serpins such as
ai-antichymotrypsin and arPI (Schechter et al 1989) but these act as better substrates than
inhibitors for chymase, this therefore implying that plasma is not solely responsible for
regulation of chymase activity (Schechter et al 1989). Of particular interest to the regulation
of chymase in the skin is the presence of the proteinase inhibitor Elafin in psoriatic epidermis
(Wiedow et al 1990) and that ai-PI and ai-antichymotrypsin have been detected in human
skin mast cells (Ruck, Horny and Kaiserling 1990, Harvima et al 1993). Certainly, chymase
can be inhibited by the serpins ai-antichymotrypsin and ai-PI in plasma
(kass~7.5 x 103 M'V1 for human chymase and ai-PI), as well as partially by a2-macroglobulin
(Schechter et al 1989). The half-life for chymase (based on the combined inactivations of
chymase by arPI and ai-antichymotrypsin) was calculated to be 1.3s, this being 650 times
slower than for inactivation of neutrophil cathepsin G in the same study (Schechter et al
1989). This, in conjunction with the estimated dermal concentration of chymase (after
complete mast cell-release) of IpM, suggests that chymase has the potential to contribute
substantially to proteolytic activity in the dermis.
1.5.3. Sheep Mast Cell Proteinase (SMCP)
When mucosal mast cells (MMC) were isolated from the abomasal mucosa of Ostertagia
circumcincta parasitized sheep (Huntley, Wallace and Miller 1982), a chymotrypsin-like
esterase was demonstrated histochemically within these abomasal mucosal mast cells
(Huntley, Newlands and Miller 1984, Huntley et al 1985). A cationic proteinase, sheep mast
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cell proteinase (SMCP) was successfully isolated from abomasal mucosal mast cells (Huntley
et al 1986), and the mast cell source of this enzyme confirmed immunohistochemically
(Huntley et al 1986). The catalytic properties of SMCP were initially defined as those of a
chymotrypsin-like enzyme (Knox, Gibson and Huntley 1986), this description being refined to
that of a serine endopeptidase (Knox and Huntley 1987). Following development of an
ELISA to detect SMCP, it was demonstrated that SMCP was released locally into lymph and
systemically into blood following abomasal challenge with Haemonchus contortus and
Ostertagia circumcincta respectively (Huntley et al 1987), despite the presence of inhibitors
of the ELISA in both lymph and serum (Huntley et al 1987, Huntley 1991). Increased blood
pepsinogen activity (Smith et al 1984) accompanied the raised SMCP levels demonstrable
following challenge with Ostertagia circumcincta (Huntley et al 1987; the same samples
being analysed as in Smith et al 1984), suggesting that the former was a consequence of a
hypersensitivity response involving MMC. SMCP hydrolyses substance P (sP), bradykinin,
met-lys-bradykinin and oxidised insulin B chain at Pi Phe or Leu residues in accordance with
its chymotrypsin-like activity (Pemberton, Huntley and Miller, submitted). However, SMCP
exhibits an unexpected trypsin-like activity on bovine, ovine and equine serum albumin,
cleaving bovine serum albumin after Pi Lys residues flanked by acidic amino acids at the P4
and P4' positions (Pemberton, Huntley and Miller, submitted). Following purification from
sheep serum, arPI and a2-macroglobulin were confirmed as the two most potent inhibitors of
SMCP present therein (Pemberton, Huntley and Miller, submitted). Like human chymase
(Schechter et al 1989), SMCP is inhibited relatively slowly (-15 minutes) by its homologous
arproteinase inhibitor (kCiSS~ 1.1 xlO3 M'V1; Pemberton, Huntley and Miller, submitted),
which would enable its persistence at the site of cutaneous responses but also enable it to be
functional at some distance from its point of release (or injection).
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A second putative chymase (in addition to SMCP) was detected by Western blotting in ovine
bone marrow cells grown in the presence of lymphocyte-derived conditioned media from
nematode-infected sheep (CM-BMMC) but it was not present in blots from purified gastric
MMC (Huntley et al 1992). Additionally, mast cell tryptase has yet to be isolated from ovine
tissues, although tryptase has been isolated from bovine liver capsule (Fiorucci, Erba and
Ascoli 1992). However, it has been shown that APC 366 (a tryptase inhibitor) reduces both
the late phase response evoked by allergen challenge (Clark et al 1995) and the mast
cell-mediated immediate cutaneous response to intradermally injected A.suum antigen in
allergic sheep (Molinari et al, in press). These results suggest that tryptase may be present in
ovine mast cells.
Thus, even from the broad, largely in vitro, biochemical data outlined (1.5.1.-1.5.3.) above
there is evidence that chymases and tryptases possess marked proteolytic potential and to be
relatively persistent once released from activated mast cells. The hypothesis that they are able
to participate in cutaneous inflammatory responses will be expanded upon by consideration of
their potential biological substrates, discussed later.
1.6. Mast Cell Heterogeneity
1.6.1. General Introduction And Contribution OfMast Cell Proteinases
Currently, comparatively little is known about the ovine mast cell nor of mast cell phenotypic
heterogeneity in the sheep. As phenotypic heterogeneity is one theme of the studies described
in this thesis, a brief review will be given of this topic. Indeed, mast cells in various species
are a phenotypically heterogeneous cell population with respect to a range of characteristics
(reviewed in Bienenstock 1988, Galli 1990, Huntley 1992, Barrett and Pearce 1993). These
characteristics can include tissue site, fixation characteristics, and histochemical staining
patterns (Becker et al 1985, Aldenborg and Enerback 1988), biochemistry (Katz, Stevens and
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Austen 1985, Stevens et al 1986a), proteinase content (Gibson and Miller 1986, Irani et al
1986, Reynolds et al 1990), cytokine content (Bradding et al 1995) and functional activity
(Foreman 1993, Anion 1994).
Enerback (1966a, 1966b) demonstrated histochemical differences between rat dermal mast
cells (CTMC) and rat intestinal MMC, cytoplasmic granules staining red and blue
respectively following sequential treatment with alcian blue and safranin. This distinction is
not absolute as there is variability in safranin staining at different connective tissue-type sites
in the rat (Aldenborg and Enerback 1988, Tainsh and Pearce 1992). Additionally, differences
in tissue fixation (formalin sensitivity) and staining exist within the canine dermal mast cell
population (Becker et al 1985). Similarly, within both human intestine (Befus et al 1985) and
skin (Marshall, Ford and Bell 1987) formalin-sensitive and -insensitive sub-populations exist.
Tissue fixation and histochemical staining of glycosaminoglycans are therefore inconsistent,
proving an unreliable guide to the delineation of mast cell subsets.
Analysis of the content of mast cell-specific neutral proteinases is currently the most definitive
method of comparing heterogeneity between mast cell populations (Miller et al 1989, Galli
1990, Miller 1993a). Mast cell heterogeneity is based upon either the presence or absence of
chymase in addition to tryptase (as in man) or on differences in the types of chymases
expressed (as in rodents), and is broadly outlined in Tablel.2. and briefly discussed below.
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DISTRIBUTION OF SERINE PROTEINASES IN THE GRANULES OF MAST
CELLS FROM DIFFERENT TISSUES


























Table 1.2. General distribution of serine proteinases in the granules of mast cells from




Following the initial isolation of mast cell chymases in the rat (Lagunoff and Benditt 1963,
Lagunol'f and Pritzl 1976, Yurt and Austen 1977, Woodbury et al 1978), two distinct
chymases were identified, antibodies to these being used to define mast cell heterogeneity
(Gibson and Miller 1986, Gibson et al 1987). Rat mast cell proteinase-I (RMCP-I) is
associated with the CTMC subset (i.e. skin), whereas rat mast cell proteinase-II (RMCP-II) is
predominantly found in the gastrointestinal MMC subset (Gibson and Miller 1986, Gibson et
al 1987). However, RMCP-II-positive mast cells have been demonstrated at non-mucosal
sites (e.g. thymus; Gibson and Miller 1986) and, additionally, dual RMCP-I- and
RMCP-II-staining cells have been identified at tissue sites including the gastric submucosa
and mesenteric lymph node (Huntley et al 1990). Thus, although general proteinase
heterogeneity exists in the rat, proteinase heterogeneity also occurs within certain rat mast cell
populations. Tissue location alone cannot therefore be used to explicitly define all mast cell
subsets in the rat, although no RMCP-II has as yet been demonstrated in skin (Chernin et al
1988), indicating that RMCP-I can be used to define dermal mast cells in this species.
1.6.1.2. Mouse
Seven mouse mast cell proteinases (MMCP) have currently been identified, these including
five chymases (MMCP-1 to MMCP-5) and two tryptases (MMCP-6 and MMCP-7)
(Newlands et al 1987, Reynolds et al 1990, Schwartz 1994), although MMCP-7 has presently
only been detected as the mRNA in interleukin-3-dependent BMMC (IL-3 BMMC) in vitro
(M°Neil et al 1992). (N.B. MMCP-L represents a further putative proteinase identified when
a mouse genomic library was screened with an MMCP-4 cDNA probe [Springman and
Serafin 1995]. However, this has not been shown to be present in any mast cell type as yet).
MMCP-1 is present in the MMC subset (Newlands et al 1987, Le Trong et al 1989), and is
not demonstrable in any connective tissue mast cell subset (Newlands et al 1993, Miller et al
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1995). MMCP-3, MMCP-4 and MMCP-5 also help delineate the CTMC subset (Stevens et al
1994, Schwartz 1994). However, MMCP-2 (which is considered a predominantly MMC
proteinase) can also be detected immunohistochemically in murine cutaneous mast cells
(Stevens et al 1994). Thus, as MMCP-1 is absent in skin, tongue or peritoneal mast cells
(Newlands et al 1993, Miller et al 1995), then this provides a correlation between proteinase
content and mast cell subtype (MMC or CTMC) in the mouse.
1.6.1.3. Man
Mast cell heterogeneity in man is defined by the presence or absence of chymase in cells which
all contain tryptase. This has been used to delineate two mast cell subtypes, the MCtc
(containing both tryptase and chymase) and MCT (containing tryptase alone) (Irani et al 1986,
Tf
Schwartz 1989, Irani and Schwartz 1990). The MC is chiefly present in skin and small
intestinal submucosa, whereas MCr is present in lung and small intestinal mucosa (Irani et al
1986, Schwartz et al 1987, Schwartz 1989, Irani and Schwartz 1990). The MCtc subtype
accounts for between 88% and 99% ofmast cells in skin (Irani et al 1986, Schwartz et al
1987). In addition, a third subtype of mast cells containing chymase alone (MCC) has been
described, although these cells are present in extremely low numbers in skin (Weidner and
Austen 1993).
1.6.1.4. Dog
Most work on canine proteinases has focused on their isolation or release from mastocytoma
cell lines (Slavin et al 1987, Caughey et al 1988a, Caughey et al 1988b, Schechter et al 1988)
or on their biological activity (reviewed in Sommerhoff 1995). Canine dermal mast cells
contain both a chymase and a tryptase (Schechter et al 1988), these proteinases being
differentially expressed in mastocytoma cell lines (Caughey et al 1988c). Additionally, a
second, tryptase-related proteinase (Dog Mast Cell Proteinase-3, dMCP-3) has recently been
identified, and demonstrated immunohistochemically (using an antibody raised against a
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peptide [residues 166-181] from the deduced sequence) in mast cells of the lung, jejunum and
dermis (Yezzi, Hsieh and Caughey 1994). However, dMCP-3 can also be detected in canine
neutrophils (Yezzi, Hsieh and Caughey 1994). In one study which looked at the distribution
of tryptase in the dog (Myles et al 1995), the gastrointestinal tract was shown to have the
highest tryptase levels with lower levels in skin (30ng/mg [dorsum] to 68ng/mg [ventrum]).
However, further morphometric analysis is required before mast cell proteinase heterogeneity
can be defined in the dog, and is therefore not included in Table 1.2.
1.6.1.5. Sheep
Although the concentration of SMCP in the gastrointestinal mucosa is known to be
significantly correlated with mast cell counts (Huntley 1991), the distribution of SMCP in
non-mucosal tissues was unknown (Table 1.2). Thus, it was also unknown whether
heterogeneity, as demonstrated in other species based on proteinase content, existed in the
sheep. This, therefore, provided the impetus to elucidate the tissue distribution of SMCP.
1.6.2. Proteoglycan Content
Proteoglycan heterogeneity was demonstrated indirectly in rat mast cells by Enerback
(1966b), who showed that CTMC, but not MMC, could be stained with safranin in the alcian
blue/safranin staining sequence. Rat MMC, unlike rat dermal mast cells (Homer 1971,
Enerback 1987, Enerback et al 1989) contain little or no heparin (Tas and Berndsen 1977),
but instead were stated to contain predominantly chondroitin sulphate di-B (Stevens et al
1986b, Barrett and Pearce 1993, Schwartz 1994). However, at variance to this, Enerback et
al (1985) have demonstrated biochemically that rat gastrointestinal MMC appear to contain
chondroitin sulphate E.
As in the rat, human cutaneous mast cells contain heparin (Metcalfe et al 1980), with MMC
originally being stated to contain chondroitin sulphate E alone (Gilead et al 1987). It is now
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believed that all human mast cells in skin, lung and bowel contain heparin (Craig et al 1993),
which supports previous findings suggesting that human lung mast cells contained both
proteoglycans (Stevens et al 1988).
The CTMC subset in the mouse contains heparin (Schwartz 1994), whereas it is suspected
that murine MMC do not contain heparin given that they cannot bind berberine sulphate dye
(Kitamura et al 1987) and are alcian blue-positive but safranin-negative on sequential staining
(Crowle and Phillips 1983).
Heparin is therefore the predominant proteoglycan of the CTMC subset in various species
(Katz, Stevens and Austen 1985, Schwartz 1994), although it is not known whether this
generalisation can be extended to include the ovine dermal mast cell population.
1.6.3. Arachidonic Acid Metabolism Product Heterogeneity
Mast cells from different sources also differ in their metabolism of arachidonic acid following
activation, leading to the differential synthesis of prostaglandins [PG] (via the cyclooxygenase
pathway) or leukotrienes [LT] (via the lipoxygenase pathway).
Cutaneous mast cells in man synthesize PGD2 in preference to LTC4 (Lawrence et al 1987,
Benyon, Robinson and Church 1989; preparations < 85% purity), which is similar to rat
serosal mast cells following ionophore (Roberts et al 1979) or anti-IgE-mediated activation
(Lewis et al 1982). Human uterine and lung mast cells produce equivalent quantities of PGD2
and LTC4 upon activation (Fox et al 1985, Massey et al 1991). However, studies on human
dispersed (Leung et al 1987) or bronchoalveolar lavage-derived lung mast cells (Cohan et al
1989) suggest that PGD2 synthesis predominates.
In vitro, rat BMMC and partially purified intestinal mast cells synthesize comparable amounts
of PGD2, LTB4 and LTC4 upon IgE-dependent activation (Broide, Metcalfe andWasserman
1988). In contrast, murine BMMC synthesize LTB4 and LTC4 in preference to PGD2 (Razin
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et al 1982, 1983), but this can be modulated by cytokines (particularly stem cell factor [SCF])
resulting in a more "CTMC'-like phenotype of PGD2 generation (Murakami, Austen and Arm
1995).
Ovine CM-BMMC were shown to generate LTC4 upon activation (Huntley et al 1992),
although it is not known if ovine dermal mast cells would respond similarly.
1.6.4. Functional Heterogeneity
The differential response of mast cell populations in vivo or in vitro to chemical secretagogues
and to the effect of anti-allergic drugs on mediator release has also been used to distinguish
mast cell subsets in various species (reviewed in Cohan et al 1989, Foreman 1993, Barrett and
Pcarce 1993). The functional response of mast cells is the most clinically relevant of the
methods used to define mast cell heterogeneity. In the series of studies described in this thesis
three known mast cell secretagogues (compound 48/80 [48/80], substance P [sP] and calcium
ionophore A23187 [A23187]) and one mast cell chymase (SMCP) were used in an attempt to
activate ovine mast cells in vivo and in vitro.
Functional heterogeneity was originally demonstrated in the rat by injecting the polycationic
secretagogue 48/80, which depleted dermal but not gastrointestinal mast cells [the MMC
phenotype] (Enerback 1966c). Compound 48/80 is a mixture of polymers which evoke
histamine release from mast cells in a non-cytotoxic process (Johnson and Moran 1969) that
requires the presence of extracellular calcium (Foreman and Mongar 1973). It is postulated
that, as suggested for substance P, 48/80 may activate, via a peptidergic pathway, mast cell
Gi-like proteins in a receptor-independent but membrane-assisted process that is limited to
serosal mast cells (Mousli et al 1994). Compound 48/80 is generally an activator of the
serosal or CTMC phenotype (Table 1.3(a)), although one exception is the cow, as dispersed
cutaneous mast cells could not be activated by 48/80 (Hunt et al 1991, Table 1.3(b)).
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The neuropeptide substance P (reviewed in Regoli, Bondon and Fanehere 1994) will activate
mast cells, but only at relatively high biological concentrations (10~6M, 10"5M)( Regoli,
Bondon and Fanchere 1994). Substance P will activate cutaneous mast cells in man, but does
not activate cells of the MMC phenotype (Table 1.4). This rule holds for most species,
although sP can activate the MMC of the rat intestine (Befus ct al 1986; Table 1.4).
Calcium ionophore A23187 (A23187) is considered a universal activator of mast cell
populations in vivo and in vitro (Table 1.5), although different populations may show a
gradation of response (Pearce 1986). As A23187 acts by increasing intracellular calcium
levels (Foreman, Mongar and Gomperts 1973), responses can be evoked in other cell types
(Amon et al 1994) and therefore its action is not mast cell-specific. Thus, although useful as a
mast cell activating agent, it is of limited use in helping to define mast cell heterogeneity.
A23187 is, however, the only chemical secretagogue to have successfully activated ovine
CM-BMMC (Huntley et al 1992).
Chymase can activate rat serosal mast cells in vitro in an active site-dependent process
(Schick and Austen 1986), although the exact mechanism of this activation is unknown. Both
RMCP-I and RMCP-II can evoke (^-hexosaminidase release from rat CM-BMMC, although
the extent of release was less than that from isolated rat peritoneal mast cells (Gardner 1990).
Thus, by comparing the effects of the four agents discussed above on ovine mast cell



























































Table 1.3(a). Studies which have reported or cited compound 48/80-induced mast cell
activation in various mast cell populations from various species. (Thymus/fibroblast
culture indicates mast cell culture derived from thymus cells grown with fibroblast
monolayers. Peritoneal/fibroblast coculture indicates peritoneal mast cells grown in coculture
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Table 1.3(b). Studies which have reported or cited a lack of compound 48/80-induced
mast cell activation in various mast cell populations from various species. (CM-BMMC
indicates bone marrow cells grown in the presence of conditioned medium. Umb.cord + 3T3
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Table 1.4. Studies which have reported or cited the presence or absence of
substance P-induced mast ceil activation in various mast cell populations from various
species. (Umb.cord + 3T3 indicates mast cell culture derived from umbilical cord blood
mononuclear cells grown with 3T3 fibroblasts. CM-BMMC indicates bone marrow cells
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Table 1.5. Studies which have reported or cited calcium ionophore (A23187)-induced
mast cell activation in various mast cell populations from various species. (CM-BMMC
and IL-3 BMMC indicates bone marrow cells grown in the presence of conditioned medium
and IL-3 respectively. Umb.cord + 3T3 indicates mast cell culture derived from umbilical
cord blood mononuclear cells grown with 3T3 fibroblasts. Pearce 1986* indicates that the
cell population was activated, but could be considered hyporesponsive relative to other cell
types).
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1.7. Mast Cell Development In Vitro And In Vivo
It is considered that mast cell development and heterogeneity in vitro and in vivo is closely
regulated by a range of cytokines (reviewed in Galli 1990, Schwartz 1994).
1.7.1, In Vitro
1.7.1.1. Conditioned Medium And InterIeukin-3
Early in vitro-derived mast cells in rats and mice were generated from thymic (Ginsburg 1963,
Ishizaka et al 1976, 1977) or lymph node-derived (Ginsburg and Lagunoff 1967, Denburg,
Befus and Bienenstock 1980) cell populations. Subsequently, mast cells were generated in
vitro from bone marrow cells of the mouse (Nagao, Yokoro and Aaronson 1981, Razin,
Cordon-Cardo and Good 1981, Sredni et al 1983) and rat (Haig et al 1982) using conditioned
media derived lfom stimulated splenocytes and T cells respectively.
T cells were shown to synthesise a factor that evoked proliferation of cloned mast cells (Nabel
et al 1981), and the factor in conditioned media from concanavalin A-stimulated lymphocytes
that possessed mast cell growth activity was demonstrated to be interleukin-3 (IL-3) (Ihle et al
1983). When grown in the presence of IL-3, bone marrow cells from the mouse (Ghiara et al
1985, Rennick et al 1985, Chiu and Burrall 1990) and rat (Haig et al 1988a) differentiate into
mast cells. However, in human bone marrow cultures supplemented with IL-3, the production
of basophils is favoured (Kirshenbaum et al 1989, Valent et al 1989), although small numbers
ofmast cells can be generated (Kirshenbaum et al 1989, 1992). IL-3 is considered an "early
acting" cytokine in haematopoiesis (Ogawa 1993), targeting haematopoietic stem cells or
multipotential progenitors (Arai et al 1990). Yet, uniquely in the case of the mast cell, IL-3 is
believed to support lineage-restricted development (Ogawa 1993). Human mast cells are,
however, unresponsive to IL-3 (Agis and Valent 1995), IL-3 binding sites on these cells being
as yet undetected (Valent et al 1990).
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In the sheep, as in the mouse and rat, mast cells can be produced from bone marrow grown in
the presence of lymphocyte-derived conditioned media from nematode-infected sheep (Haig et
al 1988b, Huntley et al 1992). These CM-BMMC developed rapidly after two weeks of
culture and could be grown for two to three months in vitro, mast cells accounting for 90% of
cultured cells by day 28 (Haig et al 1988b). The CM-BMMC were ultrastructurally
immature, and contained arylsulfatase, ^-hexosaminidase, dopamine and SMCP (Huntley et al
1992). The cells could be activated by A23187 to induce release of arylsulfatase,
^-hexosaminidase and SMCP and to generate LTC4 (Huntley et al 1992). A second putative
chymase (in addition to SMCP) was detected by Western blotting. The second
immunoreactive band was not detected in blots from purified gastric MMC and it was
suggested that CM-BMMC represented a mixed population of CTMC and MMC phenotypes
(Huntley et al 1992).
IL-3 promotes the proliferation of precursor erythroid cells, megakaryocytes, macrophages,
neutrophils, eosinophils and mast cells. The IL-3 receptor expresses both high and low
affinities for IL-3 (i.e. dual affinity; Foxwell, Barrett and Feldmann 1992). The a-chain of
the heterodimeric receptor expresses low affinity binding, high affinity binding occurring as a
result of the association of each a-chain with a larger (3-chain (Foxwell, Barrett and Feldmann
1992). The (3-chain, which by itself cannot bind IL-3, is also shared by the receptors for IL-5
and GM-CSF (Foxwell, Barrett and Feldmann 1992), all three receptors being members of the
haematopoietic growth receptor family. IL-3, IL-5 and GM-CSF induce tyrosine
phosphorylation on a similar set of cytoplasmic proteins (discussed in Foxwell, Barrett and
Feldmann 1992), and this may be the reason that these cytokines are able to demonstrate
apparently overlapping effects on different cellular compartments (reviewed in Lopez et al
1992). Transformed murine mast cell lines and purified peritoneal mast cells (Plaut et al
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1989) produced IL-3 when activated by cross-linkage of FceRI or by calcium ionophores.
Murine CM-BMMC (Wodnar-Filipowicz, Heusser and Moroni 1989) and murine
IL-3-dependent or -independent cloned mouse mast cells (Burd et al 1989) expressed increased
levels ofmRNA for IL-3 and also IL-3 bioactivity when stimulated through FceRI. Recently,
IL-3 and IFN-y have been shown to modulate the release of serotonin and arachidonate
(eicosanoids) from mouse peritoneal mast cells, IL-3 enhancing, while IFN-y inhibits, their
antigen-induced release (Holliday et al 1994). Tlius, locally produced IL-3 could also play a
role in the modulation of inflammatory mediators at sites of cutaneous inflammation and,
importantly, the in vivo release of mast cell-derived IL-3 may facilitate the local proliferation
of mast cells and help determine their final phenotype.
Latterly, the ovine IL-3 gene was cloned and the recombinant protein expressed (MTnnes,
Haig and Logan 1993). The exons of the ovine IL-3 gene share approximately 50% identity
with those of man (MTnnes 1993, MTnnes, Haig and Logan 1993). Ovine IL-3 protein is
35% and 24% homologous in terms of predicted amino acid sequences with human and
murine IL-3 respectively (MTnnes 1993, MTnnes, Haig and Logan 1993). Preliminary
studies have suggested that rOv.IL-3 supports the development of cell colonies of mixed
phenotype in vitro (including neutrophils, macrophages and eosinophils; Haig 1993).
Additionally, this study suggests that rOv.IL-3 supports the development of mast cells from
ovine bone marrow in vitro (Haig 1993). However, the kinetics of development of these cells,
their mediator content, functional activity and likely phenotype were not determined.
1.7.1.2. Stromal Cell-Derived Factors (Stem Cell Factor And Nerve Growth Factor)
Stem cell factor (SCF), which was initially identified as a novel mast cell growth factor
(Copeland et al 1990, Williams et al 1990, Zsebo et al 1990a) and ligand for the c-kit tyrosine
kinase receptor (Huang et al 1990, Nocka et al 1990), has been shown to regulate mast cell
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proliferation and maturation (Galli, Tsai and Wershil 1993), and specifically to act
synergistically with IL-3 to promote the growth of both rat (Haig et al 1994) and mouse (Tsai
et al 1991a) IL-3-derived BMMC. In the rat, the addition of IL-3 or CM to peritoneal mast
cells (CTMC) grown in the presence of SCF in vitro resulted in a subpopulation of CTMC
expressing and storing RMCP-II (Haig et al 1994). However, in the same study, SCF
favoured the maintenance of RMCP-I in CTMC and rat BMMC grown in the presence of
SCF demonstrated a reduction in RMCP-II levels without a concomitant increase in RMCP-I
(Haig et al 1994). Thus, the presence of SCF can influence the production of proteinases in
these two cell types. SCF alone can stimulate small numbers of murine BMMC (Boswell et al
1990, Migliaccio et al 1991). SCF was also shown to induce the development of human mast
cells from both bone marrow and peripheral blood mononuclear cells (Valent et al 1992) and
from umbilical cord blood cells (Mitsui et al 1993), although other studies suggest it cannot,
in the absence of other factors, induce mast cell growth (Grabbe et al 1994). The ovine stem
cell factor gene has recently been cloned (C.MTnnes, personal communication) and its
subsequent expression should provide recombinant ovine stem cell factor which will allow
investigation of its role in ovine mast cell development in vivo and in vitro. In addition to the
interplay between interleukins and SCF, nerve growth factor (NGF) can also induce murine
CTMC-type mast cell growth from bone marrow cells (Matsuda et al 1991).
1.7.1.3. Other Cytokines
Interleukin-4, although having no direct effect on mast cell growth, synergizes with IL-3 to
promote growth of BMMC in the mouse (Smith and Rennick 1986) and, similarly, IL-10 in
combination with either IL-3 or IL-4 has been shown to support the growth of murine mast
cells in vitro (Thompson-Snipes et al 1991). Interleukin-9, produced by activated Tm clones
in vitro (Renauld et al 1995), can enhance the proliferation of murine mast cell lines induced
by IL-3 or IL-4 (Hiiltner et al 1989, Moeller et al 1989, Hiiltner et al 1990), the latter
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cytokines being able to inhibit the IL-9-induced expression ofMMCP-1, MMCP-2 and
MMCP-4 (Eklund et al 1993). Recently, several cytokines (IL-3, IL-4 and IL-10) have been
demonstrated to be necessary for stem cell factor-dependent growth ofmurine mast cell
progenitors (Rennick et al 1995). However, IL-4, IL-9 and IL-10 fail to support the growth of
human mast cells in vitro (Agis and Valent 1995).
1.7.1.4. Use Of Fibroblast Co-Culture Systems
Co-culture systems, where progenitor cells are cultured in the presence of fibroblasts, have
been used extensively to generate and investigate mast cells from rodents (Ginsburg,
Ben-Shahar and Ben-David 1982, Levi-Schaffer et al 1985 and 1986, Nakamura et al 1994)
and man (Furitsu et al 1989, Ishizaka, Furitsu and Inagaki 1991, Irani et al 1992) in vitro.
Specifically, such co-culture experiments have been used to provide evidence that the local
tissue microenvironment may regulate the phenotype of mast cells in tissues (Levi-Schaffer
1985, 1986; Dayton et al 1988). For example, the study by Dayton et al (1988) indicated that
murine IL-3-dependent BMMC could alter their proteoglycan content and therefore acquire
characteristics of the connective tissue mast cell subset in the presence of fibroblasts. This
study assumed that the IL-3-dependent BMMC population was analogous to the MMC
population. However, it is known that the murine IL-3-dependent BMMC population is
heterogeneous (discussed later; Newlands et al 1991) and, therefore, these results may merely
represent the subsequent selection by fibroblast co-culture of a subset of the original BMMC.
Thus, the interpretation of in vitro findings based on heterogeneous cell populations whose
similarities to in vivo cell populations are open to speculation must be viewed critically.
It has been demonstrated that the survival of rat BMMC when co-cultured with murine 3T3
fibroblasts is dependent upon fibroblast-derived stem cell factor (MacDonald 1994).
Preliminary studies indicated that a well-granulated, adherent mast cell population developed
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when ovine CM-BMMC were grown in a co-culture system (J.Huntley, personal
communication). However, it is not known if the ovine CM-BMMC phenotype would be
altered, as is suggested to occur with murine IL-3 BMMC (Levi-Schaffer et al 1986).
1.7.2. In Vivo
1.7.2.1. Stem Cell Factor
The importance of SCF in the development of CTMC and MMC populations in vivo was
indicated by the lack of mast cells in WBB6F|-1P/1TV [W/Wv](Kitamura, Go and Hatanaka
1978) or WCB6F1 -Sl/Sld [5//5/rf](Kitamura and Go 1979) mice, which lack c-kit receptor and
SCF production respectively (reviewed in Nakano et al 1985, Nakano et al 1987, Galli, Tsai
and Wershil 1993). SCF is produced in vivo by fibroblasts (Flanagan and Leder 1990, Nocka
et al 1990), keratinocytes (Longley et al 1992), dermal endothelium (Weiss et al 1995), bone
marrow stromal cells (Williams et al 1990), hepatocytes, thymic stromal cells, mast cells and
Langerhans cells (Grabbe et al 1994) and is expressed either as a soluble or membrane-bound
form (Anderson et al 1990, Flanagan, Chan and Leder 1991). The c-kit tyrosine kinase
receptor is expressed on primordial stem cells, intrathymic stem cells, CD34+ bone marrow
cells, megakaryocyte precursors, erythroid precursors, granulocyte precursors, melanocytes
and mast cells (Grabbe et al 1994). SCF at high concentrations can evoke histamine release
from human skin mast cells, but not from human lung mast cells (Bischoff and Dahinden
1992, Columbo et al 1992). Daily subcutaneous injection of recombinant rat SCF (rrSCF)
induces cutaneous mast cell development in the Sl/Sld mast cell-deficient mouse (Zsebo et al
1990b). Additionally, local administration of rrSCF in normal mice results in cutaneous
CTMC development (Tsai et al 1991b), and intravenous rrSCF induces the development of
both MMC and CTMC populations (Tsai et al 1991b, Newlands et al 1995). Systemic
injection of anti-SCF antibody ablates the MMC population in normal rats but only partially
depletes peritoneal cells and has only very limited effects on CTMC in other sites (Newlands
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et al 1995). Similarly, in primates, mast cell numbers at various tissue sites increase
following subcutaneous injection with recombinant human SCF, these falling again upon
cessation of SCF treatment (Galli et al 1993). Mast cell hyperplasia in mice due to a primary
Trichinella spiralis infection was abrogated by treatment with a monoclonal antibody to c-k.it
(Grencis et al 1993). Therefore, SCF and c-kit are closely associated with mast cell
development in vivo and, from the evidence discussed above, also in vitro.
1.7,2.2. Cytokines
The subcutaneous injection of IL-3 in Rhesus monkeys results in a perivascular dermal
cellular infiltrate (composed mainly of lymphocytes, monocytes and eosinophils) with
increased numbers of mast cells (Volc-Platzer et al 1991), although the phenotype of these
cells was not determined. This is of particular interest given that, as discussed above, only
small numbers of mast cells can be generated by supplementing human bone marrow cultures
with IL-3 (Kirshenbaum et al 1989, 1992). Given that human mast cells can be generated
from peripheral blood mononuclear cells (Valent et al 1992) grown in the presence of SCF,
the implication from these observations would be that a combination of growth factors are
necessary to evoke human mast cell development. In the study by Volc-Platzer et al (1991)
these may have been provided by cells in the local microenvironment activated by IL-3. This
theory would be supported by the current lack of evidence for the presence of the IL-3
receptor on human mast cells (Valent et al 1990). Systemic administration of IL-3 evokes the
generation of mast cells of an apparent MMC phenotype based on alcian blue staining in mice
(along with cells from other haematopoietic lineages; Metcalfe et al 1986). IL-3 also acts as a
signal for the expansion of the intestinal MMC population during parasitic infection in vivo
(Abe and Nawa 1988).
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Interestingly, following the observation that increased numbers of mast cells are associated
with the inoculation of a keratinocyte-derived squamous cell carcinoma cell line (KCMH-1) in
mice in vivo, a KCMH-1-derived factor has been identified that induces mast cell growth in
conjunction with 3T3 fibroblasts in vitro that is not IL-3, IL-4, IL-9, IL-10 or SCF
(Nakamura et al 1994, Yamamoto et al 1995).
The evidence discussed above suggests that a number of growth factors can favour the
development ofmast cells in vitro and in vivo. If this is coupled with the consideration of
mast cell heterogeneity, then the crucial question is:- What actually regulates the development
of tissue-specific mast cell phenotypes? For example, differences in the content of mast cell
proteinases in different tissues (e.g. skin versus gut) may reflect differences in the role of the
mast cell at these respective sites. Currently, there are two hypotheses to explain the
regulation of tissue-specific mast cell phenotypes. The first hypothesis speculates that
progenitors will only develop along a lineage-specific pathway once lodged into the
appropriate tissue (i.e. CTMC progenitors would only develop in a CTMC site e.g. skin). The
second hypothesis, for which there is supportive in vivo evidence, suggests that the mast cell
precursor has the potential to express a variety of gene products and that this expression is
regulated by microenvironmental factors in the vicinity of the precursor cell. Certainly,
peritoneal mast cells from congenic normal WBB6F1 (+/+) mice transplanted into the gastric
mucosa of WAV1 mast cell-deficient mice, result in the development ofMMC-like cells
(Kitamura et al 1987). In vitro studies, where BMMC are grown in combinations of
cytokines and the cells monitored for changes in proteinase phenotype, are faced with the
problem of the initial cell population possibly being heterogeneous (as demonstrated in murine
BMMC; Newlands et al 1991). Thus, apparently cytokine-induced alterations in proteinase
expression could merely reflect the cytokine-dependent selection of different precursor cell
subsets from the original heterogeneous population. For example, the MMCP-1 mRNA
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transcript was stated to be undetectable in murine BMMC (it being stated to be a
"late-expressed" proteinase), whereas the addition of IL-10 resulted in the expression of
MMCP-1 mRNA (Ghildyal et al 1992). However, it is known that MMCP-1 can be detected
by immunofluorescence andWestern blotting and that the content ofMMCP-1 ofmurine
BMMC varies with culture conditions in vitro (i.e. IL-3 versus CM; Newlands et al 1991).
Thus, the former study (Ghildyal et al 1992) may have merely selected a receptive subset of
the heterogeneous murine BMMC population.
As stated previously, the relevance of in vitro studies based upon non-homogeneous cell
populations must be viewed with scepticism based on the likely complex nature of phenotypic
regulation in vivo. One substantial piece of evidence against mast cell phenotypic
heterogeneity being derived from multiple progenitor populations is the recent study by Gurish
et al (1995), which demonstrated the acquisition and loss of specific proteinases in an
immature v-abl transformed mast cell line (V3-MC) injected intravenously into BALB/c mice
following infiltration of these cells into liver, spleen and intestine. Thus, cultured Y3-MC
(based on immunohistochemical and RNA blot data) demonstrated MMCP-5 and MMCP-6,
whereas liver infiltrates demonstrated MMCP-1 to MMCP-7 and intestinal infiltrates
MMCP-1 and MMCP-2 two to three weeks after administration (Gurish et al 1995). Thus,
although further in vivo investigations need to be undertaken, the scant evidence available
suggests against a multiple progenitor cell population and favours the differentiation and
maturation of progenitor cells being regulated primarily by the tissue microenvironment.
1.8. The Potential Function Of Cutaneous Mast Cells: Evidence To Support A
Role In Cutaneous Inflammation
1.8.1. Cell Adhesion Molecules And Cell Trafficking
In inflammatory disorders of the skin many of the histopathological changes are due to
increased immune cell trafficking, this invariably appearing initially as a perivascular
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accumulation of leukocytes (Walsh, Lavker and Murphy 1990). Changes in cell trafficking
can result from mast cell-derived mediators activating endothelial cells and other cell types,
and a brief discussion of adhesion molecules on cells and endothelium (reviewed in Nickoloff
1990, Springer 1994) is necessary before discussing the respective actions of the mediators
themselves.
Endothelial-leukocyte adhesion molecule-1 (ELAM-1) is a lectin-like cell surface glycoprotein
that mediates adhesion of blood leukocytes to the endothelial lumenal membrane, ELAM-1
being expressed exclusively by cytokine-activated endothelial cells (Bevilacqua et al 1987).
Expression of ELAM-1 in cultured endothelial cells is induced by IL-1 and TNF-a, and is
maximal at 6 hours and receding by 24 hours (Pober et al 1986). In human skin, ELAM-1
expression is confined to post capillary venules (the skin equivalent of high endothelial
venules)(Klein et al 1989). ELAM-1 binds strongly to a carbohydrate ligand on neutrophils
(reviewed in Springer 1994) and, to a lesser degree, to monocytes and lymphocytes
(Bevilacqua et al 1987). VCAM-1 (vascular cell adhesion molecule-1) is also expressed on
cytokine-activated (e.g. by TNF-a; MacKay and Imhof 1993) endothelial cells (Osborn et al
1989), but binds selectively to lymphocytes and not to neutrophils (Osborn et al 1989).
Intercellular adhesion molecule-1 (ICAM-1) is expressed by endothelial cells, lymphocytes,
monocytes and fibroblasts in vivo (Dustin et al 1986); high levels of ICAM-1 expression are
induced by cytokines (e.g. IL-1), are maximal at 24 hours, and are maintained for 72 hours in
vitro (Dustin et al 1986, Wawryk et al 1989). An integrin, leukocyte function-associated
antigen (LFA-1), expressed on all blood mononuclear cells, acts as a ligand for ICAM-1
(Preito et al 1988). Leukocyte adhesion to endothelium occurs in three stages (Fig. 1.1,
reviewed in Springer 1994). The initial attachment of leukocytes to a vessel wall is mediated
by selectins (P- or E-selectin [ELAM-1] on endothelium, L-selectin on leukocytes), leading to













Figure 1.1. Diagram of the three stages involved in cell trafficking. Stage 1: The initial attachment of
leukocytes (1.1) to a vessel wall is mediated by selectins (P- or E-selectin on endothelium, L-selectin on
leukocytes), leading to "rolling adhesion" (1.2). Stage 2: The activation of leukocyte integrins (2 and 3)
results in firm attachment of the leukocyte to endothelium via LFA-1 and ICAM-1 or VCAM-1 and VLA-4
(integrin). Stage 3: The leukocyte then alters shape and migrates through the endothelium, in response to
chemoattractants.
52
leukocyte to endothelium via LFA-1 and ICAM-1 or VCAM-1 and VLA-4 (integrin). The
leukocyte then alters shape and migrates through the endothelium, due to chemoattractants
(Colditz 1991a, Springer 1994).
Mast cell-derived mediators, including histamine, prostaglandins and leukotrienes,
proteoglycans, proteinases and cytokines may all contribute to the vascular and cellular
responses that accompany cutaneous inflammation. Each mediator, and its prospective role in
cutaneous inflammation, will be briefly discussed below.
1.8.2. Mast Cell-Derived Mediators
1.8.2.1. Histamine
Histamine (P-imidazolyethylamine) is stored, preformed, in mast cell granules, bound to the
anionic side chains of proteoglycans from which it is released upon secretion (Falus and
Meretcy 1992). Once released it diffuses rapidly into surrounding tissues, appearing in blood
within 2V2 minutes and returning to baseline levels within 15 to 30 minutes (White, Slater and
Kaliner 1987). Histamine evokes increased vascular permeability (following endothelial cell
contraction and junctional widening) by causing leakage from small and medium sized
venules, these vessels having a greater concentration of histamine receptors than either
arteriolar or capillary endothelium (Pasyk and Cherry 1990).
In skin, all of the cardinal features of urticaria (vasodilation, increased vascular permeability
and pruritus) can be mediated via the Hi receptor (White 1990). However the classical "triple
response" effects of histamine in skin (i. Central erythema due to histamine-induced
vasodilation, ii. Peripheral erythema due to neuropeptide-mediated axon reflex
vasodilation, iii. Weal formation due to increased vasopermeability by histamine) require a
combination of both Hr and H2-receptor antagonists to be completely abrogated (Robertson
and Greaves 1978).
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In addition to the effects on vasopermeability in skin, histamine can also regulate the
production of cytokines (e.g. i. Down-regulation of IL-1 and TNF-a production from human
monocytes, ii. Potentiation by IL-1 of the effect of histamine-induced release of prostaglandins
by endothelial cells (Revtyak et al 1988), iii. Inhibition of T cell proliferation and
immunoglobulin production, iv. Enhancement (via the Hi receptor) or inhibition (via the H2
receptor) of the generation of complement and acute phase proteins (reviewed in Falus and
Meretey 1992)). Histamine acts upon endothelial cells via H2 receptors to release PGI2
(prostacyclin), which is a potent inhibitor of platelet aggregation (Harvima and Schwartz
1993).
Plasma leakage in response to intradermal injection of histamine in ovine skin occurs
maximally by 10 minutes following injection, and effectively ceases 30 minutes thereafter
(Colditz 1991b), although no histological analysis of the intradermal test site for the presence
of a cellular infiltrate was undertaken. As mast cells are in close proximity to dermal blood
vessels, a rapid increase in vasopermeability can occur due to the release of histamine and
other newly-generated lipid mediators upon activation (see below), and other broader effects
on the skin immune system can be evoked.
1.8.2.2. Prostaglandins And Leukotrienes
As discussed above, activated mast cells can generate PGD2, LTB4, LTC4 and LTD4 from
arachidonic acid. PGD2 (produced predominantly by the CTMC subset of most species) is a
potent vasodilator, whereas LTC4 and LTD4 evoke a short-lived vasoconstriction (Dahlen et al
1981) followed by an increase in vascular permeability (Orange and Austen 1972, Dahlen et
al 1981). In the skin, these mediators may act synergistically (Soter et al 1983), thereby
augmenting the LTB4-mediated accumulation of neutrophils. PGD2 levels are increased in
blood following urticarial reactions (Heavey et al 1986). The weal response to LTC4 and
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LTD4 is of greater duration (weal 2 hours, erythema 6 to 8 hours; Soter et al 1983) than that
due to histamine or PGD2) the mechanism for this being due to arteriolar constriction and then
vasodilation, venular permeability being subsequently increased (discussed in Harvima and
Schwartz 1993).
In sheep, as in man (Soter et al 1983), intradermal injection of LTB4 evokes dermal neutrophil
influx (Colditz and Movat 1984, Colditz and Watson 1992). LTB4 failed to evoke ovine
neutrophil migration in vitro (Mulder and Colditz 1993), the in vivo LTB4-induced neutrophil
influx depending neither on the induction of adhesion molecules nor on synthesis of IL-8
(Mulder and Colditz 1993). One possible mechanism for the observed neutrophil influx could
be direct activation of neutrophils by LTB4 (Krogsgaard Thomsen 1991), resulting in the
development of neutrophil-induced oedema (Wedmore andWilliams 1991) and subsequent
increased neutrophil influx. LTB4 also potentiates the differentiation of IL-4-responsive B
lymphocytes, which is of particular relevance as activated mast cells are one of the major
sources of IL-4 in skin (Bradding et al 1992, Horsmanheimo et al 1994), this possibly
contributing to the regulation of immunoglobulin production (particularly IgE).
Although it is not known which of the arachidonic acid metabolites can be produced by
activated ovine dermal mast cells, it is known that ovine CM-BMMC can be activated by
A23187 to release LTC4 (Huntley et al 1992). This indicates that mast cell-derived
arachidonic acid products are likely to contribute to vasopermeabiltiy changes in ovine
cutaneous inflammation.
1.8.2.3. Proteoglycans
As discussed previously, heparin is the predominant proteoglycan present in CTMCs. Both
tryptase (Caughey et al 1988a) and chymase (Sayama et al 1987) are bound to heparin upon
release, this binding enhancing the activity of human chymase (McEuen, Sharma and Walls
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1995) and stabilising tryptase (Schwartz and Bradford 1986). Heparin may also modulate the
cell adhesion properties of vitronectin, fibronectin and laminin (Kjellen and Lindahl 1991),
activated mast cells being capable of adherence to both vitronectin (Bianchine, Burd and
Metcalfe 1992) and fibronectin (Dastych et al 1991). Heparin also possesses anti-coagulant
and anti-complement properties. Therefore, dermal mast cell-derived heparin release would be
pro-inflammatory overall, although it may also have a role in cell repair, as capillary
endothelial cells can be activated by heparin in vitro (Harvima and Schwartz 1993).
1.8.2.4. Mast Cell Proteinases
1.8.2.4.1. Biological substrates
Binding of human chymase to heparan sulphate (a component of the basement membrane) and
to the basement membrane in skin itself was demonstrated immunohistochemically (Sayama et
al 1987), this process leading to degradation of Hie epidermal-dermal junction (Briggaman et
al 1984) and subsequent dermatopathology (Schechter 1989) that is usually associated with
immune-mediated disease, particularly bullous pemphigoid (Goldstein, Wasserman and
Wintroub 1989). Chymases can also degrade the interstitial matrix in skin (Sage, Woodbury
and Bornstein 1979, Seppa, Vaananen and Korhonen 1979), which may imply a role for
chymases in cutaneous inflammation and repair.
Human tryptase has a relatively restricted protein substrate specificity, leaving most
uncleaved (Schwartz 1995). For example, tryptase is unable to directly activate
procollagenase nor degrade proteoglycan or collagen (Johnson and Cawston 1985), although it
converts prostromelysin to stromelysin (matrix metalloproteinase 3) which in turn activates
latent collagenase (Gruber et al 1989). Given that tryptase can also activate fibroblasts
(Ruoss, Hartmann and Caughey 1991), tryptase may be involved in the repair and resolution
of cutaneous inflammatory responses. Chymase, released following mast cell activation, has
also been shown to be responsible for alterations in the coherent structure of fibroblast
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monolayers in vitro (Ginsburg et al 1989). A putative role for chymase in enhancing the
spread of transudate during inflammatory responses was speculated (Ginsburg et al 1989).
Additionally, activated mast cells have recently been shown to be fibrogenic for 3T3
fibroblasts (Levi-Schaffer and Rubinchik 1995). This is supported by the observation that
epithelial permeability can be markedly increased in an ex vivo rat intestinal perfusion system
by RMCP-II (Scudamore et al 1995). Chymases may be able to up-regulate mast cell
responses, as rat chymase can activate mast cells in vitro (Schick, Austen and Schwartz 1984,
Schick and Austen 1986). Tryptase may also degrade neuropeptides (discussed later),
generate C3a (Schwartz et al 1983) and possess anticoagulant attributes due to fibrinogen
degradation (Schwartz et al 1985).
Enzymatic degradation is considered one of the major methods for peptide inactivation and
thus for the regulation of neuropeptide-induced inflammatory responses in vivo (Tam 1995).
Substance P can be degraded by dog (Caughey et al 1988d), rat (Le Trong, Neurath and
Woodbury 1987), human (Urata et al 1990) and ovine (SMCP; Pemberton, Huntley and
Miller, submitted) chymases, although tryptase has no effect on sP. Chymases can degrade
the vasodilatory peptides bradykinin and kallidin (Reilly, Schechter and Travis 1985) and
convert angiotensin I to angiotensin II (a vasoconstrictor) dependent on the source of chymase
(Reilly et al 1982, Wintroub et al 1984, Urata et al 1990). Vasoactive intestinal peptide (VIP)
is also degraded by dog chymase and tryptase (Caughey et al 1988d). Tryptase can also
degrade CGRP, but has no effect on neurokinins A or B (Tam and Caughey 1990, Harvima
and Schwartz 1993). It is also known that the activity of CGRP and VIP declines upon
hydrolysis by tryptase (Walls et al 1992, Franconi et al 1989). The possible contribution of
the mast cell (and particularly mast cell proteinases) to cutaneous neurogenic inflammation
due to the close anatomical relationship between mast cells and cutaneous nerves (Wiesner-
Menzel et al 1981) has been widely reviewed (Goetzl et al 1986, Baraniuk, Kowalski and
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Kaliner 1990, Foreman 1993, Fantini et al 1995). However, no study has definitively
described the cleavage of a peptide by a mast cell proteinase following mast cell activation in
vivo. Intradermal injection of sP attenuated the prolonged vasodilation induced by injection of
CGRP in human skin and this was postulated to be due to the release of proteases from
sP-activated mast cells (Brain and Williams 1988), although this was not conclusively proven.
It is known from studies in mast cell-deficientWBB6Fi-W/Wv and WCB6Fi-5//5f' mice that
intradermal injection of sP evokes both an increase in vascular permeability and granulocyte
influx that is mast cell dependent (Matsuda et al 1989, Yano et al 1989). (The granulocyte
infiltration is, in part, due to direct activation of vascular endothelial cells by the C-terminal
end of the sP peptide [Iwamoto et al 1992, Tomoe et al 1992] and expression of ICAM-1
[Nakagawa, Sano and Iwamoto 1995]). However, it is not known what contribution is played
by mast cell proteinases in this sP-induced response. Further evidence which implies, but does
not define, a role for mast cell proteinases in neurogenic inflammation is suggested by
immunohistological studies of dermatoses purported to have a neurogenic component. For
example, the number of tryptase-containing mast cells are increased in lesions of psoriasis
(Harvima et al 1993), the tryptase being in an active form at all levels within the skin
(Harvima et al 1989). Contacts of neuropeptide-containing sensory nerves with
tryptase-containing mast cells are also increased in psoriasis (Harvima et al 1994), the nerve
fibres staining positively for sP and CGRP, but not for VIP, in lesional skin (Naukkarinen et
al 1994). Tryptase also apparently evokes histamine release from ovine dermal mast cells in
vivo (Molinari et al, in press). There is thus some evidence for a role for mast cells and their
granule proteinases to contribute to neurogenic inflammation, although the extent of this




When injected intradermally, human chymase and tryptase preparations increase vascular
permeability and leukocyte infiltration in rabbit skin (Fraki 1977). When human lung tryptase
was injected intraperitoneally in mice, there was an influx of neutrophils (Walls et al 1994).
Similarly, dermal neutrophil accumulation was induced apparently equally by intradermal
injection of human chymase or tryptase in guinea pig skin (Walls et al 1994), indicating that
mast cell chymase and tryptase release in skin may be associated with neutrophil recruitment.
Rat chymase was also shown to cause pruritus when injected into human subjects
(Hagermark, Rajka and Bergqvist 1972) and the intradermal injection of canine chymase
potentiated histamine induced weal formation in the dog (Rubenstein et al 1990). Recently, in
ovine skin, intradermal injection of tryptase isolated from a human neoplastic mast cell line
(HMC-1) was associated with a histamine-mediated weal response that was increased in
magnitude by the co-injection of heparin (Molinari et al, in press), which indicates that (as
discussed previously), activity of mast cell proteinases may be modulated by the presence of
heparin (McEuen, Sharma and Walls 1995).
1.8.2.4.3. Effects on cytokines
Human chymase converts pro-IL-l() to active IL-1 (Kupper et al 1990, Mizutani et al 1991)
which, amongst many actions (see below) can directly activate vascular endothelial cells
(Pober 1988). Human chymase has been shown to inactivate IL-4 (Delara et al 1994a, Delara
et al 1994b).
The evidence provided above suggests that mast cell tryptase and chymase may contribute to
cutaneous inflammatory responses. The function of these proteinases may involve vascular
and epithelial permeability changes as suggested by the work, in vivo, of Rubenstein et al
(1990) and Scudamore et al (1995). Further suggestive evidence of a pro-inflammatory role
in cutaneous inflammation arises from the ability of chymase to generate IL-1 (Kupper et al
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1990, Mizutani et al 1991), and development of dermal neutrophilic infiltrates following
injection of proteinases in vivo (Walls et al 1994).
Whether proteinases activate endothelium directly via proteinase-activated receptors (Altieri
1995, Coughlin 1994) to promote this infiltration is open to speculation, but this would be an
additional mechanism by which proteinases could modulate inflammatory responses. The role
of proteinases in neurogenic inflammation is currently open to debate, although there is
supportive data associating mast cells with neurogenic responses. Currently, relatively few
biological substrates for mast cell chymase and tryptase have been identified in vivo.
However, those substrates identified so far suggest possible effects for these proteinases on the
extracellular cell matrix, on the basement membrane and on fibroblasts, indicating a role in
the modulation and resolution of inflammatory responses in skin.
1.8.2.5. Mast Cell-Derived Cytokines
Mast cells, following activation by immunological or non-immunological stimuli, can generate
or release various cytokines (reviewed in Gordon, Burd and Galli 1990), which are now
thought to play a major role in the pathogenesis of cutaneous inflammation (reviewed in
Harvima et al 1994). Although various mast cell-derived cytokines may participate in
cutaneous responses (Table 1.6), the two of most probable relevance to the studies described
in this thesis are tumour necrosis factor-a (TNF-a) and interleukin-8 (IL-8), these being
discussed in detail below. However, it should be remembered that many other cell types in
skin can generate cytokines (e.g. keratinocytes; Luger and Schwarz 1990, McKay and Leigh
1991) and thus the mast cell may be a relatively minor contributor to the overall production of
cytokines in skin.
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Cytokine Evidence for mast 1
cell-derived mRNA or
bioactivity
Evidence for a role in cutaneous
responses in vivo
Interleukin-1 (IL -1) Burd et al 1989
C
Dowd, Camp and Greaves 1989
ybulsky, Colditz and Movat 1986
Colditz and Watson 1992
IL-3 Burd etal 1989
Wodnar-Filipowicz, Heusser
and Moroni 1989
Volc-Platzer et al 1991
IL-4 Plautetal 1989 Kay etal 1991
Dvorak et al 1994
1I.-5 Burd etal 1989
Plaut el al 1989
Kay etal 1991
IL-6 Burd etal 1989
Plaut et al 1989
Grossman et al 1989
Basic fibroblast
growth factor
ic Qu etal 1995 Qu etal 1995
Transforming gro
factor-3
wth Gordon and Galli 1994 Roberts et al 1986
Gordon and Galli 1994
"C-C" chemokirles Burd etal 1989
Selvan, Butterfield and
Krangel 1994
Alam et al 1994




Table 1.6. Evidence supporting the mast cell origin of selected cytokines, and also for the
participation of these cytokines in cutaneous responses in vivo.
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1.8.2.5.1. TNF-a
TNF-a is a potent immunoregulatory cytokine produced by many cutaneous cells, including
mast cells, keratinocytes and Langerhans cells (reviewed in Lc and Vilcek 1987, Piguet 1993).
Mast cells contain pre-formed stores of TNF-a that is available for immediate release upon
activation (Plaut et al 1989), mast cells being the prominent TNF-a-containing cell in human
dermis (Walsh, Lavker and Murphy 1990). The injection of TNF-a into human (Groves et al
1995) or ovine (Colditz and Watson 1992) skin is pro-inflammatory, evoking a marked dermal
neutrophilic infiltrate. TNF-a failed to induce ovine neutrophil migration in vitro (Mulder
and Colditz 1993). IgE-dependent activation of mast cells induces release of pre-formed
stores of TNF-a and also induces both TNF-amRNA production and TNF-a synthesis
(Gordon and Galli 1990a). Human dermal mast cells activated by morphine sulphate, release
preformed TNF-a with immunoreactivity for TNF-a declining within 45 minutes (Walsh et al
1991). In the same study, ELAM-1 expression was induced as a direct consequence of mast
cell-derived TNF-a release (Walsh et al 1991), and in human skin ELAM-1, VCAM-1 and
ICAM-1 expression was induced by TNF-a injection (Groves et al 1995). Using the WAVV
mast cell-deficient mouse, almost all of the neutrophil infiltration occurring in IgE-dependent
passive cutaneous anaphylaxis (PCA) reactions was shown to be mast cell dependent (Wershil
et al 1991). Using an anti-TNF-a antibody, mast cell-dependent leukocyte infiltration was
reduced by about 47% in this study (Wershil et al 1991). Thus, mast cell-derived TNF-a
plays a prominent role in the dermal cellular influx that occurs following mast cell activation.
Furthermore, dexamethasone and cyclosporin A reduce mast cell-derived TNF-a mRNA
synthesis and TNF-a production in the same IgE-dependent PCA reactions (Wershil et al
1995), indicating a possible mechanism of action (by suppression of cytokine cascades) for
these agents in the treatment of allergic disease.
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In studies of immune complex-mediated inflammation using the peritoneal reverse passive
Arthus reaction, mast cells were responsible for the first part of the observed biphasic peak of
TNF-a production (Zhang, Ramos and Jakschik 1992a), this initial phase of mast cell
activation being due to complement (Ramos, Zhang and Jakschik 1994). Thus, mast
cell-derived TNF-a has a role to play in IgE-dependent, IgE-independent and immune
complex-mediated inflammation, all of which can occur in skin.
TNF-a also evokes microvascular leakage that can be neutrophil-dependent (Yi and Ulich
1992) or neutrophil- and mast cell-independent (Anderson et al 1994). TNF-a can therefore
contribute directly to the vascular, as well as the cellular, components of cutaneous
inflammation.
1.8.2.5.2. IL-8
IL-8 is a pro-inflammatory peptide of the "C-X-C" chemokine (chemoattractant cytokine)
family, produced abundantly by endothelial cells, fibroblasts and keratinocytes when activated
by primary cytokines (IL-la or (3, TNF-a). IL-8 binds to lumenal endothelial surface
glycosaminoglycans and activates leukocytes rolling on endothelial selectins (see above;
reviewed in Schall and Bacon 1994), it may, therefore, regulate the cellular infiltrate in
chronic inflammatory dermatoses (Schroder 1995). A human mast cell leukaemia line
(HMC-1) was shown to generate various chemokines including IL-8 (Selvan, Butterfield and
Krangel 1994), with exogenous IL-4 increasing IL-8 gene expression in the same cell line
(Buckley et al 1995). If this occurs in vivo, it would provide a mechanism for mast cell
amplification of the inflammatory response. Human mast cells (including those from skin)
could not be activated to release histamine by IL-8, unlike human basophils (Ftireder et al
1995b). Recombinant human IL-8 (rHu.IL-8) acts as an attractant in vitro for neutrophils of
various species (Rot 1991), and specifically for those of the sheep (Mulder and Colditz 1993).
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Intradermal injection of IL-8 in human skin evokes a neutrophilic infiltrate, in the absence of
lymphocytes (Swensson et al 1991). No weal response nor mast cell degranulation was
observed (Swensson et al 1991). Initial experiments with intradermal injections of
neutrophil-activating peptide-1 (NAP-1; IL-8) in the sheep demonstrated that rapid neutrophil
influx ensued (the rate of influx being maximal in the first 30 minutes, and detectable for up to
8 hours), with concomitant plasma leakage of shorter duration (ceased by 6 hours; Colditz,
Zwahlen and Bagglioni 1990). Further studies with rHu.IL-8 in ovine skin confirmed the
presence of a marked neutrophilic infiltrate with few lymphocytes (Colditz and Watson 1992).
Intradermal challenge with recombinant ovine IL-8 in ovine skin gave similar results, with a
marked neutrophilic infiltrate also being accompanied by small numbers of eosinophils and
increased numbers of CD4+ cells (Seow et al 1994). Assuming that ovine dermal mast cells
prove to be capable of IL-8 generation (similar to the HMC-1 cell line) then mast cell-derived
IL-8 could play a major role in ovine cutaneous responses characterized by a markedly
neutrophilic dermal infiltrate.
1.8.2.5.3. Mast cell-derived cytokine co-ordination in cutaneous inflammation.
In addition to the comparatively immediate effects of some of the mediators described above
(histamine, prostaglandins and leukotrienes, proteoglycans, chymases) on vascular
permeability, endothelial cell activation and inflammatory cell influx into the dermis, there is
probably a longer term, co-ordinated control of the resulting cytokine cascade. This will not
only involve mast cell-derived cytokines (whose contribution will be relatively minor in terms
of overall cytokine production in skin) but cytokines produced as a consequence of activation
of other cell types. Given that relatively little is known concerning the kinetics ofmast
cell-derived cytokine production in skin, the following is a brief and largely speculative
review, predominantly based on in vitro findings from cultured mast cell populations.
Immediately after mast cell activation, markedly pro-inflammatory cytokines (particularly
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TNF-a, but also IL-1, IL-6 and the members of the chemokine family) will rapidly activate
endothelial cells and cause increased vascular permeability and emigration of leukocytes to the
site of inflammation. The mRNA for this group of cytokines increases within 30 to 60
minutes after IgE-dependent activation (Burd et al 1990, Gordon and Galli 1990a), this
response in the case of TNF-a receding within 4 hours of activation (Gordon and Galli
1990a). In the later stages of inflammation, late-generated cytokines mediating autocrine or
paracrine events such as IL-13 (reducing the inflammatory activity of TNF-a and IF-1),
TGF-(3 (to stimulate collagen deposition with the development of fibrosis and to act as a mast
cell attractant), IF-5 (to recruit and activate eosinophils), IF-3, IL-4 and GM-CSF (to alter the
proliferation or function of cells recruited to the site, including mast cells) become of greater
importance in the inhibition and resolution of the inflammatory response. For example,
different combinations of cytokines are believed to support the four phases of cellular
trafficking in the skin [initiation, vasoinduction, effector and resolution](Walsh, Favker and
Murphy 1990). Supporting the above concept of late-generated cytokines, in IgE-mcdiated
BMMC activation increased levels ofmRNA for IL-3, IF-5 and GM-CSF did not appear until
comparatively late in the response (-120 minutes; Burd et al 1990, Gordon and Galli 1990a).
As well as the co-ordinated timing of the cytokine cascade, the nature of the inflammatory
response and subsequent local microenvironment may dictate the mast cell-derived cytokines
produced. In active human psoriasis for example, it is speculated that dermal mast cells
contain IFN-y, this being released upon activation to stimulate the development of Tm -cells
and to induce ICAM-1 on keratinocytes, thereby potentiating the dermatosis (Harvima et al
1994). In contrast, in human cutaneous atopic disease it is speculated that mast cells contain
and release IF-4 upon activation, favouring the development a T^-cell subset and further
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amplification of the response (Harvima et al 1994). Thus, the local microenvironment (e.g.
psoriatic versus atopic skin) could dictate the pattern of mast cell cytokine response.
1.8.3. Experimental Models OfMast Cell Involvement In Cutaneous Pathology In Vivo
The evidence for the possible contribution of individual mast cell mediators to cutaneous
responses has been outlined above. To further support the contention that dermal mast cells
can initiate or modulate cutaneous inflammatory responses a brief discussion of cutaneous
diseases (selected from both animal models and clinical conditions) in which mast cell
involvement has been defined is necessary. Mast cells, and their involvement in both acute
and chronic (or late phase) cutaneous responses have been the subject of several recent
reviews (Charlesworth 1994, Harvima et al 1994, Marshall and Bienenstock 1994).
The use of the WAVv mouse model (which has defective c-kit receptor production), that allows
local reconstitution of dermal mast cells can be achieved by intradermal injection of
CM-BMMC obtained from congenic normal (+/+) mice, enables the contribution of the
dermal mast cell in cutaneous responses to be elegantly assessed (reviewed in Galli, Tsai and
Wershil 1993). W/W mice were initially shown to possess a defect in resistance to
Haemaphysalis longicortiis ticks, which could be rescued by either bone marrow or skin
transplantation from the congenic normal (+/+) mice (Matsuda et al 1985). Tliis implied that
mast cells were important in tick resistance. Further studies using locally dermal mast
cell-reconstituted WAVV mice demonstrated that resistance was conferred only at sites where
the local deficiency of dermal mast cells had been repaired (Matsuda et al 1987) and that both
IgE antibodies and mast cells were essential for tick resistance (Matsuda et al 1990). The
mast cell was shown to play a crucial role in murine tick resistance, this possibly having
particular relevance to the sheep, where ectoparasite infestation is common. Idiopathic
chronic dermatitis occurs spontaneously in both WAVV and Sl/Sl'1 mice, this resulting in the
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local development of mature mast cells at the site of dermatitis lesions in the former but not
the latter (Galli et al 1987), possibly indicating microenvironmental generation of growth
factors. Certainly, mast cell hyperplasia has been associated with dermatitis of varying
aetiologies (Yamamoto et al 1995). Using phorbol 12-myristate 13-acetate (PMA) as a
non-immunologic mast cell activator in Sl/Sld, WAV\ locally mast cell reconstituted W/Wv and
congenic normal (+/+) mice, it was demonstrated that the presence of mast cells increased
both the tissue swelling and influx of leukocytes into the dermis, thereby amplifying this
non-immunologic response (Wershil, Murakami and Galli 1988). Repeated cutaneous
application of PMA results in the development of both a dermatitis and a significant increase
in dermal mast cell numbers in both WAW and congenic normal (+/+) mice, these mast cells
being able to express an IgE-dependent PCA response (Gordon and Galli 1990b). The
deposition of fibrin in IgE-dependent immediate hypersensitivity reactions using W/Wv and
locally dermal mast cell-reconstituted WAV" mice was shown to be mast cell-dependent
(Wcrshil et al 1987), Uiis study also proving that mast cells are required for PCA reactions.
In the same model, where IgE-dependent and contact sensitivity (using oxazolone) reactions
performed simultaneously at the same site were compared in terms of fibrin deposition against
the same two reactions occurring separately at different sites, the effect of IgE-dependent mast
cell activation on the contact sensitivity response was to increase fibrin deposition by 3 to 25
times between 2 and 6 hours post-challenge (Mekori and Galli 1990). There was no effect of
mast cell deficiency on the ability to express contact sensitivity responses, however fibrin
deposition was noted as soon as two hours after initiation of the response (Mekori and Galli
1990). Therefore, mast cells were shown to be necessary for the IgE-mediated augmentation
of fibrin deposition in contact sensitivity responses, but not for the fibrin deposition in contact
sensitivity responses themselves (Mekori and Galli 1990). In studies on the role of sP in
neurogenic inflammation using WAW and Sl/Sld mice, the increase in vascular permeability
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and neutrophil infiltration was shown to be predominantly mast cell-dependent (Yano et al
1989). The dermal mast cell was also shown to enhance the inflammatory process in
cutaneous immune-complex-induced injury (reverse Arthus reaction), local reconstitution of
mast cells in WAVV mice increasing neutrophil emigration and oedema to the same level as in
+/+ controls (Zhang, Ramos and Jakschik 1991). Additionally, the contribution of the dermal
mast cell and mast cell-derived histamine and leukotrienes to immune-mediated basement
membrane damage in skin was ascertained (Zhang, Ramos and Jakschik 1992b). The mast
cell-deficient mouse model was also used to show that the subcutaneous injection of rrSCF
into Sl/Sld or +/+ congenic normal mice induced the development ofCTMC, in part due to the
proliferation of differentiated dermal mast cells (Tsai et al 1991b).
Thus, the use of W/Wv or SI/SI'1 mast cell-deficient mice has allowed the contribution of the
dermal mast cell to be ascertained in various cutaneous responses (i. Non-immunologic,
ii. IgE-mediatcd, iii. Contact sensitivity, iv. Neuropeptide-induccd, v. Immune
complex-mediated).
1.9. Aims Of The Study
Comparatively little is known specifically about the ovine dermal mast cell and ovine mast cell
heterogeneity, although from the above there is ample in vitro and in vivo evidence to
implicate mast cells and mast cell-derived mediators in the pathogenesis of cutaneous
inflammation. Furthermore, few studies have addressed the question of the role of direct mast
cell activation on the alteration of dermal inflammatory cell trafficking in vivo. The aims of
the study were therefore:-
1) To determine if mast cell heterogeneity, as defined in other species by differences between
tissues in the distribution ofmast cell chymase, existed in the sheep.
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2) To characterize and define, using secretagogues known to activate cutaneous mast cells in
other species, the inflammatory responses and changes in dermal inflammatory cell trafficking
evoked by these agents in the sheep in vivo.
3) To determine if the ovine chymase SMCP could evoke an inflammatory response when
injected into the skin of the homologous host in vivo and, if so, to characterize this cutaneous
response.
4) By cannulating afferent lymphatics in flank skin, to monitor the changes in inflammatory
cell trafficking through the dermis after direct mast cell activation with the secretagogues
defined in (2) above and, similarly, following injection of SMCP (Discussed in Chapter 8).
5) To characterize the in vitro kinetics of development of rOv.IL-3 BMMC, their mediator
content and likely heterogeneity.
6) To determine the functional activity of optimally cultured rOv.IL-3 BMMC in response to






All chemicals, (unless indicated otherwise) were purchased from either BDH Ltd., Poole,
Dorset, UK. ('AnalaR' [analytical reagent] or GPR [general purpose reagent] grades), Sigma
Chemical Company Ltd., Poole, UK or Fisons Scientific Equipment, Loughborough, UK.
2.2. Animals
All sheep were bred at the Moredun Research Institute, Gilmerton Road, Edinburgh and were
either Blackface, Suffolk-cross or Finn-Dorset crosses. For tissue culture studies animals
were between four and nine months old, whereas cast ewes were used in all other studies. All
experiments involving the use of animals conformed to ethical guidelines and were peer
reviewed by committee (including statistical assessment of the study protocol) before being
undertaken. All sheep to be housed were treated with a topical ectoparasiticide to remove lice
and other ectoparasites (deltamethtrin 1% w/v, Spot On Insecticide, Coopers®; Pitman-Moore
Ltd., Crewe, UK) four weeks before being housed, and once while housed.
2.3. Ovine Bone Marrow Cultures
2.3.1. Ovine Bone Marrow Cell Culture Set-up
Immediately post mortem, the sternum of a four to nine month old lamb was removed, sprayed
with 70% alcohol and the attached fat and muscle removed. After again spraying with
alcohol, the sternum is placed in a vice, and sawn longitudinally (manubrium to xiphoid). The
half-sternum is clamped in the vice (cut surface uppermost), pressure applied, and the bone
marrow expressed. Using a sterile scalpel blade or sterile 5ml syringe (Plastipak, Becton
Dickinson, Oxford, UK, Cat.No. 302187) with a sterile 19g needle (Microlance®, Becton
Dickinson, Oxford, UK, Cat.No. 001500110) the bone marrow is collected and placed into a
universal containing Hanks' Balanced Salt Solution (HBSS)(Gibco BRL, Life Technologies
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Ltd., Paisley, UK, Cat.No. 041-04020M) to which penicillin, streptomycin and heparin has
been added (HBSS/heparin medium, Appendix A). The closed universal is sprayed with
alcohol, transferred to sterile conditions in a tissue culture hood (ICN Flow Gelaire® Class II
BSB48, ICN Pharmaceuticals Ltd., Thame, UK) and allowed to settle. The cell suspension
from below the fat layer is removed and passed through a double layer of sterile lens tissue
into a clean universal. The cell suspension is then spun at 1300 r.p.m. in a Beckman® Model
TJ-6 centrifuge at 4 °C for five minutes. Six universals are prepared, each containing 8ml of
Lymphoprep™ (Nycomed Pharma AS, Oslo, Norway, Cat.No. 1001967). The cell pellet is
resuspended in 24ml HBSS/heparin, and this suspension divided equally between the six
Lymphoprep™ universals. The cell suspension is carefully layered onto the Lymphoprep™
using a 5ml sterile disposable pipette (Sterilin, Bibby Sterilin Ltd., Stone, UK, Cat.No.
03122). Without agitation, the universals are placed in the centrifuge and spun at 1800-2000
r.p.m. for 30 minutes at 4 °C. The interface cells are collected using a sterile syringe and
needle, and placed in a 50ml centrifuge tube (Costar UK Ltd., High Wycombe, UK, Cat.No.
6751). HBSS/heparin is added to a total volume of 50ml to wash the cells, and the suspension
centrifuged at 1300 r.p.m. for five minutes at 4 °C. This washing procedure is repeated twice.
The final pellet is resuspended in Iscove's Modification of Dulbecco's Medium (IMDM) to
which heat-inactivated foetal calf serum, penicillin and streptomycin has been added
(IMDM/10% FCS; Appendix A). A viable cell count is undertaken and the cells plated out at
2 x 105 cells/ml of tissue culture medium in either sterile, disposable 24 well tissue culture
plates (24Well Cell Culture Cluster, Costar UK Ltd., High Wycombe, UK, Cat.No. 3524) or
flasks (75cm2 canted neck flasks, Corning Inc., New York, USA, Cat.No. 25110-75).
Recombinant ovine interleukin-3 (rOv.IL-3), a generous gift from Dr.G. Entrican (Moredun
Research Institute, Edinburgh), was used to supplement the fMDM/10%FCS. This had been
expressed in a Chinese Hamster Ovary (CHO) cell expression system (MTnnes, Haig and
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Logan 1993), the rOv.IL-3 being in the form of a tissue culture supernatant. In the case of
experiments where 24 well tissue culture plates were used, the batch of rOv.IL-3 used was
3/2/4/TF/3/A/19/2/10; 750pM MSX + FBS 1/8/94. The inclusion ratio of rOv.IL-3 was
expressed as the final dilution of this original supernatant in each tissue culture well or plate.
Cells were maintained in an atmosphere of 5% C02/air at a temperature of 37 °C in a tissue
culture incubator (ICN Flow Automatic C02 Incubator Model 160, ICN Pharmaceuticals
Ltd., Thame, UK). Cells were generally fed every five to seven days. For 24 well plates this
involved removal of a known volume of supernatant without agitating the plate, and
replacement of this with an equivalent volume of fresh medium. The progress of the culture
was routinely monitored by daily examination under a Leica DM 1L microscope (Leica
Microscopy, Germany, Cat.No. 520802/152192), and by microscopic examination of
Leishman's and/or anti-SMCP stained cytosmear preparations.
2.3.2. Harvesting Procedure For Cell Populations In 24 Well Plates
Without disturbing the plate, lOOpl of cell supernatant was removed from the well, placed in
an eppendorf and stored at -70 °C until assayed. The well was then gently agitated to produce
a uniform cell suspension. This was removed and placed in an eppendorf tube, the total
volume of cell suspension being noted. 25Opl of cell suspension was removed and used to
make two 125pl cytosmears (one for Leishman's staining and one fixed for anti-SMCP
immunohistochemistry). A further 15pi of cell suspension was removed and a viable cell
count performed. The remaining cell suspension was centrifuged for 5 minutes (Anderman
Eppendorf centrifuge 5414, Germany) at 12000 r.p.m. The supernatant was discarded, the
cell pellet being stored at -70 °C until being assayed.
73
2.3.3. Cell Counts
Cell viability was assessed by nigrosin dye exclusion. Nigrosin (0.1% nigrosin in PBS;
Nigrosin [Acid Black 2, Cat.No. N4754] from Sigma Chemical Company Ltd., Poole, UK)
was mixed 1:1 with the cell suspension and left for five minutes before being counted. Using
an improved Neubauer haemocytometer, the number of viable and non-viable cells in four
large squares (each comprising 16 smaller squares of total volume 0.1 pi) was counted. After
correcting for the dilution effect due to the addition of nigrosin/PBS, the result was expressed
as the mean number of viable cells per ml of cell suspension.
2.3.4. Cvtosmear Preparations
Cytosmear preparations were prepared using a Shandon Cytospin 2 cytocentrifuge (Shandon
Southern Products Ltd., Runcorn, UK), 125pl of cell suspension (routinely 5 xlO5 cells/ml,
but for cell culture studies (Chapter 6) this was dependent on the cell density in Pre well) being
centril'uged at 600 rpm for five minutes. Cytosmears were air-dried before fixation and/or
staining.
2.3.5. Leishman's Staining Of Cvtosmear Preparations
After air-drying the cytosmear, a sufficient volume of Leishman's staining solution (eosin
mePiylene blue compound 0.2% w/v in methanol, Gurr® microscopy materials, BDH, Poole,
UK, Cat.No.35022) to cover the slide was added for two minutes. An equivalent volume of
distilled water was subsequently added for a further eight minutes. After rinsing thoroughly in
tap water the slides were air-dried and mounted using CoverBond™ (American Scientific
Products, American Hospital Supply Corporation, Illinois, USA, Cat.No. M7639-16)
mountant.
74
2.3.6. Fixation Of Cytosmear Preparations For Immunohistochemistry
After air-drying, cytosmear preparations were fixed in 4% paraformaldehyde (PF; Fisons
Scientific Equipment, Loughborough, UK, Cat.No. P/0840/53)/PBS pH 7.4 (Appendix A) for
1 hour at 45 °C. Fixed preparations were then stored in 70% ethanol at 4 °C until use.
2.3.7 Affinity Purification Of Rabbit Anti-Sheep Mast Cell Proteinase (rabaSMCP)
Polyclonal Antibody From High Titre Serum
Initially an IgG fraction was prepared from high titre anti-SMCP rabbit serum, using a
Protein A-Sepharose column (Pharmacia Biotech Ltd., Milton Keynes, UK, Cat.No. 17-0403-
01) and a Pharmacia® FPLC system. This was to ensure that inhibitors of SMCP
(a2-macroglobulin or rabbit serpins [serine proteinase inhibitors]) were removed prior to the
affinity chromatography step. The Protein A column was initially equilibrated with
PBS/0.01% sodium azide running buffer, pH 7.5. 2ml of serum was applied to the column,
the immediate fiow-tlirough being discarded. The bound IgG fraction was subsequently eluted
with 0.1M citric acid/0.5M sodium chloride pH 2.5 elution buffer. The eluate was titrated to
pH 7.0-7.5 with 1M Tris. The Protein A-Sepharose column was again equilibrated with
running buffer, and a further two runs with high-titre serum undertaken.
SMCP had been previously bound to cyanogen bromide-activated sepharose (CNBr-activated
Sepharose 4B, Pharmacia Biotech Ltd., Milton Keynes, UK, Cat.No. 17-0430-01), to produce
an SMCP affinity column. Once equilibrated with running buffer (see above), the eluted IgG
fraction from the protein A column was applied in aliquots, and the flow-through discarded.
The bound anti-SMCP antibody was eluted using elution buffer (see above) and the pH was
adjusted to pH 7.0-7.5 with 1M Tris. The affinity column was equilibrated with running
buffer and the cycle was repeated until all of the eluted IgG fraction had been affinity purified.
The affinity purified rabocSMCP antibody was concentrated using a collodion bag (Saitorius
Ltd., Epsom, UK, Cat.No. SM 13200) and negative pressure. Once concentrated, a Pierce
75
assay (BCA* Protein Assay Reagent, Pierce & Warriner, Chester, UK, Cat.No., 23225) was
undertaken to determine the protein concentration of the rabaSMCP, and the affinity purified
antibody stored at -70 °C at lmg protein/ml. From the original 6ml of high titre serum,
2.55mg affinity purified rabaSMCP was obtained (i.e. a yield of 0.425mg rabaSMCP/ml
high titre serum). The presence of affinity purified rabaSMCP antibody was confirmed by
titrating on SMCP coated microtitre plates in a modified ELISA, and by positive
immunohistochemical staining of SMCP on tissue sections of ovine thymus or gut and on
cytosmear preparations of ovine bone marrow-derived mast cells grown in the presence of
recombinant interleukin-3. The antibody (batch 148/93) was subsequently titrated for use in
routine immunohistochemical staining of tissue sections and cytosmear preparations.
(N.B. The monospecificity of rabaSMCP prepared by this method had been previously
investigated by Western blotting of samples prepared from homogenales of abomasal tissue,
or extracts of isolated mucosal mast cells from Haemonchus infected sheep (Huntley 1991).
RabaSMCP had been shown to react with a single polypeptide band of MW 25000. No
bands had been observed in control blots where rabaSMCP was substituted with normal
rabbit immunoglobulin. A monoclonal antibody to SMCP was made available towards the
end of the period of these studies, this being shown to have the same degree of specificity as
that of the affinity purified polyclonal antibody).
2.3.8. Demonstration Of SMCP In Fixed Cvtosmears
2.3.8.1. 3,3'- Diaminobenzidine (DAB) Method
Fixed cytosmears, stored at 4 °C in 70% ethanol, were subjected to the following protocol:-
i. Wash in tap water for 15 minutes.
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ii. Treat with 1% aqueous Periodic acid (Periodic Acid GPR, BDH Ltd., Poole, UK,
Cat.No.29842 2P) for five minutes.
iii. Wash in tap water for 10 minutes.
iv. Incubate for five minutes with 0.2% Sodium borohydride GPR (BDH Ltd., Poole, UK,
Cat.No. 301143N) in 1% disodium hydrogen orthophosphate (Fisons Scientific
Equipment, Loughborough, UK, Cat.No.301143N). [Steps (ii) and (iv) are included to
block any endogenous peroxidase activity that may be present; Heydermann and Neville
(1977)].
v. Wash in tap water for 10 minutes.
vi. Place in 5% Bovine serum albumin (BSA, Sigma Chemical Company Ltd., Poole, UK,
Cat.No.A2153 or BSA, protease free, fraction V, ICN Pharmaceuticals Ltd., Thame, UK,
Cat.No.810035)/PBS (Appendix A) for 15 minutes at room temperature.
vii. Incubate with affinity-purified rabbit IgG anti-SMCP (2.5pg /ml 5% BSA/PBS)(Huntley
et al 1986; batch numbers 90/90 and 148/93) in a humidity chamber for 1 hour at room
temperature. Controls consisted of normal rabbit serum (NRS, 1:500 dilution in
5%BSA/PBS) or 5%BSA/PBS in place of rabaSMCP.
viii. Wash three times in PBS.
ix. Incubate in a humidity chamber with goat anti-rabbit IgG-horseradish peroxidase
(2.5pg/ml, Sigma Chemical Company Ltd., Poole, UK, Cat.No.A0545; cross-adsorbed
against sheep IgG, in 5% BSA/PBS) for 1 hour at room temperature.
x. Wash three times in PBS.
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xi. Reveal peroxidase activity with 3,3'-diaminobenzidine (DAB; 3,3'- diaminobenzidine
tetrahydrochloride, Sigma Chemical Company Ltd., Poole, UK [Cat.No.D5637]/PBS
(Appendix A) or Sigma Fast® tablet sets, Sigma Chemical Company Ltd., Poole, UK
[Cat.No.D4293]).
xii. Wash in tap water for five minutes.
xiii. Counterstain with haematoxylin (Ehrlich's haematoxylin original formula, Gurr®
microscopy materials, BDH, Poole, UK, Cat.No. 350172Q) for one minute, wash in tap
water for five minutes.
xiv. Dehydrate stained cytosmears through graded alcohol, clear in xylene and mount in
CoverBond™ (see "Leishman's staining of cytosmear preparations" above).
2.3.8.2. Vectastain ® ABC-Alkaline Phosphatase (ABC-AP) Method
This involved the use of a commercially available biotin/avidin-AP system in conjunction with
the rabocSMCP primary antibody. As optimisation of the system for use on cytosmear
preparations and tissue sections led to differences between the staining procedure
recommended with the Vectastain® ABC-AP kit (Vector Laboratories Inc., Peterborough, UK,
Cat.No. AK5001) and that actually used, the method is outlined in full below.
i, ii, iii. These steps are as outlined above (2.3.8.1.).
iv. Incubate cytosmears for five minutes with 0.2% Sodium borohydride GPR (BDH Ltd.,
Poole, UK, Cal.No.301143N) in 1% disodium hydrogen ortliophospliate (Fisons Scientific
Equipment, Loughborough, UK, Cat.No.301143N). [As a range of tissue sections
including intestine were also stained using this method, steps (iii) and (iv) were included
routinely for all preparations. These steps inhibit the intestinal isoenzyme of alkaline
phosphatase (Bulman and Heydermann 1981)].
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v. Wash in tap water for 10 minutes.
vi. Incubate in normal goat serum (NGS, from kit) at 1:67 dilution in PBS (Appendix A) in a
humidity chamber at room temperature for 20 minutes.
vii. Blot excess NGS from cytosmears.
viii. Incubate with affinity-purified rabbit IgG anti-SMCP (2.5pg rabaSMCP/ml
PBS)(Huntley et al 1986; batch numbers 90/90 and 148/93) in a humidity chamber
overnight at 4 °C. Controls consist of NGS (as above), NRS (1:500 dilution in PBS) or
PBS in place of primary antibody.
ix. Wash in PBS for 10 minutes (4 changes of PBS).
x. Incubate with goat biotinylated anti-rabbit IgG (H + L) (from kit, 1 drop to 10ml PBS) in a
humidity chamber for 1 hour at room temperature.
xi. Prepare Vectastain® ABC-AP reagent (from kit) and allow to stand for 45 minutes before
use (2 drops reagent A plus 2 drops reagent B to 10ml PBS).
xii. Wash cytosmears in PBS for 10 minutes (4 changes of PBS).
xiii. Incubate in a humidity chamber for 60 minutes at room temperature with Vectastain®
ABC-AP reagent.
xiv. Wash in PBS for 10 minutes (4 changes of PBS).
xv. Incubate for 30 minutes in alkaline phosphatase substrate (Vector® Red, [Alkaline
phosphatase kit I], Vector Laboratories Inc., Peterborough, UK, Cat.No. SK-5100) to
which levamisole has initially been added (1 drop of 125mM levamisole [Levamisole
solution, Vector Laboratories Inc., Peterborough, UK, Cat.No.SP-5000] to 5ml lOOmM
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Tris HC1 substrate buffer, pH 8.2). (The addition of levamisole inhibits isoenzymes of AP
other than the intestinal form).
xvi. Wash in tap water for 15 minutes.
xvii. Counterstain with haematoxylin (Ehrlich's haematoxylin original formula, Gurr®
microscopy materials, BDH, Poole, UK, Cat.No. 350172Q) for one minute and wash in
tap water for five minutes.
xviii. Dehydrate stained cytosmears through graded alcohol series, clear in xylene and mount
in CoverBond™.
2.3.9. Toluidine Blue Staining Of Fixed Cvtosmears
Fixed cytosmears, stored in alcohol at 4 °C, were washed in tap water for ten minutes. They
were then placed in 0.5% toluidine blue (Toluidine blue 0, Sigma Chemical Company Ltd.,
Poole, UK, Cat.No. T3260) in 0.5N HC1 pH 0.5 for 30 minutes (Encrback 1966a) before
washing in water and dehydrating through a graded alcohol series. Cytosmears were cleared
in xylene and mounted in CoverBond™.
2.3.10. Enumeration OfMast Cells In Anti-SMCP Stained Cvtosmear Preparations
Cytosmear preparations were routinely stained to demonstrate the presence of SMCP by the
Vectastain® ABC-AP method previously described. Using a Leitz Wetzler Dialux 20 EB
microscope at 500x magnification the number of mast cells identified in a random sample of
200 cells in each cytosmear was noted (based on positive staining for SMCP and compatible
nuclear morphology). The percentage of mast cells present in the cytosmear preparation could
thus be calculated.
80
2.3.11. Extraction Of Cell Pellets For Assay Of SMCP Content, Arylsulfatase And
B-hexosaminidase Activity
This has been previously described by Huntley et al (1992). Cell pellets, stored at -70 °C,
were thawed and 2()0pl of extraction buffer (20mM Tris/HCl buffer pH 7.5 containing 2M
KC1) added. The cell suspension was freeze-thawed rapidly three times with vortex-mixing
between cycles, and centrifuged for two minutes at 12000 r.p.m. (Anderman Eppendorf
centrifuge 5414, Germany). The supernatant was removed and assayed for the appropriate
mediator.
2.3.12. ELISA For Sheep Mast Cell Proteinase (SMCP)
For all initial studies, the SMCP ELISA utilised polyclonal antibodies for capture and
detection of SMCP (method A below). Towards the end of these studies monoclonal
antibodies to SMCP were produced in the laboratory, and thus a polyclonal/monoclonal
antibody ELISA was developed (method B below). All measurements concerning release of
SMCP from rOv.IL-3 derived BMMC were determined using the latter method.
2.3.12.1. Method A : Polyclonal Antibody Based SMCP ELISA
i. Coat 96 well microtitre ELISA plates (M129B [of German origin], Dynatech Laboratories
Ltd., Billingshurst, UK) with 5Opt per well of affinity-purified rabbit IgG anti-SMCP
capture antibody (Batch 114/91) at lpg/ml in 0.1M carbonate ELISA coating buffer, pH
9.6 (Appendix A) overnight at 4 °C.
ii. Wash plates six times with PBS/0.05% Tween 20 (Poloxyethylenesorbitan monolaurate,
Sigma Chemical Company Ltd., Poole, UK, Cat.No. PI379).
iii. Load SMCP standards (0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 and 12.0 ng SMCP/ml) or
samples made up in PBS/0.05% Tween 20 in duplicate onto the coated plate (50pl of
standard or sample per well). Samples were assayed at a range of dilutions (normally 1:10
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to 1:10000) in order that the OD492nm reading of the sample would lie (for at least one of
the dilutions) on the linear portion of the standard curve. Controls consist of 50pl
PBS/0.05% Tween 20 alone. Incubate plate for 1 hour at room temperature.
iv. Wash plate six times with PBS/0.05% Tween 20.
v. Add 50pl of a 1:2000 dilution of rabocSMCP-horseradish peroxidase conjugate (Batch No.
105/91; prepared by G.Newlands, Moredun Research Institute, Edinburgh - conjugation
method as per Nakane and Kawaoi (1974)) in PBS/0.05% Tween 20 to each well, and
incubate the plate for 1 hour at room temperature.
vi. Wash plates six times with PBS/0.05% Tween 20.
vii. Colour reaction was developed by the addition of 50jil per well of orthophenylenediamine
(OPD) in citrate/phosphate buffer, pH 5.0 (Appendix A) or of substrate produced from
SigmaFast™ OPD tablet sets (Sigma Chemical Company Ltd., Poole, UK, Cat.No.
P9187).
viii. Stop colour development by the addition of 25pi of 2.5M H2S04 per well, and read plates
at OD492nm in a Titertek® Multiskan MC Reader (Titertek® Flow Laboratories).
A standard curve produced from the SMCP standard set was plotted using Dynatech data
analysis software (Dynatech Laboratories Ltd., Billingshurst, UK), and the concentration of
SMCP in samples calculated from the linear portion of the standard curve. A sample standard
curve for the SMCP ELISA is shown in Fig.2.1. Results were expressed as ng of SMCP per
cell pellet, as ng SMCP per cell population of the tissue culture well, or as ng SMCP per ml
tissue culture well supernatant. (For assay of tissue samples [see later] results were expressed
as pg SMCP per g wet weight of tissue).
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2.3.12.2. Method B : Polyclonal/Monoclonal Antibody Based SMCP ELISA
i, ii, iii, iv. These steps are as outlined above (2.3.12.1.).
v. Add 50|il of a 1:500 dilution of biotinylated monoclonal rataSMCP antibody (Batch
No. 165/95) in PBS/0.05% Tween 20 to each well and incubate the plate for 1 hour at
room temperature.
vi. Wash plates six times with PBS/0.05% Tween 20.
vii. Add 5Op I of a 1:4000 dilution of Streptavidin-peroxidase conjugate (Streptavidin-POD,
Boehringer Mannheim UK, Lewes, UK, Cat.No. 1089153) to each well, and incubate the
plate for 30 minutes at room temperature.
viii. Wash plates six times with PBS/0.05% Tween 20.
Add 50pl per well of substrate produced from SigmaFast™ OPD tablet sets (Sigma Chemical
Company Ltd., Poole, UK, Cat.No. P9187). Stop colour development by the addition of 25pl
of 2.5M H2S04 per well and read the plates at ODw.m in a Titertek® Multiskan MC Reader
(Titertek® Flow Laboratories). Sample SMCP concentrations were calculated as described in
method A.
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Concentration of SMCP (ng/ml)
Figure 2.1. Representative example of an SMCP ELISA Standard curve. In this case only
the first four datapoints lie on the linear portion of the curve.
2.3.13. Assay Of Arvlsulfatase Activity
i. Add 20|ll of sample or standards (Sulfatase type V, Sigma Chemical Company Ltd.,
Poole, UK, Cat.No. S 8629; 1.95pg arylsulfatase/ml to 250|ig arylsulfatase/ml) to 80pl
substrate (6.255mM p-nitrocatechol sulphate [Sigma Chemical Company Ltd., Poole, UK,
Cat.No. N7251] in 0.2M acetate buffer, pH 5.7, Appendix A) in a microtitre plate.
ii. Incubate the plate for 60 minutes at 37 °C and terminate the reaction by the addition of
100|il of 5M NaOH. The plate is read at OD492nni in a Titertek® Multiskan MC Reader
(Titertek® Flow Laboratories).
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iii. From the arylsulfatase standard readings a standard curve is plotted, and using FigP
software (Fig.P Corp®, Biosoft®, Cambridge, UK) a regression line calculated. The
activity of arylsulfatase in samples was calculated from
sample arylsulfatase activity = (sample OD492nm - c)/ m
where m = gradient of regression line and c = regression line constant. A sample standard
curve is shown in Figure 2.2. below.
iv. Arylsulfatase activity in unknown samples derived from the standard curve was expressed
as units of arylsulfatase activity (u) per cell population of each tissue culture well or for
supernatants as units of activity (u) per total well tissue culture supernatant.
Concentration of Arylsulfatase (pg/ml)
Figure 2.2. Representative standard curve from arylsulfatase assay.
2.3.14. Assay Of B-Hexosaminidase Activity
p-hexosaminidase activity was assayed by hydrolysis of the substrate p-nitrophenyl-N-acetyl-
P-D-glucosaminide (Sigma Chemical Company Ltd., Poole, UK, Cat.No.N9376); 1 unit of
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enzyme cleaving 1 pinole of substrate per hour at 37 °C (Schwartz, Austen and Wasserman
1979). 25pi of sample is added to 50pl of substrate solution (5mM substrate in citrate buffer,
pH 4.5; Appendix A) for 45 minutes at 37 °C. The reaction is stopped by the addition of
200pl of ice-cold glycine NaOH buffer, pH 10.7 (Appendix A) and the plate read at OD405nm
in a Titertek® Multiskan MC Reader (Titertek® Flow Laboratories). The OD4o5nm for controls
(where buffer had been used in place of sample) were subtracted from the OD^nm for samples
and sample p-hexosaminidase activity calculated using E=18.8xl03l/mol/cm at OD405„m.
Using the experimental set up described above, the activity was calculated from the formula:-
p-hexosaminidase activity (units) =
(AOD405„m at 45 min)/(0.8 x 18.8xl03) x (TRV/TSV) x 1.2735
(where TRV is the total reaction volume and TSV the total sample volume).
The result was expressed as units of p-hexosaminidase activity per cell population of the
tissue culture well or for supernatants as units of activity per total well tissue culture
supernatant.
2.3.15. rOv.IL-3-Dependent BMMC Mediator Release Studies
Bone marrow cells grown in flasks in the presence of an optimal dilution of rOv.IL-3 were
centrifuged at 800 r.p.m. for five minutes at 4 °C (N.B. Release studies were performed only
when cultures contained 40-50% mast cells assessed by examination of Leishman's stained
cytosmear preparations). The supernatant was discarded, and the cell pellet resuspended in lx
Earle's medium (Gibco BRL, Life Technologies Ltd., Paisley, UK, Cat.No. 042-04050H).
The 'washed' cell suspension was centrifuged at 800 r.p.m. for five minutes at 4 °C, the
supernatant discarded and the cell pellet resuspended in Earle's medium. A cell count was
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undertaken, and cytosmear preparations of the cell suspension made for both Leishman's
staining and fixed for anti-SMCP immunohistochemistry. Aliquots of cell suspension
equivalent to 0.5 or 1 xlO6 cells were placed in sterile eppendorfs. The putative release agent
(sP, 48/80, A23187, SMCP or HI-SMCP) was added at a range of concentrations to give a
final total volume of 200|il. As controls, the diluent in which each agent had been prepared
was added to a second series of pellets across the same range of concentrations, again giving a
final volume of 200|il. Additional controls consisted of the addition of Earle's medium alone
in place of agent. After incubation at 37 °C for 45 minutes (with gentle mixing) the
eppendorfs were centrifuged at 12000 r.p.m. for 5 minutes at 4 °C. The supernatants were
removed and stored at -70 °C for subsequent assay of mediator content or activity. To assess
the total mediator content or activity of the cell pellet, separate control, non-stimulated pellets
were subjected to the addition of 200pl of 20mM Tris/HCl pH 7.5 containing 2M KC1, the
cell suspension being freeze-thawed rapidly three times with vortex-mixing between cycles,
and centrifuged at 12000 r.p.m. for five minutes at 4 °C. The extracted pellet supernatant
was removed and assayed for its SMCP, arylsulfatase and (^-hexosaminidase content. All
measurements were undertaken on duplicate pellets, and in a minimum of two separate
cultures. The percentage of mediator release for test and diluent-treated samples was
expressed as a percentage of the total content or activity of mediator assayed after extraction
from separate duplicate, non-stimulated control cell pellets, i.e.:-
Percentage release
= {(quantity of mediator in secretagogue- or diluent-treated pellet supernatant)/
(quantity ofmediator in extracted pellet)} x 100
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2.3.16. Transmission Electron Microscopy Of rOv.IL-3 BMMC
This was undertaken with the generous help of Mr. S.Mitchell, Electron Microscope Unit,
RDSVS. Samples were processed as per the following protocol:-
i. Fix samples in 3% glutaraldehyde in 0.1M sodium cacodylate buffer for 24 hours.
ii. Wash samples in 0.1M sodium cacodylate buffer (three cycles of 20 minutes).
iii. Post-fix in 1% osmium tetroxide in 0.1M sodium cacodylate buffer for 60 minutes.
iv. Wash in distilled water (three cycles of 20 minutes).
v. Dehydrate through graded (50%, 70%, 90%, 100%) acetone series with single ten minute
cycles, except for 100% acetone with three cycles of ten minutes.
vi. Infiltrate sample with 50:50 araldite:acetone mix (mixed for 30 minutes prior to use)
overnight in 60°C oven. Then place sample through three 60 minute cycles using fresh
50:50 araldite:acetone mix. To complete sample infiltration use araldite mix with
accelerator through two 60 minute cycles.
vii. Embed sample in araldite mix with accelerator for 48 hours in a 60°C oven.
viii. Cut 60nm sections on a Reichert OMU4 Ultracut® ultramicrotome using a diamond knife
and mount on 200 mesh copper grids.
ix. Stain sections with uranyl acetate and lead citrate using an LKB Ultrostainer®.
x. View and photograph sections using a Philips 400® transmission electron microscope.
All processing must be undertaken in a fume-chamber, with constant rotation of specimens
except during the overnight infiltration (vi) and embedding (vii).
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2.4. Ovine Mast Cell Heterogeneity Studies
2.4.1. Tissue Fixation For Histochemistry and Immunohistochemistrv
Tissue was fixed in 4%PF/PBS (Appendix A) for six hours at room temperature (Newlands et
al 1984). Fixed samples were transferred to 70% ethanol and stored at 4 °C until processing
(Miller et al 1983), when they were embedded in paraffin wax.
2.4.2. Histochemical And Immunohistochemical Staining Of Paraffin Embedded Tissue
Sections, usually cut at 4pm, were deparaffinized in xylene, rehydrated through a graded
alcohol series to water, and stained by the appropriate stain as described below.
2.4.2.1. Toluidine Blue Stain For Mast Cells
The method is as described under "Toluidine blue staining of fixed cytosmears".
2.4.2.2. Carbol Chromotrope (Lendrums) Stain For Eosinophils
i. Stain tissue sections with haematoxylin (Ehrlich's haematoxylin original formula, Gurr®
microscopy materials, BDH, Poole, UK, Cat.No. 350172Q) for one minute.
ii. Wash in tap water for five minutes.
iii. Stain in carbol chromotrope (0.5% chromotrope in 1% phenol, Appendix A) for 30
minutes.
iv. Wash in tap water for five minutes.
2.4.2.3. Haematoxylin and Eosin Stain
i. Stain tissue sections with haematoxylin (Ehrlich's haematoxylin original formula, Gurr®
microscopy materials, BDH, Poole, UK, Cat.No. 350172Q) for one minute.
ii. Wash briefly in Scotts tap water substitute and then in tap water for five minutes.
iii. Counterstain in Eosin (1% aqueous solution).
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iv. Wash in tap water for five minutes.
2.4.2.4. Demonstration Of SMCP
2.4.2.4.1. 3,3'- Diaminobenzidine (DAB) method
The procedure used is as described under "Demonstration of SMCP in fixed cytosmears"
(2.3.8.1.) from steps ii to xiii.
2.4.2.4.2. Vectastain® ABC-alkaline phosphatase (ABC-AP) method
The method used was as described under "Demonstration of SMCP in fixed cytosmears"
(2.3.8.2.) from steps ii to xvii except that slides were coated with a tissue section adhesive
(Vectabond™, Vector Laboratories Inc., Peterborough, UK, Cat.No. SP-1800) prior to
processing. In addition, in initial experiments the tissue section was incubated with the
rabaSMCP primary antibody for 30 minutes in a humidity chamber at room temperature.
Optimisation of the staining procedure for cytosmear preparations indicated that incubation
overnight in a humidity chamber at 4 °C gave greater intensity of staining, this protocol being
adopted in later experiments.
Stained tissue sections were subsequently dehydrated through a graded alcohol series, cleared
in xylene and mounted in CoverBond™.
2.4.3. Preparation Of Tissue Samples For Assay By SMCP ELISA
Universal containers were pre-weighed, labelled, and held on ice. Immediately post mortem
tissue samples were collected, weighed, and stored at -70 °C until assay. After thawing, five
volumes of ice cold 20mM Tris/HCl buffer pH 7.5 containing 1.5M NaCl were added per
tissue volume and the tissue homogenised using a Silverson heavy duty laboratory mixer
emulsificr, care being taken to hold all samples on ice. After centrifugation at 800g at 4 °C,
tire supernatant fraction was removed and stored at -70 °C prior to assay.
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2.4.4. Enumeration Of Mast Cell Numbers In Toluidine Blue And rabocSMCP Stained
Sequential Sections
Tissue sections were examined using a Leitz Wetzler Dialux 20EB microscope at x500
magnification. For non-mucosal tissues, graticule counts were started from a known point of
reference so that the same relative area could be counted and compared on both the toluidine
blue and anti-SMCP stained sequential sections. In mucosal tissues cells were counted
similarly, cell counts within the lamina propria being spread between the basement membrane
and epithelium. A minimum of 50 successive graticule fields were counted on each of two
adjacent sequential sections stained with toluidine blue or with anti-SMCP. Four pairs of
sections were examined for each tissue. The results were expressed as the mean number of
positive mast cells (for toluidine blue or SMCP) per mm2 of tissue.
2.5. Cutaneous Response Studies
2.5.1. Secretauouue Studies - Agents And Diluents
2.5.1.1. Substance P, Compound 48/80 And Calcium Ionophore A23187
Substance P (sP) was obtained from Cambridge Research Biochemicals Limited, Northwich,
UK, Cat.No. B1323 and compound 48/80 (48/80) from Sigma Chemical Co. Ltd., Poole, UK,
Cat.No. C4257. Dilutions were made in sterile pyrogen-free isotonic saline (Baxter
Healthcare Limited, Thetford, UK) which also served as the diluent control. Dilutions of
lO^M, 10"5M, 10"6 M and 10"7 M sP and 1, 10, 25, 50, 100, 250 and 500pg 48/80/ml were
used for intradermal injection. Calcium ionophore A23187 (A23187) was obtained from
Sigma Chemical Co. Ltd., Poole, UK, Cat.No. C7522. This was initially dissolved in ethanol,
final dilutions being made in sterile pyrogen-free isotonic normal saline (Baxter Healthcare
Limited, Thetford, UK) as above. The diluent control consisted of saline with the same
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proportion of ethanol as present in the highest concentration of A23187 used (10~4 M).
Dilutions of 10"4 M, 10° M, 10"6 M and 10"7 M A23187 were used for intradermal injection.
2.5.1.2. Sheep Mast Cell Proteinase (SMCP)
SMCP was kindly purified by Dr. A.Pemberton, Department of Veterinary Clinical Studies,
Royal (Dick) School of Veterinary Clinical Studies, The University of Edinburgh from the
abomasal mucosa of Telodorsagia circumcincta infected sheep. Briefly, abomasal samples
were collected at post-mortem and stored at -70°C until use. Abomasum (4g) was thawed,
minced and homogenised briefly in 20mM Tris/HCl, pH 7.5. The suspension was centrifuged
(6000g for 15 minutes at 4°C), the supernatant discarded and the pellet homogenised with
0.667 volumes of 20mM Tris/HCl; 1M NaCl; 0.1% Brij 35 (30% w/vsolution, Sigma
Chemical Co. Ltd., Poole, UK, Cat.No. 430AG-6); pH 7.5. After centrifugation (6000g for
30 minutes at 4°C) the supernatant was further clarified by centrifugation for 1 hour at
20000g at 4°C. The resulting supernatant was diluted with 2 volumes of 20mM Tris/HCl;
0.1% Brij 35; pH 7.5 and loaded onto a column packed with CM-sepharose FF (25ml) in the
same buffer. The column was then eluted with a 600mM NaCl gradient and the fractions
assayed for chymotrypsin-like activity by adding lOpl of each fraction to 50pl of lOOmM
Tris/HCl pH 7.5 in a 96 well ELISA plate, followed by lOpl of lOinM N-succinyl-ala-ala-
pro-phe-p-nitroanilide (Sigma Chemical Co. Ltd., Poole, UK, Cat.No. S 7388) in dimethyl
sulphoxide. Active fractions appear yellow after a short incubation at room temperature. The
active fractions were pooled, diluted with 2 volumes of 20mM Tris/HCl; 0.1% Brij; pH 7.5
and loaded onto a Mono S cation exchange column in the same buffer. This column was
eluted in a 150-350 mM NaCl gradient, and the active fractions pooled for further
chromatography on Mono S in 20mM phosphate buffer; 0.1% Brij 35; pH 7.0. SMCP was
eluted in a 50-400mM NaCl gradient, the SMCP diluent control being composed of the same
proportions of 20mM phosphate buffer; 0.1% Brij 35; pH 7.0 and NaCl concentration as at
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the point of SMCP elution. A doublet (representing SMCP) was detectable on a coomassie
blue-stained SDS-PAGE gel (Fig.2.3). (This was generously undertaken by Dr. Alan
Pemberton, RDSVS, utilising discontinuous SDS-PAGE (Laemmli 1970) on a 12% gel that
was electrophoresed for 3hr at 5°C at a constant current of 20mA per gel). 36pg, 3.6|ig,
360ng and 36ng SMCP were used for intradermal injection. SMCP and SMCP diluent
control solutions were negative for the presence of endotoxin (kindly undertaken by
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Figure 2.3. SDS-PAGE gel (12%) of purified SMCP from ovine abomasal tissue stained
with coomassie brilliant blue R250. Note the doublet at approximately 25kDa, representing
SMCP. This indicates a glycoform of SMCP, which is also apparent when the monoclonal
antibody to SMCP is used. Arrows indicate the positions of the protein standards at 94kDa,
67kDa, 43kDa, 31kDa and 21kDa.
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2.5.1.3. Preparation Of Heat-Inactivated SMCP (HI-SMCP) And Heat-Inactivated
Diluent Control
Aliquots of SMCP and SMCP diluent control were placed in a water bath at 64°C for 10
minutes. Chymotryptic activity of active and heat-inactivated SMCP was assessed by
cleavage of N-succinyl-ala-ala-pro-phe-p-nitroanilide in dimethyl sulphoxide to p-nitroaniline,
the optical density being read at 405nm, duplicate samples of both agents being used.
Therefore, lOpl of sample was added to 20|il of lOmM N-succinyl-ala-ala-pro-phe-p-
nitroanilide in dimethyl sulphoxide and 170pl of 20mM phosphate buffer; 0.1% Brij 35;
pH 7.0. The rate of reaction for each sample was determined in a Beckman
Spectrophotometer at 405nm. The percentage residual activity in heat-inactivated SMCP was
calculated as follows:-
Percentage Residual Chymotryptic Activity (%) =
I (Cleavage rate inactive SMCP sample 1 + Cleavage rate inactive SMCP sample 2)1/2 X100
[(Cleavage rate active SMCP sample 1 + Cleavage rate active SMCP sample 2)]/2
Representative results (26/1/95 and 23/6/95) for SMCP after heat-inactivation gave residual
activities of 2.4% and 1.35% respectively.
All of the above agents and diluents were stored at -70 °C as stock solutions, and were thawed
and made up to working dilutions immediately prior to use. All dilutions were kept on ice
until shortly prior to injection.
2.5.2. Intradermal Skin Testing
2.5.2.1. Method
An area of skin on the left or right flank was shaved on the day prior to undertaking the study.
For ethical reasons, the number of injection sites per flank was restricted to six, these being
marked in a three by two grid with a felt-tip pen (Figures 2.4. and 2.5.). (It should be noted
that benzalkonium chloride, which can be used in routine skin preparation and cleansing
(Debuf 1994), is a competitive antagonist of 48/80 (Read et al 1982) and was therefore
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avoided for use in the studies described in this thesis). 50jxl of the appropriate agent or diluent
control was injected intradcrmally at each site using a 27 gauge 1ml syringe (Myjector®;
Terumo, Leuven, Belgium, Cat.No. SS-NIH273) and monitored for weal development.
2.5.2.2. Measurement OfWeal Volume
Using an adapted low-tension spring-loaded micrometer (Draper®, UK, Cat.No. SI-510) the
skin thickness was measured at the injection site before and at time points after injection of the
agent or diluent. The diameter of the test weal response at the appropriate time point was
measured in two horizontal planes at right angles to each other and a mean value of weal
diameter calculated. The weal volume was determined from the weal thickness and weal area
(Coulson and Holden 1990; formulae below) and expressed in mm3.
Weal Area = nU[(d\ +rf2)/2]2
Weal Thickness = (7) - T0)/2
Weal Volume = Area x Thickness
(Where d\ is the maximum horizontal weal diameter and di the weal diameter at right
angles to it. T0 is the skin thickness prior to the intradermal injection of the agent or diluent.












Figure 2.4. Diagram of intradermal injection sites. Injection sites are marked by 'X'.




Local anaesthetic (Lidocaine hydrochloride, 1ml Xylocaine 2%® per injection site; Astra
Pharmaceuticals, Kings Langley, UK) without adrenaline (Henfrey, Thoday and Head 1991)
was injected subcutaneously prior to biopsy collection. Biopsies were excised using sterile,
disposable 6mm skin biopsy punches (Kruuse, The Netherlands). Each biopsy site was closed
using a single Michel surgical clip (12 mm Martin 100 Michel clips, Germany). In all cases,
healing was unremarkable and complete by 10 days post-biopsy.
2,5.3. Cell Counts On Skin Sections
A Leitz Wetzler Dialux 20 EB microscope was used at a magnification of 500x to enumerate
mast cell (toluidine blue stained sections), neutrophil (haematoxylin and eosin stained
sections) and eosinophil (carbol chromatrope stained sections) numbers. Moving from
epidermis to dermis in a consistent grid pattern to a maximum depth of 10 graticule field
widths (generally the limit of the deep dermis)[Figure 2.6.], the appropriate cells in 20
graticule fields (equivalent to a total area of 1.51 mm2 per section) were counted for each
section and expressed as cells mm"2 skin. The grid pattern ensured that the same graticule
area of skin was not counted twice, and that all areas of epidermis, superficial and deep
dermis would be included in cell counts. This pattern also reduced the possibility of operator
bias by not allowing the preferential inclusion of foci of cellular infiltrates in counts. The
observer was blinded to the identity of individual sections until after the counts for a particular
experiment had been completed. This ensured that the operator was blinded to the
experimental protocol. On occasion where the skin thickness was less than ten graticule field
widths, the same grid counting pattern was followed, but extended upon reaching the
epidermis.
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Figure 2.6. Diagram depicting consistent graticule grid counting pattern for enumeration of
cell numbers in skin sections (20 graticule fields equivalent to 1.51mm2 were counted for each
section, represented by the open squares above).
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2.5.4. Subjective Assessment Of The Extent Of Mast Cell Degranulation In Toluidine
Blue Stained Tissue Sections
In order to assess the extent ofmast cell degranulation, between 50 and 150 toluidine blue
stained mast cells (dependant on the section) were examined with a Leitz Wetzler Dialux 20
EB microscope at xlOOO magnification. Cells were allocated to one of three separate
categories 1) non-degranulated cells (up to 10% degranulation), 2) moderately degranulated
cells (10% to 50% degranulation) and 3) extensively degranulated cells (greater than 50%
degranulation) (adapted from Iwamoto et al [1992]). The percentage of extensively
degranulated cells per tissue section was subsequently calculated.
2.5.5. Computer Hardware/Software
The thesis was compiled on a Dell® Dimension 450Si computer (Dell Computers Ltd, Eire).
Text was written on Microsoft® Word 6.0 for Windows™, data being analysed using
Microsoft® Excel 5.0 for Windows™, Fig.P® 1.0 forWindows™ (Biosoft®, Cambridge, UK),
and Minitab® version 7.2. The Reference Manager® 5.0 program (Research Information
Systems Inc., USA), in conjunction with the on-line BIDS database (accessed by e-mail), was
used for reference handling.
2.5.6. Photography
Photomicrographs were taken on a Leitz Wetzler Ortholux II microscope system, using Ilford
FP4 Plus 125 ASA black and white and Kodak Ektachrome 64T EPY (Professional) colour
film. Photographs were taken predominantly using a Canon EOS 1000FN SLR camera and
Ektachrome film.
2.5.7. Statistical Analyses
The sample mean, standard deviation (SD) and standard error of the mean (SEM) were
calculated on a standard scientific calculator.
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Data analysis was undertaken using the Minitab® statistical program version 7.2 (Minitab
Inc., State College, PA, USA). In order to determine whether the data within samples was
normally distributed, the data was tested for normality of distribution using a method
approximating to the Shapiro-Wilk test. This calculates the degree of correlation between the
actual distribution of data and a theoretically calculated normal distribution of the same data.
By reference to a table of probability values (Minitab® Reference Manual) the likelihood of
the data approximating a normal distribution can be ascertained. Dependant on the result, the
data was subsequently analysed using the following tests.
2.5.7.1. Student's t - Test
Where data within samples approximated to a normal distribution, the Student's two sample t
test was performed using the Minitab program.
2.5.7.2. Mann-Whitney U Test
Where data within did not approximate to a normal distribution, the non-parametric
Mann-Whitney U test was applied, using the Minitab program.
In the above tests, P< 0.05 was taken to denote statistical significance.
2.5.7.3. Linear Regression Analysis
This was performed using Fig.P® software (Biosoft®, Cambridge, UK).
2.5.7.4. Analysis Of Variance (ANOVA)
The analysis of variance between groups of data was undertaken using the Minitab® program.
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CHAPTER 3
The tissue distribution of sheep mast cell




3.1.1. Chymases and mast cell heterogeneity - general points
Mast cells in rodents and man represent a phcnotypically heterogeneous cell population with
respect to tissue site, fixation properties, histochemical staining, biochemistry and functional
activity (Galli 1990). These differences are a reflection of differences in their granule
constituents, most notably in their content of intra-granule proteinases. Chymotrypsin-like
mast cell proteinases (chymases) have been isolated from mast cells of the rat (Lagunoff and
Pritzl 1976, Yurt and Austen 1977, Woodbury et al 1978), mouse (Newlands et al 1987,
Reynolds et al 1990), dog (Slavin et al 1987, Caughey et al 1988b, Schechter et al 1988),
sheep (Huntley et al 1986) and man (Schechter et al 1983, Schechter et al 1986). The
elucidation of differences in mast cell proteinase expression at different tissue sites has led to
the identification of mast cell subsets, as outlined below, in the rat (Gibson & Miller 1986,
Gibson et al 1987, Huntley et al 1990), mouse (Miller et al 1988, Miller et al 1989, Reynolds
et al 1990) and man (Irani et al 1986, Schwartz et al 1987, Schwartz 1989).
3.1.2. Ratchymases
In the rat and mouse, distinct proteinases are predominantly associated with either the mucosal
mast cell (MMC) or connective tissue mast cell (CTMC) subsets. Rat mast cell proteinase-II
(RMCP-II) is chiefly associated with the gastrointestinal MMC subset (Woodbury, Gruzenski
and Lagunoff 1978), whereas rat mast cell proteinase-I (RMCP-I) is predominantly associated
with the CTMC subset. Thus, the mucosa of the stomach and small intestine contains
exclusively RMCP-II staining mast cells, whereas the submucosa at these sites contains 63%
and 100% of RMCP-I staining cells respectively (Huntley et al 1990). Uniquely RMCP-I
containing CTMC-type mast cell populations have been defined in tongue and in small
intestinal submucosa (Huntley et al 1990). The presence of RMCP-II in non-mucosal sites
such as liver and thymus (Gibson and Miller 1986), and the identification of dual RMCP-I
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and RMCP-II staining cells in gastric submucosa, liver, mesenteric lymph node,
peribronchiolar region of the lung and pleura also indicates that proteinase heterogeneity exists
within rat mast cell suhpopulations (Huntley et al 1990).
3.1.3. Mouse chymases
In the mouse, five chymases have currently been identified (Reynolds et al 1990), mouse mast
cell proteinase-1 (MMCP-1) and mouse mast cell proteinase-2 (MMCP-2) being present in the
MMC subset, whereas MMCP-3, MMCP-4 and MMCP-5 delineate the connective tissue
subset (Newlands et al 1993, Stevens et al 1994, Schwartz 1994). However, it is known that
proteinase heterogeneity exists within both the intestinal (MMC; Miller et al 1988) and
cutaneous (CTMC; Stevens et al 1994) mouse mast cell subpopulations. For example,
MMCP-2 (as well as MMCP-5) can be detected in murine cutaneous mast cells (Stevens et al
1994).
3.1.4. Human chymase
Mast cell subpopulations in man are divided into those that contain tryptase and chymase (the
MCtc type) and those that contain tryptase alone (the MCT type) (Irani et al 1986). Most
tissues are believed to contain a mixture of both MCtc and MCT types, although MCT is
TC
predominant in the lung and small intestinal mucosa and MC is chiefly found in the skin and
small intestinal submucosa (Irani et al 1986, Schwartz et al 1987, Schwartz 1989, Irani and
Schwartz 1990). However, the validity of the belief that human mast cell heterogeneity can be




Although it is known that canine cutaneous mast cells contain both a chymase and a tryptase
(Schechter et al 1988), little is known regarding mast cell heterogeneity at other tissue sites in
this species.
3.1.6. Ovine chvmase
Sheep mast cell proteinase (SMCP) has been isolated and characterised as a serine
endopeptidase (Knox and Huntley 1987), and the mast cell source of this enzyme confirmed
immunohistochemically (Huntley et al 1986). SMCP is released locally into lymph and
systemically into blood following abomasal challenge with gastric nematodes in immune sheep
(Huntley et al 1987). Indeed, although the concentration of SMCP in the gastrointestinal
mucosa is significantly correlated with mast cell counts (Huntley 1991), the distribution of
SMCP in non-mucosal tissues was unknown. Additionally, it was not known whether mast
cell heterogeneity existed in the sheep.
3.2. Experiment 3.1 - Investigation Of The Tissue Distribution Of SMCP In
The Sheep
3.2.1. Experimental Aim and Design
The aims of the experiment were therefore to determine the tissue distribution of SMCP in
both mucosal and non-mucosal sites, and to establish whether or not mast cell heterogeneity,
as a consequence of differences in the distribution of SMCP between tissues, was present.
These aims were accomplished by firstly determining whether or not SMCP was present in
tissues by immunohistochemistry and ELISA (using an affinity purified, polyclonal
RabaSMCP antibody), and secondly by comparing the number ofmast cells identified
histochemically (toluidine blue pH 0.5) with the number detected immunohistochemically on
sequential tissue sections.
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At post-mortem examination, samples from trachea, bronchial lymph node, lung, thymus,
spleen, liver, flank skin, abomasum, duodenum, jejunum, ileum, colon and mesenteric lymph
node were removed from four Suffolk-cross lambs. Samples were weighed, homogenized in
buffer, and the amount of SMCP present determined by ELISA (2.4.3, 2.3.12.1). This was
expressed as ng SMCP per g wet weight of tissue. Pairs of sequential sections were stained
histochemically with toluidine blue pH 0.5 and immunohistochemically to demonstrate the
presence of SMCP (2.4.2), using either the 3,3'-Diaminobenzidine (DAB) method or, in
heavily pigmented skin, the Vectastain® ABC-AP method. The use of the latter technique
allowed the distinction between immunostaining of SMCP in dermal mast cells and
endogenous melanin in dermal melanocytes to be made. A minimum of 50 successive
graticule fields covering the same area on both the toluidinc blue and anti-SMCP stained
sequential sections were counted (2.4.4), the resultant counts being compared for each tissue
using the Mann-Whitney U test and for all tissues using linear regression analysis.
Additionally, the number of SMCP-positive mast cells were compared against the respective
tissue SMCP concentrations, by the use of linear regression analysis.
3.2.2. Results
The median and ranges for the toluidine blue and SMCP mast cell counts, and for the SMCP
mast cell counts and respective tissue SMCP concentrations, are given in Tables 3.1 and 3.2
respectively. The highest median mast cell counts (215.8/mm2 with toluidine blue and
211.2/mm2 with anti-SMCP), and the highest median concentration of SMCP (24.76pg
SMCP/g wet tissue) were in the thymus which contained diffusely scattered focal
accumulations of cells, with a predominantly peri-vascular distribution (Fig. 3.1). The
gastrointestinal tissues as a group had relatively high cell counts with both techniques
(Fig. 3.2), and comparatively high tissue SMCP concentrations (Table 3.2). Despite
appreciable numbers of mast cells determined by both histochemical (Fig. 3.3) and
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immunohistochemical means, SMCP was not detected in tracheal homogenates by ELISA
(Table 3.2). The cells in this instance were chiefly subepithelial in location.
Number of toluidine Number of
blue-positive mast cells SMCP-positive mast
per mm2 of tissue cells per mm2 of
tissue
Tissue Examined n Median Range Median Range
Gastrointestinal Svstem
Abomasum 4 41.4 21.0-223.7 43.3 24.9-250.5
Duodenum 3 52.9 20.1-168.5 78.4 25.3-146.0
Jejunum 4 188.3 90.2-205.8 173.2 78.4-194.8
Ileum 4 109.1 43.6-242.0 118.2 34.8-241.4
Colon 4 37.0 35.2-152.9 35.3 27.5-124.8
Respiratory Svstem
Trachea 3 19.6 13.8-25.9 24.9 13.2-28.6
Bronchus 3 24.3 18.0-31.2 23.8 16.4-31.2
Bronchial Lymph Node 4 48.9 20.9-128.5 55.6 19.6-111.4
Lung 4 39.7 20.6-100.0 39.7 22.2-103.7
Other Tissues
Thymus 3 215.8 190.9-270.3 211.2 210.6-221.6
Spleen 4 55.5 48.8-117.1 46.6 42.1-84.6
Liver * 4 89.1 46.0-98.9 14.3 8.89-15.2
Skin * 4 43.3 26.6-55.3 0.7 0.0-2.1
Mesenteric Lymph Node 4 131.7 64.0-225.2 121.6 49.8-244.5
Table 3.1. Table comparing the median and range values for the number of toluidine blue and
SMCP-positive mast cells per mm2 tissue for all tissues examined. (* represents statistical
significance for the number of toluidine blue- versus SMCP-staincd mast cells at P<0.05
assessed by the Mann-Whitney U test).
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Number of Tissue SMCP
SMCP-positive mast concentration
cells per mm2 of tissue (pg SMCP per g of
wet tissue)
Tissue Examined n Median Range Median Range
Gastrointestinal System
Abomasum 4 43.3 24.9-250.5 0.08 0.00-0.32
Duodenum 3 78.4 25.3-146.0 1.40 0.00-2.42
Jejunum 4 173.2 78.4-194.8 0.89 0.69-2.31
Ileum 4 118.2 34.8-241.4 2.29 0.85-7.92
Colon 4 35.3 27.5-124.8 0.60 0.09-0.98
Respiratory System
Trachea 3 24.9 13.2-28.6 0.00 0.00-0.00
Bronchus 3 23.8 16.4-31.2 0.00 0.00-0.15
Bronchial Lymph Node 4 55.6 19.6-111.4 0.10 0.03-0.25
Lung 4 39.7 22.2-103.7 0.09 0.07-0.18
Other Tissues
Thymus 3 211.2 210.6-221.6 24.76 1.66-32.81
Spleen 4 46.6 42.1-84.6 0.07 0.03-0.14
Liver 4 14.3 8.89-15.2 0.00 0.00-0.02
Skin 4 0.7 0.0-2.1 0.01 0.00-0.06
Mesenteric Lymph Node 4 121.6 49.8-244.5 0.37 0.04-0.45
Table 3.2. Table comparing the median and range values for the number of SMCP positive
mast cells per mm2 against the tissue SMCP concentration (pg SMCP per g wet tissue) for all
tissues examined.
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Figure 3.1. Toluidine blue-stained section of ovine thymus (x250). Note large numbers of
darkly stained mast cells focally distributed throughout the section.
«
Figure 3.2. Toluidine blue-stained section of ovine jejunum (x400). Numerous mast cells are
present.
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Figure 3.3. Toluidine blue-stained section of ovine trachea (x400). Note predominantly
subepithelial location ofmast cells.
109
There were fewer SMCP-positive cells in comparison to toluidine blue-positive cells in both
skin (p<0.05) and liver (p<0.05) (Table 3.1). No statistically significant differences were
observed for the other individual tissues examined. For direct comparison, representative
sections of thymus and skin stained with toluidine blue and for SMCP are shown (Fig. 3.4).
The anti-SMCP reactive dermal cells were morphologically identical to mast cells (well
granulated, mononuclear cells). Dermal basophils were infrequently observed. Their distinct
polymorphonuclear appearance and smaller, finer granules allowed them to be differentiated
histologically from mast cells. In the liver, far fewer cells (16%) reacted with antibody than
with toluidine blue. Morphological examination suggested that many of the toluidine blue
stained cells were likely to be large granulated lymphocytes (LGL).
There was a positive correlation between toluidine blue and SMCP mast cell counts
0*2 = 0.96, pcO.OOl; Fig. 3.5) and between SMCP cell counts and tissue SMCP
concentrations (r^ = 0.30, p<0.02; Fig. 3.6) from gastrointestinal tissues.
When the number of cells stained by toluidine blue from all tissues except liver and skin was
compared to the number of SMCP-stained cells in the same tissues there was a high degree of
correlation (r^ = 0.96, p<0.001; Fig. 3.7), in contrast to the finding in skin and liver. A
statistically significant correlation was observed between overall SMCP cell counts and
concentrations of SMCP in all of the tissues (excluding trachea) [r^ = 0.23, p<0.0011.
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Figure 3.4(a) and (b). Toluidine blue (a) and anti-SMCP (b) stained sections of ovine
thymus (xl25). Note that relative numbers of mast cells detectable by both methods is
similar.
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Figure 3.4(c) and (d). Toluidine blue (c) and anti-SMCP (d) stained sections of ovine
skin (xl25). Note the disparity in mast cell numbers detectable by the two methods.
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300 i
Figure 3.5. Comparison of tire number of toluidine blue and SMCP-positive mast cells per
mm2 tissue in the gastrointestinal tract (abomasum, duodenum, jejunum, ileum, colon). Each
datapoint represents the counts from sequential sections from an individual tissue, (r = 0.98,
r2 = 0.96, p< 0.001).
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Figure 3.6. Comparison of the number of SMCP-positive cells per mm2 tissue versus the
concentration (pg SMCP/g wet tissue) of SMCP in the gastrointestinal tract (abomasum,
duodenum, jejunum, ileum, colon). Each datapoint represents values for an individual
tissue (r = 0.55, r2 = 0.3, p < 0.02).
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Figure 3.7. Comparison of the numbers of Toluidine blue- and SMCP-positive mast cells per
mm2 for all tissues. The regression line is calculated including all tissues except liver and skin
(r = 0.98, r2 = 0.96, p < 0.001). Each datapoint represents the counts for sequential sections
from an individual tissue.
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3.3. Discussion
Mast cells were detected with the anti-SMCP antibody in virtually all of the tissues examined,
but SMCP positive cells were scarce in skin. This indicates the presence of two distinct mast
cell populations in sheep, lliis finding being in accordance with previous studies demonstrating
mast cell proteinase heterogeneity in the rat (Gibson and Miller 1986, Gibson et al 1987,
Huntley et al 1990), mouse (Reynolds et al 1990, Newlands et al 1993, Stevens et al 1994)
and man (Irani et al 1986, Schwartz et al 1987, Schwartz 1989, Irani and Schwartz 1990),
where two major mast cell sub-classes have been identified.
However, a few SMCP-positive cells were observed in skin indicating proteinase heterogeneity
in the dermal mast cell population. This observation may be analogous to the situation in
man, where dermal CTMC can be divided into two sub-populations based on the presence or
absence of a chymase (Schwartz 1989, Haas 1995). In the rat, in marked contrast to man,
the chymase (RMCP-I) is pre-eminent, and it is the presence or absence of tryptase that
delineates subpopulations of the cutaneous CTMC subset (Chen et al 1993). In the dog, in
cutaneous mastocytoma cell lines, although chymase and tryptase can be asynchronously
expressed, it is not known if this is a reflection of true heterogeneity within the cutaneous mast
cell population, or if it is purely as a result of differences in the state ofmaturation of these
neoplastic cells (Caughey et al 1988c). On the basis of cellular morphology, the anti-SMCP
antibody did not appear to react with basophils. However, because of the difficulty in
distinguishing basophils and mast cells in tissue sections and the apparent paucity of the
former in tissues, the possibility that antibody to SMCP cross-reacts with basophils cannot be
discounted.
The presence in the liver of a relatively large population of cells putatively identified as LGLs
was noted. However, careful examination indicated that these cells did not contribute to the
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toluidine blue-positive cell population in other tissues as stained cells were typically well-
granulated and mononuclear suggesting a mast cell, rather than a basophil or lymphocyte
lineage. Moreover, these tissues (with the exception of skin) had a high correlation between
cell numbers detected with toluidine blue and with antibody to SMCP (r^ = 0.96, p<0.001).
The presence of high numbers of thymic mast cells has been reported previously during
studies in rats, although their role remains obscure (Huntley et al 1993). However, since mast
cells produce a wide range of cytokines (Burd et al 1989, Gordon and Galli 1990a), it is
tempting to speculate that mast cell-derived cytokines may modulate or augment T-cell
responses. Certainly, the role and function of ovine thymic mast cells warrants further study.
Despite there being appreciable numbers of mast cells identified both histochemically and
immunohistochemically in trachea, no SMCP could be detected in tracheal homogenates. It is
possible that this indicates the presence of a distinct proteinase that is able to cross-react with
the anti-SMCP antibody in paraformaldehyde fixed tissue sections, but is refractory to
detection by the ELISA method. Alternatively, it is known that both serum and lymph contain
"factors" that may interfere with SMCP - antibody interactions (Huntley et al 1987), these
possibly being 0.2 macroglobulin or serpins (Huntley 1991). It can be speculated that high
inhibitor content in tracheal tissue may have prevented determination of SMCP by ELISA,
although immunohistochemical identification in fixed tissue was still possible. Certainly, it is
known that a2-macroglobulin and ai-proteinase inhibitor can block the detection of SMCP by
the ELISA (Huntley 1991). This anomaly warrants further investigation, which could initially
be undertaken by "spiking" the tissue homogenates with SMCP, and identifying the molecular
weight of the SMCP-inhibitor complexes present on blots.
Previous studies have shown a correlation between the number of gastrointestinal mast cells
detected with anti-SMCP and the tissue content of SMCP (Huntley 1991). On the basis of
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these results, and the finding that this proteinase was released systemically into blood and
lymph following nematode challenge in immune sheep (Huntley et al 1987), SMCP was
considered a "MMC" enzyme and analogous to RMCP II in the rat (Gibson et al 1987).
However, the present investigation suggests that SMCP is not unique to MMC, as although
there are significant correlation's (r2 = 0.28, p<0.001) between SMCP tissue content and
mast cell numbers for the majority of tissues, the skin and liver are apparent exceptions.
The results of this study indicate that SMCP is present in all mast cells in most of the tissues
studied, with the exception of skin. This is quite distinct from the situation in man and
rodents, where chymase is the predominant mast cell protease in skin. These ovine dermal
mast cells presumably contain a proteinase which is antigenically distinct from SMCP and the
sheep is, therefore, similar to other species studied in that there is heterogeneity of granule
proteases. However, there are also species differences which may have important implications
in terms of function and activity of these cells. For instance, in the rat, RMCP-I-containing
CTMC predominate in a variety of connective tissues including skin and are widely
distributed throughout these organs. Although RMCP-II - containing MMC are found
principally in the gastrointestinal tract they are not confined to this tissue, and indeed can be
located in non-mucosal sites (Huntley et al 1993). The distribution of ovine mast cell subsets
is apparently different to the rat, with clearly defined anatomical locations for the mast cell
proteinase populations. By inference from data in other species a number of granule
proteinases have yet to be identified. For example, a second chymase, related to but distinct
from SMCP, may be present in ovine mast cells (Huntley 1991). Secondly, ovine mast cell
tryptase has not, as yet, been isolated. (Interestingly, tryptase has recently been demonstrated
both histochemically and immunohistochemically in bovine cutaneous mast cells (Welle et al
1995)). Once these two enzymes have been isolated and their distribution determined, it will
be possible to further define ovine mast cell subsets. From a functional standpoint it is
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important to determine whether chymase (as in rats and mice) or tryptase (as in the dog and
man) is the more functionally significant. (Nadel 1991). As SMCP is present in the majority
of ovine mast cells, it may be the more important of the two enzymes. However, the recent
unexpected finding that SMCP also possesses trypsin-like activity (Pemberton, Huntley and
Miller, submitted) may make such a simplistic classification impractical. The tryptic activity
of SMCP is manifest by the cleavage of bonds in bovine albumin with a lysine at Pi and
aspartate or glutamate (acidic residues) at P4 and P4, a structure that occurs frequently in
ovine albumin and which suggests that this could act as a native substrate for SMCP. Indeed,
apart from this dual activity (as both a tryptase and chymase), SMCP is very similar to
human and rodent chymases in terms of the relative effect of inhibitors (e.g. aj-PI) and the
possession of similar N-terminal amino acid sequences (Pemberton, Huntley and Miller,
submitted).
The findings of this study could be further clarified by the use of ovine anti-IgE or ovine
anti-c-kit. However, these reagents are currently not available for use in the sheep.
This investigation has defined the tissue distribution of SMCP, and established that mast cell
heterogeneity, based on differences in proteinase expression, occurs in the sheep. Apparent
proteinase heterogeneity within the ovine dermal mast cell population has also been identified.
Diversity appears to exist between species in mast cell proteinase heterogeneity and
expression, and further studies involving the isolation of ovine dermal mast cell proteinase(s)
are required for a full evaluation of mast cell heterogeneity in the sheep.
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Given that SMCP was shown to be present in a proportion of ovine dermal mast cells, further
investigation of the effects of SMCP and of putative mast cell secretagogues in ovine skin in
vivo (Chapters 4 and 5) and on recombinant ovine interleukin-3-dependent bone marrow-
derived mast cells (rOv.IL-3 BMMC) in vitro (Chapter 7) is warranted.
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CHAPTER 4
Cutaneous responses to substance p, compound 48/80
and calcium ionophore a23187 : their identification
as putative ovine dermal mast cell secretagogues.
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4.1. Introduction
Given that the results from experiment 3.1 suggested that ovine dermal mast cells were
distinct from mast cells at other sites and that, within the dermis, two populations of mast cells
could be identified based on their content of granule chymase, it was logical to investigate the
inflammatory response evoked by activation of the dermal mast cell population. It is known
that mast cells in rodents and in man are functionally heterogeneous in their responses to
activation and degranulation by chemical secretagogues. For example, rat cutaneous mast
cells are sensitive to the neuropeptide substance P (sP) and the polybasic compound 48/80
(48/80), whereas rat intestinal mast cells are relatively insensitive to these agents (Enerback
1966c, Galli 1990). Likewise, human cutaneous mast cells are responsive to sP, 48/80 and
the calcium ionophore A23187 (A23187), whereas mast cells from lung and colon are
insensitive to the actions of both sP and 48/80 (Lowman et al 1988). In mice, sP and 48/80
evoke neutrophil infiltration in skin as a consequence of mast cell degranulation (Tomoe et al
1992). Furthermore, since bovine cutaneous mast cells release histamine in response to sP
and A23187 (Hunt et al 1991), it is likely that ovine cutaneous mast cells respond to the same
secretagogues. Indeed, several studies have reported that cutaneous mast cells in a variety of
species can be activated by sP, 48/80 and A23187 (Table 4.1). Therefore, the responses of
ovine dermal mast cells to these secretagogues could be compared with those in other species,
which would extend our knowledge of the phenotypic heterogeneity of the ovine dermal mast
cell population. Likewise, these in vivo responses could be similarly compared to those of
rOv.IL-3 BMMC generated in culture (Chapters 6 and 7). Although cytotoxic and known to
affect a wide range of cell types, A23187 was used in these studies as it was the only
secretagogue that had previously been used to activate an ovine mast cell population
(Huntley et al 1992). This therefore provided a baseline of response against which other
secretagogues could be assessed. The overall aim of the experiments described in this chapter
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was, therefore, to determine if sP, 48/80 and A23187 were secretagogues for ovine cutaneous
mast cells.




Ebertz et al 1987
Foreman 1987
Lawrence et al 1987
Lowman, Benyon
and Church 1988
Lowman et al 1988
Cohan et al 1989
Tainsh et al 1991
Benyon, Lowman and
Church 1987
Lawrence et al 1987
Tainsh et al 1991
Benyon etal 1986
Benyon, Lowman and Church
1987
Benyon et al 1987
Lowman et al 1988
Kaminer et al 1991
Tainsh et al 1991
Goldstein et al 1992
Tainsh et al 1992
Rat Brain and Williams
1988
Galli 1990
Pearce 1986 Barrett, Ali and Pearce 1985
Mouse Matsudaetal 1989
Yano et al 1989
Tomoe et al 1992
Matsudaetal 1989
Tomoe et al 1992
Cow Hunt et al 1991 Huntctal 1991
Gerbil Nawa et al 1994
Table 4.1. Studies in various species reporting cutaneous mast cell activation by sP, 48/80
and A23187.
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4.2. Experiment 4.1 - Assessment Of Mast Cell Numbers In Flank Skin
4.2.1. Experimental Aim and Design
The aim of the investigation was to determine whether there were differences in the regional
distribution of mast cells within the area of the flank chosen for intradermal skin testing
(Fig. 2.5). This information is necessary so that subsequent measurements of the magnitude
of cutaneous response following intradermal challenge with mast cell secretagogues could be
evaluated in relation to cutaneous mast cell density.
At post-mortem examination, the left and right flanks of four Blackface ewes were clipped and
prepared as described (2.5.2.1). Samples of skin were removed from the cranial, caudal and
ventral margins of each prepared area of flank using a 6mm skin biopsy punch. Additionally,
further samples were taken from a sparsely haired region in the groin (both left and right
sides). Samples were fixed and processed (2.4.1), sections being stained with toluidine blue
pH 0.5 (2.3.9). The number of mast cells per mm2 skin for each section was determined as
described (2.5.3), the eight regions being compared statistically for significant differences
between individual groups by the use of one-way analysis of variance (ANOVA).
4.2.2. Results
The sample means and standard deviations (n = 4 for each group) are shown for the eight
regions (Fig. 4.1). One-way ANOVA indicated no significant difference between groups
(P = 0.22). This indicated that within the site chosen on the flank there was unlikely to be any
marked variation in mast cell distribution and thus it was warranted to use this site for















































Figure 4.1. Histological assessment of mast cell numbers in toluidine blue stained sections
from three sites on both flanks (from within the flank area as shown in Figure 2.4; left and
right cranial flank, caudal flank and ventral flank) and from an area of sparsely haired skin in
the groin (left and right haired). Datapoints depict the sample mean and error bars the
standard deviation for each group of measurements. One-way analysis of variance (ANOVA)
indicated no statistically significant difference between the individual groups (P = 0.21).
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4.3. Experiment 4.2 - Cutaneous Responses To Substance P (sP),
Compound 48/80 (48/80) And Calcium Ionophore A23187 (A23187) In The
Sheep
4.3.1. Experimental Aim and Design
The aims of this study were to determine if sP, 48/80 and A23187 could evoke a response in
ovine skin in vivo and, if so, to determine the optimal concentration of each agent required.
The cutaneous response was assessed by measurement of weal volume and by quantifying the
cutaneous mast cell and inflammatory cell changes histologically.
Twelve cast Blackface ewes were used in the study. These had been grazed at pasture and
had not had any anthelmintic treatment immediately prior to investigation. The group had
been treated once with a topical ectoparasiticide to remove lice and other ectoparasites
(deltamethtrin 1% w/v, Spot On Insecticide, Coopers®; Pitman-Moore Ltd., Crewe, UK) before
being housed, and once while housed.
4.3.1.1. Study protocol
The study was divided into two stages. In the first stage three separate dose response studies
were undertaken to assess whether each of the putative secretagogues could produce a weal
response in ovine skin and, if so, what the optimal dose of each agent was. Histological
examination of skin biopsies was undertaken for evidence of cellular infiltration and mast cell
degranulation. In the second stage three separate time course studies were performed using
the optimal dose of each agent (based on weal volume data from the first, dose response, stage
if a response had been elicited).
The initial dose range of each agent used (outlined in 2.5.1.1) was derived from published data
for their use in other species (sP : Lawrence et al 1987, Yano et al 1989, Iwamoto et al 1992;
48/80 : Lawrence et al 1987, Wahlgren, Hagermark and Bergstrom 1991, Tomoe et al 1992;
A23187 : Hunt et al 1991, Huntley et al 1992). Intradermal skin testing, weal volume
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measurement and skin punch biopsy was carried out on flank skin as described in 2.5.2, all
measurements being made blind with respect to the experimental protocol.
4.3.1.2. Dose response studies
Each of the dose response studies (sP, 48/80 and A23187) was performed on the left flank of
four sheep. A biopsy of untreated skin was taken lrom one of the six grid sites immediately
prior to the start of the study (untreated control). Four of the remaining five sites were used to
assess different concentrations of the agent under investigation, the linal site being used to
assess the appropriate diluent control. Weal volume was measured at each of the injection
sites at 5, 10, 15 (or 20), 60, 180 and 360 minutes post-injection. A skin biopsy was taken
from each of these five sites at 360 minutes post-injection.
4.3.1.3. Time course studies
Time course studies were performed on the right flank of four sheep. A biopsy of untreated
skin was taken from one of the six grid sites immediately prior to the start of the study. The
optimal dose of the agent was injected intradermally at four of the remaining sites, the final
site being used to assess the relevant diluent control. Biopsies were taken at 15, 60,180 and
360 minutes after injection of the agent. Biopsy of the diluent control was undertaken at the
peak of the weal response, as determined from the dose response study.
Mast cell (toluidine blue pH 0.5), neutrophil (haematoxylin and eosin) and eosinophil (carbol
chromatrope) cell counts on stained skin sections were undertaken (2.5.3). The percentage of
extensively degranulated mast cells on toluidine blue-stained sections was also calculated
(2.5.4).
The weal volume for each agent at each datapoint was compared against the appropriate
diluent control by use of the Mann-Whitney U test (2.5.7). The number of mast cells,
neutrophils, eosinophils and the percentage of extensively degranulated mast cells in skin
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sections for both the dose response and time course studies were compared against appropriate
diluent controls by use of the Mann-Whitney U test (2.5.7).
4.3.2. Results
4.3.2.1. Weal Responses
A significant weal response was evoked by the intradermal injection of 50|il of 103M
substance P (sP) (Fig. 4.2 (a); P<0.05), but was not seen with the other concentrations of sP
tested. When 10"5 M sP was injected in a time course study the weal response was significant
at 10 and 20 minutes post-injection (Figs. 4.3 (a) and 4.3 (b); P<0.05).
Compound 48/80 (48/80), despite being used at a wide range of concentrations (lpg/ml to
500pg/ml), failed to produce a statistically significant weal response (Fig. 4.2 (b)).
Intradermal injection of 50pl of 250pg/ml 48/80 failed to evoke a statistically significant weal
response at any time point during the time course study (Figs. 4.3 (c) and 4.3 (d)).
Intradermal injection of 50pl of HX4 M A23187, but none of the other concentrations of
A23187, evoked a significant weal response (Fig. 4.2 (c); P<0.05). Injection of 10"4 M
A23187 produced a significant weal response at 5, 10, 20 and 60 minutes (P<0.05), the peak
occurring at 60 minutes (Figs. 4.3 (e) and 4.3 (f)).
Using optimal concentrations of each agent, the volume of the peak weal response to A23187
(median 63.1 mm3, range 36.9 mm3 to 163.7 mm3 at 60 minutes; Figs. 4.3 (e) and 4.3 (f))
exceeded that produced by sP (median 14.2 mm3, range 11.2 mm3 to 41.6 mm3 at 20 minutes;
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Figure 4.2. Dose response studies (weal volume against concentration) for sP (a), 48/80 (b)
and A23187 (c). Datapoints depict the median and error bars demonstrate the range for each
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Figure 4.3. Time course studies (weal volume against time) for 10"5 M sP (a), 250|ig/ml
48/80 (c), 10"4 M A23187 (e), and their respective diluent controls (b), (d), and (f). Datapoints
depict the median and error bars demonstrate the range for each group of measurements.
* represents statistical significance in comparison to diluent controls (P<0.05). Note that for
sP and A23187 the diluent controls were biopsied at the time ofmaximal statistically
significant weal response i.e. 15 minutes and 60 minutes respectively. Therefore, no weal
volume measurements are available for each agents diluent control after these time-points.
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4.3.2.2. Histology
For the dose response studies, all biopsy samples (except for those controls from time zero,
untreated skin) were taken at 360 minutes. As it was not known prior to the experiment when
the maximum histological change for each agent would occur, and because there were
limitations on the number of biopsies available from each animal, in time course studies the
biopsy of the respective diluent control was taken at the time of the maximal weal response
(i.e. sP 15 minutes, A23187 60 minutes). In the case of 48/80, where no weal response had
been evoked, the diluent control was biopsied at 360 minutes. Therefore, the biopsy of the
diluent control coincided with the time of maximal weal response where present, but not
necessarily with the time of maximal histological change.
4.3.2.2.1. Mast cells
There was no statistically significant effect of sP, 48/80 or A23187 on the absolute number of
mast cells in either the dose response or time course studies (Figs. 4.4 (a) to 4.4 (f)). In the
dose response study a significant increase in the percentage of extensively degranulated mast
cells occurred with 10"5 M sP, but not with the other concentrations of sP used, in comparison
to the diluent control at 360 minutes (Figs. 4.5 (a) and 4.6). This statistically significant
increase (P<0.05) was first demonstrable by 15 minutes post-injection and remained constant
thereafter (Fig. 4.5 (b)).
An apparent increase in the percentage of extensively degranulated mast cells was seen with
all of the concentrations of 48/80 used in the dose response study (Fig. 4.5 (c)). However,
these changes were not statistically significant. Owing to the absence of a demonstrable weal
response to the initial injections of 48/80, in total a range of six concentrations were used in
the four sheep involved in the dose response study. This resulted in there being fewer
individual biopsies (n = 2 or 3) for each concentration of 48/80 used. As a result, owing to
reduced sample group size, statistical significance was not attained, although the trend was
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apparent. However, in the time course study, four biopsies were available for each of the
diluent control and 48/80 challenged sites at 360 minutes post-injection. Thus, in this study, a
significant increase (P<0.05) in the percentage of extensively degranulated mast cells was
noted at this time point (Fig. 4.5 (d)). Although diluent controls were not available for the 15,
60 and 180 minutes post-injection 48/80-challenged biopsies, the degree ofmast cell
degranulation in these is of the same magnitude as at 360 minutes post-injection.
Only the highest concentration of A23187 (10"4 M) produced a significant increase in the
percentage of extensively degranulated mast cells in comparison to the diluent control at 360
minutes post-injection (Fig. 4.5 (e); P<0.05). From the time course study, this significant
effect had occurred by 60 minutes post-injection (Fig. 4.5 (f)).
4.3.2.2.1. Neutrophils
Neutrophil influx was evoked by intradermal injection of 5Opt of 10"5 M sP, in comparison to
the diluent control, by 360 minutes post-injection (Fig. 4.7 (a); P<0.05). In the time course
study, no significant neutrophil influx had occurred by 15 minutes post-injection (time of the
maximal weal response for sP) (Fig. 4.7 (b». The neutrophil influx increased up to 180
minutes post-injection, and receded thereafter (Fig. 4.7 (b)).
Compound 48/80 evoked neutrophil influx in an apparently dose-responsive fashion
(Fig. 4.7 (c)), but again, as a consequence of reduced group size owing to the wide range of
48/80 concentrations used in the dose response study, statistical significance was not attained.
Intradermal injection of 50pl of 250pg/ml 48/80 in the time course study evoked significant
neutrophil influx in comparison to the diluent control at 360 minutes post-injection
(Fig. 4.7 (d); P<0.05). Neutrophil influx was still increasing between 180 and 360
minutes (Fig. 4.7 (d)).
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Intradermal injection of 50pl of 10"4 M A23187 evoked significant neutrophil influx at 360
minutes post-injection in the dose response study (Fig. 4.7 (e)). This was not significant at 60
minutes (Fig. 4.7 (f)), the time of the peak weal response of A23187. Neutrophil influx still
appeared to be increasing between 180 and 360 minutes post-injection (Fig. 4.7 (f)).
The initial pattern of neutrophil influx was the same for all three agents. By 15 minutes post-
injection there was congestion of deep dermal vessels with the occasional neutrophil present
within the lumen (Fig. 4.8). Margination of neutrophils was obvious by 60 minutes post-
injection (Fig. 4.9), neutrophil emigration being underway. Marked dermal oedema was
present. By 180 minutes post-injection a dense neutrophilic infiltrate had developed (Fig.
4.10).
In assessing the diluent injected sites at six hours post-injection in comparison to the time zero
control sites (TO), significant neutrophil influx (P<0.05) was seen in both the sP and A23187
diluent control treated sections (median 69.8 neutrophils mm"2, range 37.7 to 73.4 neutrophils
mm2 [ sP diluent] versus median 13.6 neutrophils mm"2, range 10.6 to 13.9 neutrophils mm"2
[time zero control] and median 21.5 neutrophils mm"2, range 14.6 to 31.1 neutrophils mm"2
[A23187 diluent] versus median 5.3 neutrophils mm"2, range 0.7 to 9.3 neutrophils mm"2
[time zero control]).
4.3.2.2.3. Eosinophils
Substance P failed to evoke statistically significant eosinophil influx in either the dose
response or time course studies (Fig. 4.11 (a) and (b)).
Compound 48/80 appeared to evoke eosinophil influx in a dose-responsive manner
(Fig. 4.11 (c)) but again, owing to reduced group size, statistical significance was not
attained. However, in the time course study, the injection of 50pl of 250pg/ml 48/80 resulted
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in statistically significant eosinophil influx at 360 minutes post-injection (Fig. 4.11 (d),
P<0.05).
As with neutrophil influx, only the intradermal injection of 50pl of 10^ M A23187 evoked
statistically significant eosinophil influx (Fig. 4.11 (e), P<0.05; Fig. 4.12).This effect was not
apparent by 60 minutes post-injection in the time course study (Fig. 4.11 (f)).
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Figure 4.4. Histological assessment of mast cell numbers in toluidine blue stained sections.
Dose response studies at 360 minutes (mast cell number against concentration) are shown for
sP (a), 48/80 (c) and A23187 (e). Time course studies (mast cell number against time) are
shown for 10"5 M sP (b), 250|lg/ml 48/80 (d) and lO'4 M A23187 (1). TO represents
measurements for time zero, untreated skin. Datapoints depict the median and error bars
demonstrate the range for each group ofmeasurements. Dotted lines represent the range for
each group of measurements for the respective diluent control.
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Figure 4.5. Histological assessment of percentage of extensively degranulated mast cells in
toluidine blue stained sections. Dose response studies at 360 minutes (percentage extensive
degranulation against concentration) are shown for sP (a), 48/80 (c) and A23187 (e). Time
course studies (percentage extensive degranulation against time) are shown for 10"5 M sP (b),
250pg/ml 48/80 (d) and 10^ M A23187 (f). TO represents measurements for time zero,
untreated skin. Datapoints depict the median and error bars demonstrate the range for each
group ofmeasurements. Dotted lines represent the range for each group of measurements for
the respective diluent control. * represents statistical significance in comparison to the
appropriate diluent control (P<0.05).
136
Figure 4.6. Degranulation of dermal mast cells in substance P treated section (biopsy taken
at 15 minutes post-injection). Mast cell granules can be seen free in the dermis (arrowed).
(Toluidine blue x 500).
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Figure 4.7. Histological assessment of dermal neutrophil influx in Haematoxylin and Eosin
stained sections. Dose response studies at 360 minutes (number of neutrophils against
concentration) are shown for sP (a), 48/80 (c) and A23187 (e). Time course studies (number
of neutrophils against time) are shown for 10"5 M sP (b), 250pg/ml 48/80 (d) and 10"4 M
A23187 (f). TO represents measurements for time zero, untreated skin. Datapoints depict the
median and error bars demonstrate the range for each group of measurements. Dotted lines
represent the range for each group ofmeasurements for the respective diluent control.
* represents statistical significance in comparison to the diluent control (P<0.05).
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Figure 4.8. Congestion of dermal vessels (arrowed) in response to intradermal injection of
5Op I of 10"4 M substance P at 15 minutes post-injection. Neutrophils were occasionally
observed in the lumen. (H & E x 500).
Figure 4.9. Margination of neutrophils (arrowed) in dermal vessels at 60 minutes post-
injection in response to intradermal injection of 50pl of 1 (J4 M substance P. (H & E x 500).
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Figure 4.10. Neutrophilic dermal infiltrate at 180 minutes post-injection in response to
intradermal injection of 50pl of 104 M substance P. (H & E xl25).
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Figure 4.11. Histological assessment of dermal eosinophil influx in carbol chromotrope
stained sections. Dose response studies at 360 minutes (number of eosinophils against
concentration) are shown for sP (a), 48/80 (c) and A23187 (e). Time course studies (number
of eosinophils against time) are shown for 10"5 M sP (b), 250pg/ml 48/80 (d) and 10"4 M
A23187 (f). TO represents measurements for time zero, untreated skin. Datapoints depict the
median and error bars demonstrate the range for each group ofmeasurements. Dotted lines
represent the range for each group ofmeasurements for the respective diluent control.
* represents statistical significance in comparison to the diluent control (P<0.05).
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A
Figure 4.12. Eosinophil in A23187 treated section (104 M A23187, biopsy taken at 360
minutes post-injection). (Carbol chromotrope x 500).
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4.4. Discussion
The purpose of this study was to determine the effects of known mast cell secretagogues on
ovine dermal mast cells and to quantify the weal responses and cellular infiltration in the skin
post-challenge. In man, the characteristic finding in response to histamine injection or to
positive intradermal allergen testing is of an immediate weal and flare reaction, the weal being
considered a more accurate estimator of response in comparison to the flare (Champion and
Burton 1992). Given that mast cell degranulation had occurred in response to each of the
three agents, the dominant feature in the sheep was that of a weal, with no flare response being
noted. The lack of a consistent flare response is also a feature in the dog, where weal
production is prominent (Sture et al 1995). It is known, however, that ovine mast cells do
contain histamine (200ng/106 MMC, 48ng/106 CM-BMMC; Huntley et al 1992) and can
generate LTC4 (5.3ng per 106 CM-BMMC, in response to A23187; Huntley et al 1992). The
results indicate that sP, 48/80 and A23187, used at optimal concentrations and assessed at
appropriate time points, can evoke statistically significant mast cell degranulation and
neutrophil influx in vivo. Of these agents, only sP and A23187 were capable of evoking a
statistically significant weal response in ovine skin, and none of these three agents altered the
absolute number of mast cells present at challenged sites.
The weal response to (sP) appeared to be subject to a "window" effect, only 10"5 M sP
producing a statistically significant response. This is in contrast to the dose-dependant effect
observed in man (Coulson and Hoiden 1990, Gianetti and Girolomani 1989). It is interesting
that the only statistically significant neutrophil influx was also seen to occur with this
concentration of sP. This "window" effect may be responsible for the failure to demonstrate
plasma leakage following intradermal injection of sP in sheep (Colditz 1991b) as, correcting
for the volume per injection site, the optimal amount of sP injected in the present study was
1000 times greater than the maximum injected in the plasma leakage study. The presence of a
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statistically significant weal response at 10 and 20 minutes (maximal mean weal response) for
sP was consistent with the occurrence of maximal weal volume in man (Coulson and Holden
1990, Gianetti and Girolomani 1989). The present study has also shown that sP evokes
neutrophil influx in ovine skin, which is in agreement with studies in the mouse (Yano et al
1989, Matsuda et al 1989, Tomoe et al 1992). However, unlike the mouse, significant
eosinophil influx was not evoked (Yano et al 1989, Matsuda et al 1989, Tomoe et al 1992).
Furthermore, sP-induced neutrophil recruitment is mast cell-dependant (Matsuda et al 1989,
Yano et al 1989), and has been shown to be due to the N-terminal portion of sP (Iwamoto et al
1992). Statistically significant mast cell degranulation occurred by 15 minutes and neutrophil
infiltration was maximal at 3 hours in ovine skin, although it is not known if this response is
due to a direct effect of sP on mast cells. Substance P is a basic, positively charged peptide
which may activate mast cells in a non-receptor-dependent process (Mousli et al 1994). It has
been shown in the mouse that mast cells contain pre-formed stored TNF-a which, by
activation through IgE-dependant or -independent mechanisms, can be immediately released
(Gordon and Galli 1990a, Gordon and Galli 1991), although it is not known currently if ovine
mast cells contain TNF-a. As TNF-a can promote leukocyte infiltration through effects on
vascular endothelial cells (Pasyk and Cherry 1990), this represents one possible mechanism
for the neutrophil influx observed in the present study. Indeed, it is known that TNF-
a-stimulated endothelial cells express endothelial leukocyte adhesion molecule-1 (ELAM-1)
and intercellular adhesion molecule-1 (ICAM-1) that can mediate the subsequent adhesion of
neutrophils and eosinophils (Kyan Aung et al 1991). Furthermore, human dermal mast cells
have been shown to contain and release (upon activation) TNF-a, which directly induces
ELAM-1 expression on dermal vascular endothelium (Walsh et al 1991) and, additionally,
intradermal injection of TNF-a evokes neutrophil infiltration in ovine skin (Colditz and
Watson 1992). Substance P reactivity is present in ovine skin (Nitsos and Rees 1993), and
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thus the interaction between sP present in C nerve fibres (Foreman 1987) and mast cells could
play a role in neurogenic inflammation (as is believed to occur in man) through cutaneous
axon reflex vasodilation (Foreman 1993). Imbalances in sP and other neuropeptides have
been implicated in the pathogenesis of human atopic disease (Gianetti et al 1992, Alabadie et
al 1994) and psoriasis (Pincelli et al 1994). Mast cell chymases may help regulate cutaneous
neurogenic inflammation (Caughey et al 1988d, Naukkarinen et al 1994) and thus modulate
these disorders. Having demonstrated that ovine dermal mast cells also contain chymase
(Chapter 3), it may indicate that similar regulatory mechanisms may occur in the sheep and
this therefore provides a strong impetus for determining the mode of action and relationship
between sP and the ovine cutaneous mast cell.
The lack of development of a weal response but with the presence of statistically significant
mast cell degranulation, apparently dose-dependant neutrophil influx and statistically
significant eosinophil influx with 48/80 was surprising, since the induction of a weal response
to the agent in sheep has been previously reported (Lucio et al 1992). Given that 48/80
activates mast cells selectively (Foreman 1993) in a non-cytotoxic process (Johnson and
Moran 1969), that it does not activate vascular endothelial cells (Tomoe et al 1992), and is
known to activate cutaneous mast cells in other species (Table 4.1), the supposition would be
that mast cell activation has played a role, at some stage, in the neutrophil and eosinophil
influx. Certainly, in vitro, it has been demonstrated that 48/80-induced dermal mast cell
degranulation can induce ELAM-1 expression (Klein et al 1989). The lack of a weal response
could be dose-related, with the concentrations used not producing a "bolus" of histamine
release, thereby preventing weal formation but inducing mast cell activation and mast cell
cytokine induction (Gordon, Burd and Galli 1990) as part of the acute inflammatory response
of which neutrophil infiltration is a part. It may be that the generation of a weal response
requires accessory pathways involving activation of other cell types by mast cell-derived
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mediators (e.g. leukotrienes), which are not generated during the cutaneous response to the
intradermal injection of 48/80. Indeed, there are known species differences in the response to
48/80, as, for instance, much higher doses arc required to produce histamine release in man in
comparison to the rat (Lichtenstein et al 1979). It is conceivable that the lack of a weal
response to 48/80 could be a feature of the breed of sheep used, hut the presence of weal
responses to other agents tends to reduce this possibility. Interestingly, bovine skin mast cells
failed to release histamine in response to 48/80 (Hunt et al 1991).
Only the highest concentration of A23187 (10"4 M) gave a statistically significant weal
response and neutrophil and eosinophil influx after intradermal injection. Higher
concentrations of A23187 may be required to establish if a dose-dependant response is indeed
occurring. In addition to the activation of human, rat and bovine cutaneous mast cells
(Table 4.1), A23187 has been shown to activate ovine bone-marrow derived mast cells,
cultured in the presence of lymphocyte-conditioned medium (Huntley et al 1992). Given that
these cells are believed to represent a mixed population of ovine mast cells of both the
mucosal and connective tissue phenotypes (Huntley et al 1992), it would suggest that at least
one, or both, of the ovine mast cell populations is responsive to A23187. Although
statistically significant mast cell degranulation had occurred by 60 minutes after A23187
injection, it cannot be concluded that this, and the neutrophil and eosinophil influx, was due to
the direct stimulation of cutaneous mast cells. However, A23187 can presently be considered
to be a putative ovine cutaneous mast cell secretagogue.
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The neutrophil influx observed with the use of two of the diluents was not unexpected. In
addition to the mechanical disruption upon injection, the need to initially dissolve A23187 in
ethanol (and therefore produce an equivalent diluent) was unavoidable. Further studies to
identify the most suitable diluents for the secretagogues may be justified. Ideally, a diluent
control should be obtained for each time point in the time course studies. However, this was
not feasible for ethical reasons and therefore the time at which weal response was maximal
was chosen to assess the diluent control for each agent. It is essential when choosing diluents
to use those that are pyrogen-free (Colditz 1991b) and contain minimal endotoxin since the
latter has potent inflammatory potential in skin (Colditz and Movat 1984).
Both 48/80 and A23187 treated sites showed increased neutrophil influx from 180 to 360
minutes whereas neutrophil numbers in sP treated sites fell during this period. This represents
a fundamental difference in the kinetics of the inflammatory response to these agents, and
would justify further studies to investigate these responses by analysing the trafficking of cells
through the dermis into afferent lymph.
All three agents evoked extensive mast cell degranulation by 15 minutes post-injection
(Fig. 4.11(b), (d), (f)). However, a temporal dissociation was noted between mast cell
degranulation and the time of highest neutrophil/eosinophil influx, this being 180 minutes
post-injection for sP, and 360 minutes post-injection for both 48/80 and A23187 (Fig. 4.7 and
Fig. 4.11). Speculatively, differential mediator release by mast cell activation using these
different secretagogues could result in alterations in the rate of activation for neutrophils and
eosinophils, these cells being more rapidly recruited as a consequence of sP-induced mast cell
activation, in comparison to 48/80 and A23187.
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Hie experiments discussed in this chapter have demonstrated that intradermal injection of sP
and A23187, but not 48/80, produces a weal response in ovine skin. Dermal neutrophil and
eosinophil influx (the latter not being evoked by sP), is accompanied by mast cell
degranulation that occurs at some point before, or during, this cellular influx. There is thus
sufficient evidence from this study to consider sP, 48/80 and A23187 as putative ovine
cutaneous mast cell secretagogues. Assay for mast cell mediators in afferent lymph
immediately after intradermal challenge with these agents would be a logical progression to
prove that these agents are indeed true ovine cutaneous mast cell secretagogues. The use of
these agents in prefemoral afferent lymphatic cannulation preparations would also allow the
direct effect ofmast cell activation on changes in dermal inflammatory cell trafficking to be
determined (see Final Discussion).
Having defined putative secretagogue activity of sP, 48/80 and A23187 on the dermal mast
cell population, it was of interest to further investigate the secretagogue effects of these agents
on other ovine mast cell populations. This therefore led directly to the experiments described
in Chapters 6 and 7, where optimal conditions for the development of recombinant ovine
interlcukin-3-dependent ovine bone marrow-derived mast cells (rOv.IL-3-dependent BMMC)
were identified (Chapter 6), and where the secretagogue activity of these rOv.IL-3-dependent
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5.1. Introduction : Chymases And Cutaneous Inflammation
Activation of skin mast cells results in the release of preformed granule mediators such as
chymase, tryptase and histamine into the dermis (Caughey et al 1988a, Klein, Lavker and
Murphy 1989), chymase being released in combination with proteoglycans (Schwartz et al
1981a, Sommerhoff, Ruoss and Caughey 1992). Indeed, after secretagogue-induced dermal
mast cell activation, extracellular chymase has been demonstrated immunohistochemically in
human dermis (Kaminer et al 1991). Released chymases and tryptases are believed to play a
role in the initiation and modulation of cutaneous inflammatory responses (Harvima et al
1994, Harvima et al 1995, Schechter 1995), including the regulation of cutaneous neurogenic
inflammation by proteolytic degradation of neuropeptides (Caughey et al 1988d, Walls et al
1992, Foreman 1993, Tarn 1995).
The possible role of mast cell proteinases in the production of oedema has been considered for
some time (Lagunoff and Benditt 1963). More specifically, chymases have been shown to
affect the vascular response in inflammation (Seppa 1980), and to potentiate
histamine-induced weal formation in canine skin (Rubenstein et al 1990).
The injection of a rat chymase in human skin evoked pruritus (Hagermark, Rajka and
Berqvist 1972), and human mast cell chymase has been shown to convert keratinocyte-derived
pro-interleukin-lp (Mizutani, Black and Kupper 1991) to active interleukin-1 (Mizutani et al
1991). This proinflammatory cytokine is part of an "axis" in the production of cutaneous
inflammation (Kupper and Groves 1995), and can activate vascular endothelial cells as part of
the inflammatory response (Pober 1988). When injected, human mast cell proteinases can
evoke leukocyte emigration in skin (Fraki 1977), intradermal injection of human chymase
evoking neutrophil infiltration in guinea pig skin (Walls et al 1994). Chymases can also alter
the intercelluar matrix and basement membrane in skin (Sage, Woodbury and Bornstein 1979,
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Seppa, Vaananen and Korhonen 1979, Briggaman et al 1984, Schechter 1989), to the extent
that mast cells have been implicated in the pathogenesis of bullous pemphigoid (Goldstein,
Wasserman andWintroub 1989). Chymases have also been postulated to play a role in the
removal of damaged tissue, thereby aiding in tissue repair (Lewis and Austen 1981).
Chymases can also activate mast cells (Schick, Austen and Schwartz 1984, Schick and
Austen 1986), thereby providing a possible mechanism for up-regulation of mast cell
responses.
Thus, there is ample evidence in the literature to support the hypothesis that chymases
(directly or indirectly) play a role in the initiation and modulation of cutaneous inflammatory
responses. In support of its activity as a chymase, SMCP has recently been shown to cleave
the neuropeptides substance P and bradykinin at Pi Phe residues (Pemberton, Huntley and
Miller, submitted), wliich may implicate a role for SMCP in cutaneous neurogenic
inflammation. Unexpectedly however, SMCP also demonstrated trypsin-like activity against
bovine and ovine serum albumin (Pemberton, Huntley and Miller, submitted). The tryptic
activity of SMCP is defined by the cleavage of bonds in bovine albumin with a lysine at Pi
and aspartate or glutamate (acidic residues) at P4and P4\ a structure that occurs frequently in
ovine albumin (Pemberton, Huntley and Miller, submitted). Although SMCP is present in
only a small proportion of the ovine dermal mast cell population (Chapter 3), activation of
cutaneous mast cells would be likely to release SMCP into the dermis, albeit at low
concentrations. The availability of the technique of prefemoral afferent lymphatic cannulation
would also allow, in later studies, dissection of any observed response to the intradermal
injection of SMCP. Relatively few studies have investigated the effect of intradermally
injected native mast cell proteinases on the cutaneous response in the homologous host in vivo
(e.g. Fraki 1977, Rubenstein et al 1990). Intradermal injection of SMCP into the sheep
therefore provided a suitable homologous system to investigate the in vivo function of a mast
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cell granule chymase. The overall aim of the experiments described in this chapter was
therefore to show if SMCP could evoke a cutaneous response in the homologous host in vivo
and, if so, to define the nature of this response.
5.2. Experiment 5.1 - Cutaneous Responses To SMCP In The Sheep
5.2.1. Experimental Aim And Design
The aim of this study was to investigate the dose of SMCP which might evoke a cutaneous
response, the kinetics of the response and the nature of the vascular and cellular reaction. The
cutaneous response was assessed by measurement of weal volume and by quantifying the
cutaneous mast cell and inflammatory cell changes histologically.
Four Blackface and four Finn-Dorset cross ewes were used. These had been grazed at pasture
and had not had any anthelmintic treatment immediately before investigation. The group had
been treated once with a topical ectoparasiticide (Deltamethrin 1% w/v, Coopers Spot On®) to
remove lice and other ectoparasites four weeks before being housed, and once while housed.
The study was divided into two stages. In the first stage a dose response study was
undertaken to assess whether SMCP could evoke a weal response in ovine skin and, if so, to
determine the optimal dose. Histological examination of skin biopsies was undertaken for
evidence of cellular infiltration and mast cell degranulation. In the second stage two separate
time course studies (0-6 hours and 0-72 hours) were performed using the optimal dose of
SMCP (based on weal volume data from the first stage).
Intradermal skin testing, weal volume measurement and skin punch biopsy was carried out on
flank skin as described in 2.5.2.
5.2.1.1. Dose Response
SMCP and the SMCP diluent control were prepared as described (2.5.1.2, including absence
of endotoxin) and 36|ig, 3.6pg, 360ng or 36ng SMCP (in an injection volume of 50pl) were
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injected intradermally into the skin of the left flank of four Blackface sheep. A biopsy of
untreated skin was taken from one of the six grid sites immediately before the start of the
study (untreated control, TO). Four of the remaining five sites were injected with SMCP, the
final site being used for the diluent control. Weal volume was measured at 5, 10, 20, 60, 180
and 360 minutes after injection and biopsies were taken at 360 minutes.
5.2.1.2. Time Course - 0 to 6 Hours
This study was performed on the right flank of four Blackface sheep. A biopsy of untreated
skin was taken from one of the six grid sites immediately before the start of the study
(untreated control, TO). Four of the remaining five sites were injected intradermally with the
optimal dose of SMCP, the final site being used for the diluent control. Weal volume was
measured at 5, 10, 15, 60, 180 and 360 minutes after injection. Skin biopsies were removed
15, 60, 180 and 360 minutes after injection of SMCP. The diluent control was biopsied at the
peak of the SMCP weal response, as determined from the dose response study.
5.2.1.3. Time Course - 0 to 72 Hours
This study was performed on the right flank of four Finn-Dorset cross ewes. The six grid
sites on the flank were randomised, three sites being injected with the optimal dose of SMCP
and three sites with the diluent control. Weal volume was measured at all sites at 15, 60, 180
and 360 minutes after injection to confirm that a characteristic immediate response was
evoked. At 24, 48 and 72 hours the skin thickness was measured, and any increase from time
zero noted. Skin biopsies from paired SMCP-treated and diluent control sites were taken at
24, 48 and 72 hours.
The weal volume (0 to 360 minutes) or change in skin thickness (24 to 72 hours) following
injection of SMCP were compared with the appropriate controls by the Mann-Whitney U test
(2.5.7). The number of mast cells, neutrophils, eosinophils (2.5.3) and the percentage of
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extensively degranulated mast cells (2.5.4) in SMCP and diluent injected sites were compared
by the Mann-Whitney U test (2.5.7).
5.2.2. Results
5.2.2.1. Weal Responses
A dose-dependent increase in weal volume was observed at 180 minutes after injection
(Fig. 5.1(a)); significant increases in weal volume occurring with both 36ug and 3.6|ig SMCP
(P<0.05; Fig. 5.1(a)). The weal was circular to oval (no pseudopodia were present) and firm
(non-fluctuating), with variable erythema and no flare. The intradermal injection of 36|ig
SMCP consistently resulted in a very large and erythematous firm weal, so 3.6|ig SMCP was
chosen as the optimal dose for time course studies. The peak response occurred at 180
minutes (Fig. 5.1(b)) and increased weal volumes were noted at 10, 15, 60 and 180 minutes
(P<0.05; Fig. 5.1(b) and Fig. 5.1(c)). (N.B. As the diluent control had been biopsied at 180
minutes no control weal volume measurement was available at 360 minutes [Fig. 5.1(c)]).
Weals were not detected at 24,48 and 72 hours and skin thicknesses were similar in SMCP-
and diluent control-treated sites (Fig. 5.2). (N.B. The medians and ranges (n=4) for the weal
volumes at these sites at 180 minutes after injection were 132.6 mm3 (65.4 mm3 - 198.9 mm3)
for 3.6|ig SMCP and 1.66 mm3 (0 mm3 - 28.3 mm3) for the diluent control (P<0.0001)).
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Figure 5.1. Weal volume following intradermal injection of (a) different doses of SMCP,
measured 180 minutes later (this being the peak of the weal response to intradermal injection
of SMCP assessed in time course studies, Fig. 5.1(b) and Fig. 5.1(c)); (b) 3.6|ig SMCP and
measured at varying intervals after injection and (c) diluent; measured until 180 minutes when




























Figure 5.2. Change in skin thickness against time for sites treated with 3.6|ig SMCP or the




The number of mast cells in the dermis remained unaltered regardless of the dose of SMCP
(Fig. 5.3(a)) or time after injection (Fig. 5.3(b) and Fig. 5.4). However, the percentages of
extensively degranulated mast cells (Fig. 5.5) in response to 36|ig and 3.6|ig SMCP (P<0.05;
Fig. 5.6(a)) were increased 360 minutes after injection (e.g. for 3.6pg SMCP median 45.0%,
range 37.5%-56.4%; for diluent median 20.9%, range 14.7% - 25.6%).
Increased degranulation also occurred 180 minutes after injection of 3.6pg SMCP (P<0.05;
Fig. 5.6(b)). The extent of degranulation at the earlier time points was similar, indicating that
degranulation probably occurred as early as 15 minutes after injection (Fig. 5.6(b)).
Background levels of degranulation (15%-25%) at time zero were similar to those obtained in
diluent-treated sites at both 180 and 360 minutes after injection (Fig. 5.6(a) and Fig. 5.6(b)).
5.2.2.2.2. Neutrophils
SMCP evoked a dose-dependent influx of neutrophils into the dermis with significant
increases being noted with 36[tg, 3.6pg and 360ng SMCP (P<0.05; Fig. 5.7(a)). The
neutrophil count increased gradually and was significant by 180 minutes after injection of
3.6pg SMCP when compared with diluent control (P<0.05; Fig. 5.7(b)). Counts continued to
rise up to 360 minutes after injection (Fig. 5.7(b)), subsequently falling gradually over the
period from 24 to 72 hours (Fig. 5.8). The neutrophil count in SMCP-treated sites declined
markedly between 24 and 48 hours after injection (P<0.05; Fig. 5.8), although there were no
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Figure 5.3. Mast cell counts in toluidine blue-stained sections following intradermal injection
of (a) diluent and varying doses of SMCP measured 360 minutes later (TO = zero time point);
(b) 3.6pg SMCP and measured at varying intervals after injection, the diluent being measured

















Figure 5.4. Mast cell counts in toluidine blue stained-sections following intradermal injection
of 3.6|xg SMCP and diluent assessed at 24, 48 and 72 hours after injection.
(Median ± range; n=4).
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Figure 5.5. Degranulation of dermal mast cells at 180 minutes following injection of 3.6jig
SMCP. Mast cell granules (arrowed) can be seen free in the dermis (toluidine blue x500).
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Figure 5.6. The percentage of extensively degranulated mast cells in toluidine blue-stained
sections following intradermal injection of (a) diluent and varying doses of SMCP measured
360 minutes later (TO = zero time point); (b) 3.6|ig SMCP and measured at varying intervals
after injection, the diluent being measured at 180 minutes when the site was biopsied.












































Figure 5.7. Neutrophil counts in Haematoxylin and Eosin-stained sections following
intradermal injection of (a) diluent and varying doses of SMCP measured 360 minutes later
(TO = zero time point); (b) 3.6|ig SMCP and measured at varying intervals after injection, the
response to diluent being measured at 180 minutes when the site was biopsied. (Median ±


























Figure 5.8. Neutrophil counts in Haematoxylin and Eosin-stained sections following
intradermal injection of 3.6pg SMCP and diluent assessed at 24, 48 and 72 hours after
injection. (Median ± range; n=4).
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Congestion of dermal vessels was present in all animals 15 minutes after injection of 3.6|ig
SMCP (Fig. 5.9). Margination and emigration of neutrophils were apparent, predominantly in
deep dermal vessels, at 60 minutes (Fig. 5.10) and there was an intense dermal neutrophilic
infiltrate in sites biopsied at 180 (P<0.05; Fig. 5.7(b)) and 360 (P<0.05; Fig. 5.7(a)) minutes
(Fig. 5.11).
5.2.2.2.3. Eosinophils
The number of eosinophils was increased at 360 minutes after injection of 36pg SMCP
(P<0.05; Fig. 5.12(a)), but eosinophil counts were not increased at any time after injection of
3.6pg SMCP (Fig. 5.12(b) and Fig. 5.13).
The number of neutrophils far exceeded the number of eosinophils in skin sections for any
given dose of SMCP (Fig. 5.7(a), Fig. 5.12(a)).
5.2.2.2.4. General histology from 0 to 6 hours after injection of SMCP
Marked dermal oedema with separation of dermal collagen fibres was noted in SMCP-treated
sections, this being a dose-dependent effect (Fig. 5.14). Prominent bullous lesions were
present at 360 minutes in two biopsies, with dermal-epidermal separation occurring at the
level of the basement membrane (Fig. 5.15). (N.B. No bullous lesions had been noted in any
skin section from any of the other studies described in this thesis).
5.2.2.2.5. General histology from 24 to 72 hours after injection of 3.6pg SMCP
No histological evidence of a major mononuclear cell infiltrate (lymphocytes or
monocyte/macrophages) could be found in SMCP or diluent-treated sections at any of the lime
points examined.
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Figure 5.9. Congestion of dermal vessels (arrowed) in response to 3.6pg SMCP 15 minutes
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Figure 5.10. Profound margination and emigration of neutrophils in dermal vessels in
response to 3.6pg SMCP at 60 minutes. (H&E x500).
165


















(a) SMCP dose response
J




















60 120 180 240 300 360
Time in minutes
Figure 5.12. Eosinophil counts in carbol chromotrope-stained sections following intradermal
injection of (a) diluent and varying doses of SMCP measured 360 minutes later (TO = zero
time point); (b) 3.6|ig SMCP and measured at varying intervals after injection, the diluent
















Figure 5.13. Eosinophil counts in carbol chromotrope-stained sections following intradermal
injection of 3.6|ig SMCP and diluent assessed at 24, 48 and 72 hours after injection.
(Median ± range; n=4).
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Figure 5.14. Marked dermal oedema evoked by 36pg SMCP at 360 minutes. (H&E x!25).
Figure 5.15. Bullous lesion in skin treated with 3.6pg SMCP at 360 minutes after injection.
Note separation (arrowed) along the dermal-epidermal junction (H&E xl25).
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The results of these studies demonstrated that SMCP could evoke an immediate, but
apparently not a delayed, response in ovine skin in vivo. The immediate response was
characterized by production of a weal and marked neutrophil influx, with concomitant mast
cell degranulation. A significant influx of eosinophils was noted only with the highest does of
SMCP used (36pg), but this dose also resulted in an exaggerated weal response. Given that
intradermal injection of 3.6|ig SMCP resulted in a statistically significant weal response
between 10 and 180 minutes after injection (P<0.05; Fig. 5.1(b) and Fig. 5.1(c)), and also
resulted in both significant neutrophil influx (P<0.05; Fig. 5.7(a) and Fig. 5.7(b)) and
accompanying extensive mast cell degranulation (P<0.05; Fig. 5.6(a) and Fig. 5.6(b)), this
dose was chosen as optimal for use in further investigations.
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5.3. Experiment 5.2 - The Cutaneous Response To Heat-Inactivated SMCP
(HI-SMCP) In The Sheep
5.3.1. Experimental Aim and Design
The intradermal injection of SMCP was shown to evoke an immediate cutaneous response
(Experiment 5.1). The aim of this study was to investigate whether this occurs as a
consequence of the proteolytic activity of SMCP, or whether it results as a consequence of the
inherent property of SMCP to activate cells as a basic, polycationic protein.
Eight Finn-Dorset cross ewes were used, maintained and housed as previously described
(Experiment 5.1). SMCP and the diluent control were prepared (2.5.1.2), aliquots of each
being subjected to heat inactivation (HI) at 64°C for 10 minutes (2.5.1.3), this resulting in
SMCP with a residual activity of approximately 2% as described (2.5.1.3). Aliquots of
SMCP (3.6|ig) and of HI-SMCP and of diluent and Hl-diluent were prepared for intradermal
injection. The six grid sites on the skin of the left flank were randomised, two sites being left
untreated. The four remaining sites were injected with SMCP, HI-SMCP, diluent or
Hl-diluent. Weal volume was measured at 0, 15, 60,180 and 360 minutes after injection and
biopsies were taken at 360 minutes.
Weal volumes were compared by the Mann-Whitney U test (2.5.7). The number ofmast cells
and neutrophils (2.5.3), and the percentage of extensively degranulated mast cells (2.5.4) in




Heat inactivation of SMCP abrogated the immediate weal response (Fig. 5.16(a)). This effect
was significant at all time points examined (P<0.05-P<0.01; Fig. 5.16(a)).
(As anticipated from previous studies, SMCP evoked a significant weal response in
comparison to diluent at 15 and 60 minutes after injection (Fig. 5.16(a) and Fig. 5.16(b)).
There was no difference in weal volume between HI-SMCP and Hl-diluent-treated sites at
these time points (Fig. 5.16(a) and Fig. 5.16(b)).
5.3.2.2. Histology
5.3.2.2.1. Mast cells
There was no effect of heat inactivation of SMCP or diluent on the number of mast cells
(Fig. 5.17(a)). However, the percentage of extensively degranulated mast cells in
SMCP-treated in comparison to diluent-treated sites was increased (P<0.05; Fig. 5.17(b)).
Despite the range of values for SMCP and HI-SMCP overlapping, there was no significant
effect when comparing HI-SMCP against Hl-diluent. Again, similar to results in
Experiment 5.1, there was a relatively high background of extensive degranulation
(30%-35%) in both diluent and Hl-diluent-treated sites (Fig. 5.17(b)).
5.3.2.2.2. Neutrophils
An increased dermal neutrophil count was noted when comparing both values for SMCP
against diluent, and for HI-SMCP against Hl-diluent (P<0.05; Fig. 5.18). There was no
effect of heat inactivation of SMCP on the degree of neutrophil influx (Fig. 5.18). Therefore,
in contrast to the marked effect on the weal response (Fig. 5.16(a)), heat inactivation of
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Figure 5.16. Weal responses evoked by intradermal injections of (a) SMCP (3.6pg) or
HI-SMCP, and (b) diluent or Hi-diluent. (Median ± range; n=8). # P<0.05 compared to
































Figure 5.17. The effect of heat inactivation of SMCP (3.6pg) on (a) the number of mast cells
and (b) the percentage of extensively degranulated mast cells in toluidine blue-stained














Figure 5.18. The effect of heat inactivation of SMCP (3.6|ig) on neutrophil influx in
Haematoxylin and Eosin-stained sections. (Median ± range; n=8). * P<0.05 when comparing
SMCP or HI-SMCP against the respective diluent or Hl-diluent.
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5.4. Discussion
The finding that SMCP evokes both a weal response and neutrophil infiltration in skin is
consistent with results from other studies investigating the activity of skin proteinases and
chymases (Fraki 1977, Walls et al 1994), the present study being particularly significant in
that SMCP is used in the homologous host. It is interesting that heat inactivation of SMCP
abrogated the weal response, but had little effect on the extent of neutrophil influx. The
heat-inactivated SMCP had a residual activity (2.5.1.3) of about 2%. Thus, it can be deduced
that the injection of 3.6|ig heat-inactivated SMCP would be equivalent to injecting 72ng of
active SMCP. From the dose response study, it can be seen that neutrophil influx
(Fig. 5.7(a)), without a weal response (Fig. 5.1(a)), could be evoked by such a dose. The
same dose of SMCP also tended to increase the percentage of extensively degranulated mast
cells (Fig. 5.6(a)), approximating the result noted with inactivated SMCP in Experiment 5.2
(Fig. 5.17(b)). The ideal solution to this problem would be to identify an active-site inhibitor
for SMCP, which would leave the SMCP molecule intact, yet leave the chymase
enzymatically inactive. Subsequent repetition of Experiment 5.2 would determine if SMCP
inactivation abrogates both the weal response and neutrophil influx. Lack of time precluded
co-injection of SMCP with protease inhibitors to investigate this further, although soya-bean
trypsin inhibitor (SBTI) would have been the most appropriate to use in terms of the degree of
likely inhibition (Pemberton, Huntley and Miller, submitted). Although denaturing the protein
would have achieved complete inactivation of the active site, there would have been
concomitant changes to the tertiary structure of SMCP, which again may have affected
results.
Although the investigations in this Chapter have defined the biological nature of the cutaneous
response to SMCP, the underlying mechanisms remain open to speculation and are ripe for
further study. The cutaneous response to SMCP clearly involves both a vascular response
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(responsible for significant weal formation within 10 minutes of injection [Fig. 5.1(b)]) and a
cellular response (with margination and subsequent emigration of neutrophils across dermal
vascular endothelium increasing gradually from 0 to 6 hours after injection [Fig. 5.7(b)]),
which may occur due to separate, or possibly inter-related, mechanisms. Mast cell
degranulation accompanies the cutaneous response, this apparently occurring within 15
minutes of injection (Fig. 5.6(b)). This is consistent with in vitro studies on rat peritoneal
mast cells, which can be directly activated by chymase (Schick, Austen and Schwartz 1984).
To determine if SMCP could directly activate ovine mast cells, it was used subsequently in
mediator release studies on a rOv.IL-3-dependent BMMC population generated in vitro
(Chapter 7). If SMCP could, as with rat chymase, activate mast cells directly, preformed
mediators (including histamine) would be released, and other mediators and cytokines
synthesised (Gordon, Burd and Galli 1990). Histamine usually evokes an immediate but
relatively transient vascular response with leakage from dermal venules giving rise to weal
formation (Pasyk and Cherry 1990). In the dog, chymase was shown to potentiate the weal
response induced by histamine release from dermal mast cells (Rubenstein et al 1990). In
contrast to the dog, where the Hi receptor antagonist pyrilamine completely inhibits the
chymase-induced weal response (Rubenstein et al 1990), human chymase-induced responses
in guinea pig skin are not inhibited by Hi and H2 antagonists (Walls et al 1993). SMCP could
therefore act to potentiate the weal response induced by histamine release from ovine dermal
mast cells. However, the effect of Hi antagonists on the SMCP-induced response could not be
investigated, owing to lack of available time. The contribution of histamine to the
SMCP-induced weal response could be classically deduced by the use of antihistamines (Hi
and H2 antagonists) in vivo. However, as dermal mast cells in the rat have recently been
shown to possess H3 receptors (which may constitute a negative feedback mechanism for mast
cell histamine release (Ohkubo et al 1994), a similar ovine mechanism, if present, may lead to
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attenuation of histamine responses independently of the action of administered Hi antagonists
and therefore complicate interpretation of results.
Newly generated lipid-derived mediators may be involved in the cutaneous response to SMCP.
Leukotriene (LT) C4 and LTD4 have been shown to be 1000 times more potent in promoting
plasma leakage than histamine (Dahlen et al 1981), whereas LTB4 evokes adhesion of
leukocytes to endothelium in postcapillary venules (Dahlen et al 1981), this adhesion being
mediated via non-cyclooxygenase-dependent mechanisms (Buchanan, Vazquez and
Gimbrone 1983). Additionally, the phosphoglyceride platelet-activating factor is generated by
human vascular endothelial cells in response to histamine or IL-1 (Camussi et al 1983) and
has been shown to evoke increased vascular permeability and leukocyte influx in rabbit skin
(Humphrey et al 1984). Thus, there is ample evidence that histamine and other mediators
from activated mast cells or endothelium could play a role in the cutaneous response to
SMCP.
Activated mast cells can also generate a wide range of pro-inflammatory cytokines
(particularly IL-1 and TNF-a; Gordon, Burd and Galli 1990), which can in turn directly
activate vascular endothelial cells to both generate cytokines and undergo functional and
morphological changes that result in the margination and subsequent emigration of leukocytes
(Cotran 1987). Certainly, in human skin, dermal mast cells contain and release TNF-a upon
activation, this directly inducing ELAM-1 (endothelial cell adhesion molecule-1) expression in
superficial dermal venules (Walsh et al 1991). ELAM-1, which is exclusively expressed by
cytokine-activated endothelial cells, mediates adhesion of leukocytes to endothelial cells
(Walsh, Lavker and Murphy 1990). Margination and emigration of neutrophils was a
prominent feature of the cutaneous response. The kinetics of ELAM-1 expression following
secretagogue-induced human dermal mast cell activation (maximal by 6 hours, declining by 24
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hours and absent by 48 hours after activation; Klein et al 1989) are very similar to the kinetics
of SMCP-induced neutrophil influx (Fig. 5.7(b) and Fig. 5.8), and may support the hypothesis
that mast cell activation plays a role in the ovine cutaneous response. Interleukin 8 (IL-8), a
"C-X-C" chemokine, can be produced from endothelial cells activated by primary cytokines
such as the interleukins and TNF-a (Schroder 1995). IL-8 evokes marked neutrophil influx in
human (Swensson et al 1991), rabbit (Colditz, Zwahlen and Baggiolini 1990) and sheep skin
(Seow et al 1994). Also, inactive primary cytokine precursors could be cleaved by SMCP to
produce pro-inflammatory cytokines that activate endothelium (chymase has been shown to
cleave pro-IL-lp in human skin; Mizutani et al 1991), one effect of which may be to generate
IL-8. Alternatively, vascular endothelium may be directly activated by SMCP via
protease-activated receptors (Altieri 1995, Coughlin 1994), as has been described for both
cathepsin G and thrombin (Peterson, Stone and Shasby 1987, Aschner et al 1990). In addition
to the possible paracrine effect of cytokines on local vascular endothelium produced by
neutrophils recruited to the site (Lloyd and Oppenheim 1992), it is believed that neutrophils
can play a direct role in the control of vascular permeability in skin, thereby contributing to
oedema (Issekutz 1981, Wedmore and Williams 1981). Theoretically therefore, a marked
neutrophilic infiltrate can potentiate oedema and it is interesting to note that, in the case of
SMCP, the greatest increase in median neutrophil influx (Fig. 5.7(b)) is coincident with the
peak of the weal response.
Therefore, the mechanisms of the vascular and cellular responses to SMCP injection alluded
to above are probably closely inter-related and likely to involve mast cell activation at some
stage of the response, particularly as mast cells are believed to help regulate the second
(chemoattractant) phase of leukocyte margination (Springer 1994).
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It became apparent during the investigations that there was a relatively liigh background
(20%-30%) of degranulated mast cells in untreated control biopsies. Similar values were
obtained for diluent control sections (Fig. 5.6(a)). This implied that the diluent itself was not
evoking the degranulation, but that it could be due either to the mechanical effect of biopsy
removal or due to a fixation artefact (due to slow penetration of skin by fixative).
Additionally, it was noted that these relatively high levels of mast cell degranulation in diluent
control sites were not accompanied by proportionately high neutrophil counts (e.g. Fig. 5.6(a)
and Fig. 5.7(a)), which would again support the hypothesis of a mechanical or fixation
artefact.
The finding in two biopsies of apparent bulla formation is interesting, particularly as
chymases have been shown to degrade the basement membrane in skin (Briggaman et al 1984)
and may play a role in bullous pemphigoid (Goldstein, Wasserman and Wintroub 1989).
However, this was not a consistent finding, and it must be remembered that similar lesions can
be produced by both poor fixation and mechanical damage of skin biopsies (Scott, Miller and
Griffin 1995). Further investigation would be required to confirm that the latter possibility
was not the case.
Having shown that SMCP evokes a cutaneous response, its use in ovine afferent lymphatic
preparations would allow direct evaluation of its affect on cutaneous mast cells (by assay for
mast cell mediators in afferent lymph) and on the inflammatory response directly in vivo,
thereby addressing some of the points raised above (see Final Discussion).
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CHAPTER 6
The generation and development of recombinant
ovine interleukin-3-dependent ovine bone
marrow-derivedmast cells (rOv.il-3 bmmc) IN VITRO.
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6.1. Introduction
The generation of mast cell populations in vitro has helped elucidate mast cell heterogeneity in
the rat, mouse and man. Rat BMMC are considered analogous to the MMC phenotype (Haig
et al 1982, Miller 1993a). Unlike rat CTMC, both populations stain with alcian blue, are
dependent upon T cell factors for development, apparently synthesize chondroitin sulphate diB
rather than heparin as the major proteoglycan (Stevens et al 1986b) and produce leukotriene
C4 rather than prostaglandin D2 as the major arachidonic acid metabolite upon activation.
Both BMMC and MMC express RMCP II (Haig et al 1982, Gibson and Miller 1986) and not
RMCP-I (McMenamin et al 1987), the latter being associated with the CTMC phenotype.
Importantly, IL-3-dependent BMMC represent a homogeneous cell population with respect to
proteinase expression (Haig et al 1988a).
Similarly, murine BMMC were originally considered as being analogous to the MMC
phenotype. Both populations contained chondroitin sulphate E rather than heparin (Sredni et
al 1983), synthesized LTB4 or LTC4 in preference to PGD2 upon activation (Razin et al 1982)
and could not be activated by compound 48/80 unlike murine CTMC (Katz, Stevens and
Austen 1985). However, further studies revealed that murine BMMC are heterogeneous with
respect to proteinase phenotype (Newlands et al 1991). Thus, although there a number of
biochemical and functional similarities, BMMC cannot be considered the true analogue of
MMC in the mouse.
In man, mast cells have been classified into two types, based on their content of tryptase alone
(MCt) or of tryptase and chymase (MCtc) (Irani et al 1986). For example, MCtc account for
99% of dispersed skin mast cells (Schwartz et al 1987), whereas MCT predominate in
intestinal mucosa (Irani et al 1986). Proteinase heterogeneity also exists in cultured human
mast cells in vitro with cells cultured from foetal liver progenitors being largely MCT (Irani et
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al 1992), whereas those derived from cord blood mononuclear cells are predominantly MCtc
(Furitsu et al 1989).
In the sheep, mast cell heterogeneity in vivo has been defined on the basis of the distribution of
SMCP (Chapter 3). Thus, in the gastrointestinal tract mast cells are overwhelmingly
SMCP-positive (the putative MMC subset), whereas dermal mast cells are predominantly
SMCP-negative (the putative CTMC subset). Ovine mast cells have been previously
generated in vitro from bone marrow cells grown in the presence of lymphocyte-derived
conditioned medium (CM) (Haig et al 1988b, Huntley et al 1992). These CM-BMMC were
SMCP-positive, but apparently contained an additional serine proteinase detected by Western
blotting that was absent in isolated abomasal MMC (Huntley et al 1992). Thus, proteinase
heterogeneity may occur in ovine CM-BMMC, and it was hypothesized that CM-BMMC may
represent a mixed population of MMC and CTMC. MMC and CM-BMMC both contained
arylsulfatase, ^-hexosaminidase, histamine and dopamine, indicating that there were
similarities between the two cell types (Huntley et al 1992). However, as CM-BMMC were
SMCP-positive, these could not be considered the in vivo analogue of the majority of ovine
dermal mast cells. Thus, an alternative source of ovine BMMC was sought for use in future
mediator release studies, enzymatic dispersion of ovine dermal mast cells having proved
problematical (J.F.Huntley, personal communication).
When grown in the presence of IL-3, bone marrow cells from the mouse (Ghiara et al 1985,
Rennick et al 1985, Chiu and Burrall 1990) and rat (Haig et al 1988a) differentiate into mast
cells. However, in human bone marrow cultures supplemented with IL-3, the production of
basophils is favoured (Kirshenbaum et al 1989, Valent et al 1989), although small numbers of
mast cells can be generated (Kirshenbaum et al 1989, 1992). Following cloning and
expression of the ovine IL-3 gene (MTnnes, Haig and Logan 1993), it was known that
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recombinant ovine IL-3 (rOv.IL-3) could support the development of mast cells from ovine
bone marrow in vitro (Haig 1993), based on staining both with Leishman's stain and to detect
the presence of chloroacetate esterase. However, studies to optimise the growth of rOv.IL-3
BMMC in a liquid culture system were not undertaken, and no attempt had been made to
characterize the rOv.IL-3 BMMC with regard to their possible phenotypic heterogeneity.
The aims of the investigations described in this Chapter were therefore firstly to define the
culture conditions required to generate rOv.IL-3-dependent BMMC in vitro, and secondly to
characterize them in terms of their mediator content. These aims were achieved in three
stages. (1) The optimal dose of rOv.IL-3 required to generate BMMC was determined in dose
response studies. (2) The kinetics of BMMC development was defined in a time course study
using the optimal dose of rOv.IL-3. (3) Finally, in an effort to increase the percentage of
BMMC obtained in culture, the effect of transferring the non-adherent cell population at
feeding to fresh wells was investigated.
6.2. Experiment 6.1 - The Generation And Development Of rOv.IL-3 BMMC
In Vitro
General Experimental Design
Ovine bone marrow was obtained from a Blackface lamb (2.2), the purified cell population
being plated out in 24-well plates as described (2.3.1). Both test (using 10'1,10"2, 10"3, 10"4,
10 5 and 10"6 rOv.IL-3 in the dose response study and 104 rOv.IL-3 in the remaining
experiments) and control (IMDM/10% FCS (Appendix A)) samples were plated out in
triplicate wells.
At harvest, a cell count was performed for each well (2.3.3) and cytosmear preparations made
(2.3.4) for both histochemical (Leishman's, 2.3.5) and immunohistochemical (to detect
SMCP, 2.3.6, 2.3.8.2) staining. The percentage of mast cells in anti-SMCP stained
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cytosmears could therefore be calculated (2.3.10). The remaining cells in each well were
assayed as a cell pellet (2.3.2) for the presence of SMCP, and for arylsulfatase and
p-hexosaininidase activity as described (2.3.11, 2.3.12, 2.3.13, 2.3.14). Results were
expressed as the quantity or activity of mediator present in each well. Where statistical
significance could be demonstrated between groups by ANOVA, Student's t-test was
subsequently performed to compare test groups against the appropriate control. Additionally,
in the time course study, linear regression analysis was used to correlate the cell mediator
content (for SMCP) or activity (for arylsulfatase or ^-hexosaminidase) against both the total
number of cells and the absolute number of SMCP-positive mast cells for each well.
6.2.1. Dose Response Study
The aim was to determine the optimal dose of rOv.IL-3 required for mast cell development in
vitro. Final dilutions of 10"1, 10 2, 10"3, 10"4, 10"5 and 10"6 rOv.IL-3 (expressed as dilutions of
the original CHO cell-derived supernatant) were used, these being added to cultured cells in
three 24 well plates in conjunction with triplicate control wells (IMDM/10%FCS alone).
Individual plates were harvested on days 6, 12 and 17 of culture (2.3.2).
6.2.1.1. Results
There was a dose-dependent increase in viable cell count in the presence of rOv.IL-3 on days
12 and 17 of culture in comparison to IMDM/10% FCS controls (For dilutions of 10"1, l(f2
and 103 rOv.IL-3 on both days P<0.05-0.01; Fig. 6.1). This dose-dependent effect on cell
density was reflected in Leishman's-stained cytosmears (Fig. 6.2). Increasing numbers of
granulated, mononuclear cells were identified in cytosmears from wells cultured with higher
concentrations of rOv.IL-3 (Fig. 6.3). SMCP-positive cells were detected
immunohistochemically (Fig. 6.4(a)). They were categorised as putative mast cells
represented by both small and large mononuclear cells (Fig. 6.4(b)), which were distinct from
a small number (~ 1% to 2% of the total cell population) of basophil-like SMCP-positive
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polymorphonuclear cells (Fig. 6.4(c)). The percentage of SMCP-positive mast cells generated
on days 12 and 17 of culture was also a function of the concentration of rOv.IL-3 (Fig. 6.5).
The numbers of SMCP-positive mast cells were increased (P<0.05-0.01; Fig. 6.5) when
grown in the presence of 10"1, 10~2, 10"3 and 10"4 rOv.IL-3 on day 12 , and in 10"1, 10~2, 10"3,
10"4 and 10"5 rOv.IL-3 on day 17. When both the total viable cell count and the percentage of
SMCP-positive mast cells was considered (Figs. 6.1 and 6.5), the greatest numbers of mast
cells were generated in the presence of the higher doses of rOv.IL-3 (particularly 10"1
rOv.IL-3 on days 12 or 17).
The concentration of SMCP per well was increased over control values in the presence of
10"1, 10"2, 10"3, 1CT4 and 10"5 rOv.IL-3 on both days 12 and 17 (P<0.05-0.01; Fig. 6.6(a)).
This effect was dose-dependent and probably reflected the higher percentage of
SMCP-positive mast cells and the increased viable cell count that resulted when cells were
grown in higher concentrations of rOv.IL-3.
Arylsulfatase and (3-hexosaminidase activity in rOv.IL-3 supplemented wells increased in an
apparently dose-responsive fashion only on day 17, but owing to a lack of control sample
measurements at this time point (insufficient sample following repetition of original SMCP
ELISA) this data could not be evaluated statistically (Fig. 6.6 (b) and (c)).
The results of this experiment demonstrated that supplementation of IMDM/10% FCS with
rOv.IL-3 increased the total viable cell count of the culture, and favoured the development of a
population of putative BMMC. Arylsulfatase and P-hexosaminidase activities were also
demonstrated in the cultured cell population, although the source of this activity was not
identified. The peak viable cell count on day 17 was obtained with 10"1 rOv.IL-3 (9.9 + 1.2
xlO5 cells/ml; Mean ± SEM, n=3; Fig. 6.1), this cell population consisting of 35.8 ± 6.7 %
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(Mean ± SEM, n=3) mast cells (Fig. 6.5). Therefore, of the concentrations tested, 10"1
rOv.IL-3 was considered to generate the greatest numbers ofBMMC in vitro.
The dose response experiment was repeated with concentrations of 10% (equivalent to 104),
20% and 30% rOv.IL-3, harvesting occurring at days 8, 14 and 17 (Appendix B, Fig. B.l and
Fig. B.2). This confirmed that a concentration of 104 rOv.IF-3 generated the greatest
numbers of mast cells in culture. However, it was evident that variability existed between the
two cultures in terms of both the useful life-span of the cultures and the maximum percentage










Figure 6.1. Growth of bone marrow cells shown as total viable cell count (xlO5 cells/ml)
plotted against time (days) for different dilutions of rOv.IL-3 (Mean ± SEM; n=3). # P<0.05
compared with IMDM/10% FCS control and * represents a similar effect at P<0.01.
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Figure 6.2. Cytosmear preparations of ovine bone marrow cell suspension grown in the
presence of 10"1 (a), 103 (b), 10"6 (c) rOv.IL-3 and in the presence of IMDM/10% FCS alone
(d) at day 17 of culture (Leishman's stain, x312.5). Each cytosmear was prepared with 125pl
of cell suspension.
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Figure 6.3. Leishman's-stained cytosmear preparation of ovine bone marrow cells grown in
the presence of 10"1 rOv.IL-3 at day 12 of culture. Note large numbers ofmononuclear,
granulated mast cells (x625).
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Figure 6.4(a) and (b). Cytosmear preparations of ovine bone marrow cells grown in the
presence of 10"1 rOv.IL-3 on day 12 of culture stained immunohistochemically with 2.5pg/ml
PBS of affinity purified polyclonal rabbit anti-SMCP (Batch 148/93) as the primary antibody
(2.3.6, 2.3.8.2). (a): Note the intense red staining indicating the presence of SMCP and the
absence of staining of fibroblast-like cells (x312.5). (b): Small and large putative mast cells





Figure 6.4(c). Cytosmear preparations of ovine bone marrow cells grown in the presence of
10"1 rOv.IL-3 on day 12 of culture stained immunohistochemically witli 2.5pg/ml PBS of
affinity purified polyclonal rabbit anti-SMCP (Batch 148/93) as the primary antibody (2.3.6,
2.3.8.2). (c) : Basophil-like cell staining intensely for SMCP (x625). All control cytosmears
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Figure 6.5. The effect of rOv.IL-3 on the growth of BMMC. The percentage of
SMCP-positive mast cells is plotted against the dilution of rOv.IL-3 at days 12 and 17 of
culture (Mean + SEM; n=3). # P<0.05 compared with IMDM/10% FCS control and
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Figure 6.6. The concentration of SMCP (ng/well) (a), and activities (units/well) of
arylsulfatase (b) and P-hexosaminidase (c) on days 12 and 17 of culture (Mean ± SEM; n=3).
As described in the text, no control samples were available for arylsulfatase and
P-hexosaminidase assay at day 17. # P<0.05 compared with IMDM/10% FCS control and
* represents a similar effect at P<0.01.
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6.2.2. Time Course Study
Using the optimal concentration of 10"1 rOv.IL-3, the kinetics of growth and development of
ovine BMMC were investigated. Test and control cultures were plated out in triplicate in 24
well plates, cells being harvested at days 2, 5, 7, 9, 12, 14, 16 and 19.
6.2.2.1. Results
An increase in the total viable cell count in the presence of 10"1 rOv.IL-3 was seen from day 5
of culture, and reached a peak at day 16 (P<0.05-0.01; Fig. 6.7). The percentage of
SMCP-positive mast cells increased in both test and control groups on day 2 of culture, before
falling again in both groups by day 5 (Fig. 6.8). A further rise only in rOv.IL-3 supplemented
wells plateaued on days 14-16 (PcO.Ol on days 9, 12,14, 16 and 19; Fig. 6.8), the subsequent
decline in SMCP-positive cells (Fig. 6.8) being coincident with the decline in viable cell count
between days 16 and 19 (Fig. 6.7).
Concentrations of SMCP in both test and control wells followed similar kinetics to that
described for SMCP-containing cells with an initial peak on day 2, followed by a decline and
subsequent increase, with maximum concentrations occurring on days 12 to 16 (P<0.05-0.01;
Fig. 6.9(a)).
In contrast, the activity of both arylsulfatase and [3-hexosaminidase increased gradually from
day 0 of culture (P<0.05-0.01 on days 9, 12, 14 and 16 for arylsulfatse [Fig. 6.9(b)] and
P<0.05-0.01 on days 7, 9, 12 and 14 for [^-hexosaminidase [Fig. 6.9(c)]). Increased activity
in control wells (Fig. 6.9(b) and Fig. 6.9(c)) with low viable cell counts and low percentages
of SMCP-positive mast cells would suggest that these mediators were also present in cells
other than mast cells. Using linear regression analysis, the concentration or activity of each
mediator in each individual well was correlated to either the cell total or to the number of
SMCP-positive mast cells present in each well (Table 6.1). Highly significant correlations
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(PcO.OOOl) were demonstrated for each mediator with both cell populations. Thus, the
cellular source of mediator could not be identified from these results. However, it is of
interest that the r value for SMCP is apparently greater for the SMCP-positive mast cell
population (0.76) than for the general cell population (0.60). Conversely, the r values for both
arylsulfatase and ^-hexosaminidase are apparently greater when correlated with the general
cell population than with the SMCP-positive mast cell population.
In an effort to further characterize the mast cells generated in the presence of 10"1 rOv.IL-3,
electron microscopy was undertaken on cells harvested at day 13 from a separate culture
(2.3.16). Eight separate grids were examined, with approximately 40 mast cells being present
per grid. A representative mast cell is shown in Fig. 6.10. The cells were round or oval,
mononuclear, with a sparse complement of cytoplasmic granules. The granules present
contained little electron-dense material. The endoplasmic reticulum and Golgi apparatus were
not well developed in any of the cells examined. Pseudopodia were a prominent and consistent
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Figure 6.7. Growth of ovine bone marrow cells shown as the total viable cell count (xlO
cells/ml) plotted against time (days) (Mean ± SEM; n=3). # P<0.05 compared with
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Figure 6.8. The effect of time on the growth and development of BMMC. The percentage of
SMCP-positive mast cells is plotted against time (days) (Mean ± SEM; n=3). * P<0.01
compared with IMDM/10% FCS control.
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Figure 6.9. The concentration of SMCP(ng/well) (a), and activities (units/well) of
arylsulfatase (b) and ^-hexosaminidase (c) plotted against time (days) (Mean± SEM; n=3).
# P<0.05 compared with IMDM/10% FCS control and * represents a similar effect at P<0.01.
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Table 6.1. Mediator content or activity of the cell population of each well correlated to the
total cells per well or to the number of SMCP-positive mast cells per well.
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Figure 6.10. Electron photomicrograph of an ovine rOv.IL-3-dependent BMMC at day 13 of
culture. Note mononuclear appearance and relative paucity of granules. Prominent
pseudopodia are present, (x 12000).
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6.2.3. Removal Of Adherent Cells
In an attempt to increase the maximal percentage of SMCP-positive mast cells obtained in
culture, the effect of transferring non-adherent cells at feeding was investigated. The
hypothesis was that such transfer would result in depletion of the adherent fibroblast-like cells.
Using 10"1 rOv.IL-3 bone marrow cells were plated out into two 24-well plates. In plate I, the
cell population was fed at days 6 and 14, but retained in the original plate. In plate II,
non-adherent cells were transferred to wells in a fresh plate at feeding. Cell harvests from
both plates were undertaken at days 14 and 20.
6.2.3.1. Results
An increase in the percentage of SMCP-positive mast cells in rOv.IL-3 supplemented wells
was observed in plate II in comparison to plate I on both days 14 (P=0.05) and 20 (P=0.04)
(Fig. 6.11). Given that there was no significant difference in the viable cell count for rOv.IL-3
supplemented wells at day 14 between these plates (P=0.75; Fig. 6.12), the greatest total
number of BMMC would be obtained by harvesting plate II. However, by day 20, there was
a statistically significant reduction in viable cell count for rOv.IL-3 supplemented wells in
plate II in comparison to plate I. Thus, the optimal time for cell harvesting had passed by
day 20. (There were no significant differences in viable cell count for control wells between
plates I and II at all time points studied, nor when comparing rOv.IL-3 supplemented wells in
plates I and II at day 6).
This result demonstrates that tire maximal percentage of SMCP-positive mast cells generated
in vitro could be increased by transferring the non-adherent cell population to fresh wells at
feeding (Fig. 6.11). Additionally, if the viable cell count data is also considered (Fig. 6.12), a
greater absolute number of mast cells is obtained if previously transferred cells are harvested































































Figure 6.11. The effect of transferring non-adherent bone marrow cells on the growth of
BMMC. The percentage of SMCP-positive mast cells for plates I (non-transferred) and II
(transferred) is plotted against time (days) (Mean ± SEM; n=3). Plates were fed (and
non-adherent cells in plate II transferred) at days 6 and 14 of culture. # P<0.05 compared






















































Figure 6.12. The effect of transferring non-adherent bone marrow cells on cell growth. The
total viable cell count (xlO5 cells/ml) for plates I (non-transferred) and II (transferred) is
plotted against time (days) (Mean ± SEM; n=3). Plates were fed (and non-adherent cells in
plate II transferred) at days 6 and 14 of culture. # P<0.05 compared with IMDM/10% FCS
control and * represents a similar effect at PcO.Ol.
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6.3. Discussion
Marked differences were observed in the final quality of the rOv.IL-3 BMMC culture
obtained in comparison to IL-3-dependent mast cell populations derived from the mouse
(Ghiara et al 1985, Rennick et al 1985, Chiu and Burrall 1990) and rat (Haig et al 1988a).
Firstly, rOv.IL-3 BMMC cultures were relatively short lived, with cell viability declining after
approximately two weeks in culture. This contrasts with the rat (Haig et al 1988a) and mouse
(Chiu and Burrall 1990), where IL-3-dependent BMMC cultures were stable for up to 6
weeks and 5 months respectively. Secondly, the maximum percentage of rOv.IL-3 BMMC
obtained in any of the experiments was 72.5 ±4.0% (Appendix B, Fig. B.2.; 20% rOv.IL-3
harvested at day 8 of culture). However, mast cell populations of >90% purity are achieved
within 14 days in both mouse and rat (Chiu and Burrall 1990, Haig et al 1988a).
Additionally, when ovine bone marrow cells are grown in the presence of lymphocyte-derived
conditioned medium (CM), cultures consisting of 90% BMMC are attained by day 28, and
survive for up to 3 months (Haig et al 1988b).
Electron microscopy of these CM-derived BMMC (CM-BMMC) reveals more complete
granule formation (Huntley et al 1992) than in comparable rOv.IL-3 BMMC (Fig. 6.10), even
though these CM-BMMC are themselves more poorly granulated than mucosal mast cells
(MMC) from parasitized abomasum (Huntley et al 1992). As rOv.IL-3 can also act
synergistically with CM to produce increased numbers ofmast cell colonies in soft agar bone
marrow cell clonogenic assays (Haig 1993), it is likely that other cytokines or factors are
necessary to support the proliferation, differentiation and ultimate maturation of ovine
rOv.IL-3-dependent BMMC in vitro. It would therefore appear that IL-3 is not the sole factor
supporting mast cell-growth in ovine conditioned medium.
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The rOv.IL-3 BMMC were SMCP-positive, which is consistent with results for CM-BMMC
(Haig et al 1988b, Huntley et al 1992). The rOv.IL-3 BMMC were not examined for the
presence of an additional serine proteinase present in CM-BMMC but not in abomasal MMC
(Huntley et al 1992). The hypothesis that CM-BMMC may contain a mixture ofMMC and
CTMC phenotypes (Huntley et al 1992) could not, therefore, be extended to rOv.IL-3
BMMC. However, given the results from Chapter 3 that the MMC of the ovine
gastrointestinal tract are overwhelmingly SMCP-positive (putative ovine MMC phenotype)
and that the majority ofmast cells in the skin are SMCP-negative (putative ovine CTMC
phenotype ), then this would suggest that rOv.IL-3 BMMC resemble the putative ovine MMC
phenotype. In the rat, IL-3 stimulates the growth of a population of BMMC almost identical
to MMC (Haig et al 1988a) that are homogeneous in proteinase phenotypc (Haig et al 1988a).
In contrast, IL-3-dependent murine BMMC can express a non-MMC phenotype, expressing
both MMCP-5 (McNeil et al 1991) and MMCP-6 (Reynolds et al 1991). Indeed, murine
BMMC are considered a heterogeneous cell population with regard to their proteinase content
(Newlands et al 1991), with some cells expressing a serosal mast cell phenotype. Mast cell
proteinase expression can be altered by a range of cytokines (reviewed in Chapter 1). For
example, IL-9 can enhance the proliferation of murine mast cell lines induced by IL-3 or IL-4
(Hiiltner et al 1989, Moeller et al 1989, Hiiltner et al 1990), the latter cytokines also inhibiting
the IL-9-induced expression ofMMCP-1, MMCP-2 and MMCP-4 (Eklund et al 1993).
Importantly, stem cell factor (SCF) was shown to act synergistically with IL-3 to promote the
growth of both rat (Haig et al 1994) and mouse (Tsai et al 1991a) IL-3-derived BMMC. In
vivo, SCF was shown to induce the development of both CTMC and MMC at the appropriate
anatomical sites in the rat (Tsai et al 1991b). Therefore, it may be that combinations of
cytokines (particularly SCF in addition to IL-3) are required to generate ovine BMMC that
would be phenotypically analogous to the predominantly SMCP-negative dermal mast cell
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population. However, during the course of these studies, recombinant ovine SCF was not
available.
The biphasic peak of both SMCP-positive mast cells and SMCP concentration demonstrated
in the time course study warrants further investigation. SMCP-positive cells are present in
day 0 bone marrow, and it may be that these cells comprise two subpopulations. Firstly, a
subpopulation of committed progenitor cells initially stimulated by the bone marrow
microenvironment may rapidly mature in the presence of exogenous IL-3, resulting in the
initial section of the biphasic peak, these cells then rapidly dying. Secondly, a population of
stem cells may differentiate, proliferate and mature gradually from day 0 in the presence of
exogenous IL-3 to give the second phase of the biphasic peak at approximately day 14. This
hypothesis is complicated by the presence of apparently mature, SMCP-containing
basophil-like cells. No basophil-like cells were reported in ovine CM-BMMC cultures (Haig
et al 1988b, Huntley et al 1992). In both mouse (Rottem et al 1993) and man (Kirshenbaum
et al 1989, Valent et al 1989) basophils can be generated from bone marrow cells grown in the
presence of IL-3, which would favour the rOv.IL-3 BMMC population being more like mouse
BMMC than rat BMMC (no mature basophils being generated in this system; Haig et al
1988a). It is acknowledged that immature basophils can be difficult to differentiate
morphologically from mast cells (Dvorak 1986), and that these cells may have been classified
in the early stages of culture as mast cells, prior to developing a fully polymorphonuclear
appearance. Thus, these immature cells could have been erroneously included in cell counts
contributing to the magnitude of the initial phase of the biphasic peak.
Unlike SMCP (where immunohistochemistry could be readily performed on BMMC), it could
not be stated with certainty that ovine rOv.IL-3 BMMC contained arylsulfatase and
p-hexosaminidase, owing to their possible production by other cell types in the cultures.
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However, with this in mind, when time course study results for rOv.IL-3 BMMC at day 19
(the latest time point available for comparison) are expressed in terms of the quantity of
SMCP or activities of arylsulfatase or P-hexosaminidase per 106 mast cells, the results are
similar to those reported for CM-BMMC harvested between days 21 and 35 of culture
(Huntley et al 1992; Table 6.2). The figures for CM-BMMC were derived from cultures that
included between 10% and 30% of contaminating cell types, so the query regarding the
cellular source of arylsulfatase and P-hexosaminidase is still pertinent. Had time allowed, an
attempt could have been made to identify the cellular source of arylsulfatase and
P-hexosaminidase in mast cell cultures using dual immunohistochemistry on adjacent thin
sections (the arylsulfatase subtype present in the rOvIL-3 BMMC population was not defined
in these studies). The concentration of SMCP in rOv.IL-3 BMMC is approximately half of
that in CM-BMMC, which may reflect the granule immaturity of rOv.IL-3 BMMC. Mature
MMC isolated from the abomasum (Huntley et al 1992) contain considerably more SMCP
than either rOv.IL-3 BMMC or CM-BMMC (Table 6.2). Therefore, in terms of their content
of granule proteinase, rOv.IL-3 BMMC can be considered again similar to murine BMMC
(Newlands et al 1991) and unlike rat IL-3 BMMC (Haig et al 1988a), in that they contain
very low levels of granule proteinase.
Arylsulfatase activity appears similar between the two ovine BMMC populations, and
approximates that of abomasal MMC. Interestingly, both rOv.IL-3 BMMC and CM-BMMC
appear to contain more P-hexosaminidase activity than do abomasal MMC, with rOv.IL-3
BMMC containing approximately 2V2 times the activity of CM-BMMC. However, until the
contribution of the contaminating cell population is known, or until a pure ovine rOv.IL-3
BMMC population can be generated, further interpretation of these results is speculative.
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Mast cell activation during mediator release studies can be assessed by the release of
arylsulfatase and P-hexosaminidase (Stevens et al 1986a, Broide, Metcalfe and
Wasserman 1988, MacDonald et al 1989, Huntley et al 1992), owing to their localisation to
the mast cell secretory granule (Schwartz et al 1981b). However, in the rOv.IL-3 BMMC
culture where contaminating cells are present, the possible activation of these cells by
non-mast cell-specific secretagogues (e.g. calcium ionophore A23187) must be considered.
Additionally, the presence of a small population of basophil-like cells (Fig. 6.4(c)) also
complicates release studies, as it is not known if these would be capable of activation by
chemical secretagogues (Foreman 1993). Interpretation of release studies (Chapter 7) must
therefore be undertaken with caution, although it can be inferred that for rOv.IL-3 BMMC the
release of SMCP rather than arylsulfatase or P-hexosaminidase may provide a more valid and
reliable indicator of specific mast cell activation.
Given that cultnre conditions were constant the variability in cell viability and maximum
percentage ofmast cells probably reflects between sheep variability. Presumably, such
variations may result from changes in the initial combination of microenvironmental factors
(e.g. cytokines) present in bone marrow that can directly regulate the number and type of stem
or progenitor cells, thereby affecting the number of cells subsequently committed to
proliferation and differentiation into mast cells (Metcalf 1993).
The series of experiments described in this chapter successfully defined the optimal conditions
for generation of rOv.IL-3-dependent BMMC in a liquid culture system. An IMDM/10%
FCS medium (Appendix A) containing a final dilution of 10"1 rOv.IL-3 was found to be
optimal. The non-adherent cell population should he transferred to fresh plates at feeding,
with cell harvesting occurring between days 12 and 16 of culture. This protocol was therefore
209
employed for large scale generation of rOv.IL-3 BMMC in flasks for use in mediator release
studies (Chapter 7).
The initial characterisation of these rOv.IL-3 BMMC could therefore be further investigated.
This prompted the mediator release studies described in Chapter 7, where the functional
activity of these putatively MMC-like cells was elucidated using substance P, compound
48/80, calcium ionophore A23187 and SMCP as putative secretagogues. These results could
be compared with the effects of the same agents in ovine skin in vivo (Chapters 4 and 5),
where the majority ofmast cells are SMCP-negative (the putative CTMC phenotype; Chapter
3). Additionally, given that there are differences in the nature and development of the cell
populations generated by rOv.IL-3 and CM, the functional activity of rOv.IL-3 BMMC in
terms of mediator release could be compared with that reported for CM-BMMC. These
investigations would further define ovine mast cell heterogeneity.
210
Table 6.2. Comparison of means and standard errors of the mean for mediator content of
rOv.IL-3-dependent BMMC (IL-3 BMMC; day 19 of culture), conditioned medium-derived
BMMC (CM-BMMC; days 21 to 35 of culture) and isolated MMC from parasitized
abomasal mucosa (abomasal MMC). (* Data derived from Huntley et al 1992).
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CHAPTER 7
The functional heterogeneity of
rOv.IL-3 BMMC : THEIR RESPONSE TO SUBSTANCE P,




Comparison of the differential response of mast cell populations to chemical secretagogues
(Foreman 1993) is one of the standard methods of defining mast cell heterogeneity (Barrett
and Pearce 1993). As discussed in the general introduction, 48/80 and sP are generally
activators of the CTMC subset (with some exceptions), whereas A23187 is a non-specific
activator of both CTMC and MMC phenotypes (1.5). Mast cell populations generated
in vitro have also been characterized by comparing their secretagogue activity to that observed
in vivo. For example, in one study an in vitro murine IL-3 BMMC population was considered
to share properties with those of murine peritoneal mast cells (Chiu and Burrall 1990).
Additionally, chymase, as outlined earlier, can activate rat serosal mast cells (Schick and
Austen 1986) and rat CM-BMMC (Gardner 1990) in vitro.
Having shown that these agents possess putative secretagogue activity for the ovine dermal
mast cell population (Chapters 4 and 5), their application in vitro may permit further
characterization of rOv.IL-3 BMMC (Chapter 6). The studies described in this Chapter were
carried out in order to bring additional criteria to the assessment of ovine mast cell
heterogeneity.
7.2. Experiment 7.1 - Mediator Release Studies On rOv.IL-3 BMMC Induced
By Calcium Ionophore A23187, Compound 48/80, Substance P, SMCP And
Heat-Inactivated SMCP
7.2.1. Experimental Aim And Design
The aim was to determine if rOv.IL-3 BMMC are activated in vitro by A23187, sP, 48/80
and SMCP. The release of the granule-associated mediators arylsulfatase and
^-hexosaminidase was quantified for all of the secretagogues. Additionally, the release of
SMCP was determined for A23187, sP and 48/80.
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Bone marrow cells were obtained as described (2.3.1) and grown in the presence of an optimal
concentration of rOv.IL-3 (initially 10"1 rOv.IL-3 prior to using new, batch-tested
CHO cell-derived supernatants). Cultures containing 40-50% mast cells were harvested on
days 12 to 16 (Chapter 6) and mediator release studies performed (2.3.15). Where possible,
the relative amount of each secretagogue and of the respective diluent in control eppendorfs
was the same as that used in vivo (Chapters 4 and 5). (As the rOv.IL-3 BMMC were finally
suspended in 200pl ofmedium for the release study, this necessitated increasing the quantity
of secretagogue from that used in vivo by a factor of four). Thus, A23187 was used at final
concentrations of 10~4M, 10 s M, 10"6M and 10"7 M, 48/80 at 250pg/ml and substance P at
1 03 M and 10"4 M. SMCP and the diluent control was prepared (2.5.1.2), aliquots of each
being subjected to heat inactivation (HI) at 64 °C for 10 minutes (2.5.1.3), this resulting in
SMCP with a residual activity of about 2% (2.5.1.3). 3.6pg (i.e. 72p.g/ml as the final
concentration in the eppendorf), 360ng and 36ng SMCP (amounts in pg are per 50pl Earle's
medium; 200pl Earle's medium being used per eppendorf, containing 0.5 or 1 x 10s cells) and
of HI-SMCP and of diluent and Hl-diluent were used. Samples were performed in duplicate
and, for each agent, measurements were undertaken in two separate rOv.IL-3 BMMC
cultures. Assays of SMCP, arylsulfatase and (3-hexosaminidase were performed on pellet
supernatants following activation as described (2.3.12, 2.3.13, 2.3.14). The release of
mediator was expressed as a percentage of the total content or activity of mediator assayed
after extraction from separate duplicate, non-stimulated, control cell pellets (2.3.15).
7.2.2. Results
In mediator release studies undertaken with sP, the values for release due to 10"3 M sP were
appreciably higher in comparison to diluent for all three mediators in each of the experiments
(Table 7.1). Diluent-induced (3-hexosaminidase release values were similar between the two
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experiments (12% and 14.5%), 10"3 M sP evoking approximately two to three times this
baseline release (Table 7.1). The release of arylsulfatase and SMCP was more variable
between experiments and in the diluent values. From these results, sP appears to evoke
mediator release from rOv.IL-3 BMMC.
The release of [3-hexosaminidase in response to 48/80 was again consistently greater (35.6%
and 15%) than in response to diluent alone (3.1% and 8.2%). The baseline values for
arylsulfatase again varied between experiments and, for SMCP, were high (41.7% and 46.4%)
but there was, again, an apparently specific release of all three mediators in response to
challenge (Table 7.2).
For A23187 the values for the diluent controls varied between experiments (Table 7.3).
However, the trend was for the higher concentrations of A23187 (10"* M and 10~5 M) to evoke
an approximate two-fold increase in specific release of mediator (Table 7.3). This would
suggest, therefore, that A23187 is a secretagogue for rOv.IL-3 BMMC.
Exposure of rOv.IL-3 BMMC to exogenous SMCP and HI-SMCP failed to increase the
release of arylsulfatase or [^-hexosaminidase above that observed with diluent alone
(Table 7.4). When the concentration of diluent was equivalent to that used for 3.6pg
SMCP/50pl medium (Table 7.4), there was 65.3% to 68.9% release of (3-hexosaminidase.
This is much higher than for other diluents (e.g. sP 12.0% to 14.5%; 48/80, 3.1% to 8.2%;
A23187, 4.7% to 25.8%). There is, therefore, no evidence that SMCP or HI-SMCP can
evoke mediator release from rOv.IL-3 BMMC.
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103 M sP 104 M sP Diluent
Experiment 1 36.7% 24.5% 12.0%
Experiment 2 27.5% 21.3% 14.5%
Arylsulfatase
release
10 3 M sP 10 4 M sP Diluent
Experiment 1 63.0% 31.6% 30.4%
Experiment 2 50.3% 30.1% 11.3%
SMCP release 103 M sP 10 4 M sP Diluent
Experiment 1 16.7% 5.5% 5.8%
Experiment 2 67.2% 60.8% 46.1%
Table 7.1. The release of the granule constituents arylsulfatase, P-hexosaminidase and
SMCP from rOv.IL-3 BMMC in response to stimulation with substance P. The release from
aliquots of either 0.5 or 1 x 106 cells are expressed as the percentage of the total extracted
from a similar aliquot of cells with 2M KC1 in 0.02M Tris/HCl pH 7.5 and repeated freeze







Experiment 1 35.6% 8.2%




Experiment 1 25.8% 0%
Experiment 2 41.0% 19.6%
SMCP release 48/80 Diluent
Experiment 1 78.6% 46.4%
Experiment 2 74.0% 41.7%
Table 7.2. The release of the granule constituents arylsulfatase, ^-hexosaminidase and
SMCP from rOv.IL-3 BMMC in response to stimulation with 250pg/ml compound 48/80.
The release from aliquots of either 0.5 or 1 x 106 cells are expressed as the percentage of the
total extracted from a similar aliquot of cells with 2M KC1 in 0.02M Tris/HCl pH 7.5 and
repeated freeze thawing (Huntley 1991). Each secretagogue or diluent control sample was
tested in duplicate.
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Percentage mediator release induced by A23187
[^hexosaminidase
release
10 4M 10 5M 106M 10 7M Highest
diluent
release
Experiment 1 49.2% 54.7% 13.7% 21.2% 25.8%
Experiment 2 23.5% 17.8% 6.6'7c 6.4% 4.7%
Arylsulfatase
release
Experiment 1 38.4% 24.8% 16.4% 23.4% 19.0%
Experiment 2 70.1% 72.1% 10.1% 35.9% 33.6%
SMCP releasi
Experiment 1 21.7% 27.3% 15.1 % 12.7% 11.2%
Experiment 2 43.8% 38.6% 33.3% 21.1% 18.8%
Table 7.3. The release of the granule constituents arylsulfatase, (3-hexosaminidase and
SMCP from rOv.IL-3 BMMC in response to stimulation with A23187. The release from
aliquots of either 0.5 or 1 x 106 cells are expressed as the percentage of the total extracted
from a similar aliquot of cells with 2M KC1 in 0.02M Tris/HCl pH 7.5 and repeated freeze








3.6pg 52.0% 54.1% 68.9%




3.6pg 66.9% 38.7% 65.3%
360ng 8.9% 11.2% 19.6%




3.6pg 32.2% 33.2% 36.6%
360ng 3.3% 16.4% 0%
36ng 0% 0% 0%
Experiment 2
3.6pg 20.1% 19.8% 25.0%
360ng 19.8% 0% 12.6%
36ng 25.0% £o$o
Table 7.4. The release of the granule constituents arylsulfatase, ^-hexosaminidase and
SMCP from rOv.IL-3 BMMC in response to stimulation with SMCP or HI-SMCP. The
release from aliquots of either 0.5 or 1 x 106 cells are expressed as the percentage of the total
extracted from a similar aliquot of cells with 2M KC1 in 0.02M Tris/HCl pH 7.5 and repeated
lfeeze thawing (Huntley 1991). Each dose of secretagogue or respective diluent control
sample was tested in duplicate.
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7.3. Discussion
Bearing in mind the problems regarding interpretation of the data (see below) and the need for
further experimentation to allow statistical analysis (insufficient time was available to repeat
these experiments, the series depicted taking five months to complete), some conclusions can
be tentatively inferred. Secretagogue activity on rOv.IL-3 BMMC was consistently
demonstrable with sP, 48/80 and A23187, but not with SMCP or HI-SMCP. This activity
was apparently specific, as SMCP release was a consistent finding. Given that 48/80 does not
activate MMC (Table 1.3(b)), it implies that rOv.IL-3 BMMC share characteristics with cells
of the CTMC phenotype. (N.B. Substance P has been shown to activate rat intestinal mast
cells; Befus et al 1986, Table 1.4). The peptidergic pathway of mast cell activation (through
which 48/80 is proposed to act) is stated to be present in human cutaneous mast cells (CTMC
phenotype; Mousli et al 1994), which would support the above finding. However, reactivity
to 48/80 is not demonstrated by all cutaneous mast cell populations (e.g. bovine; Hunt et al
1991). Given also that rOv.IL-3 BMMC possess some MMC-like properties (Chapter 6),
then the cultured cell population may be of mixed phenotype, which would be consistent with
the apparent phenotypic heterogeneity of ovine CM-BMMC (Huntley et al 1992) and similar
to murine BMMC which may also be heterogeneous (Newlands et al 1991).
There were both similarities and discrepancies between the in vitro and in vivo effects of the
various agents. Although a dose-dependent effect of A23187 on the immediate weal response
was observed in vivo (Figure 4.2(c), the in vitro results do not consistently support a similar
effect (Table 7.3). In cultures of ovine CM-BMMC a typical bell-shaped curve ofmediator
release occurred across the range of 10"5 M to 10"9M A23187, with 1 (J6 M A23187 being
optimal (Huntley 1991). Interestingly, with the exception of arylsulfatase, the range of values
for A23187 diluent-corrected percentage mediator release for rOv.IL-3 BMMC are similar to
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those of CM-BMMC (rOv.IL-3 BMMC [derived from Table 7.3]: SMCP 1.5% to 25%,
(3-hexosaminidase 0% to 23.4%, arylsulfatase 0% to 36.5%; CM-BMMC: SMCP 0% to
47.6%, [3-hexosaminidase 0% to 31.5%, arylsulfatase 0% to 92.5% [Huntley 1991]). Thus,
despite the relatively high diluent background levels, specific mediator release by rOv.IL-3
BMMC was demonstrable. The diluents also promoted cutaneous responses (Chapter 4), so
further investigation of more suitable diluents for these agents is warranted. Care must be
taken when comparing the responses of mast cell populations from different sources (e.g. in
vivo and in vitro) to secretagogues as the relative degree of maturation of these two cell
populations may differ markedly, thereby affecting the observed response.
Compound 48/80 at a concentration of 250|ig/ml apparently activated mast cells in vitro
(Table 7.2), but failed to evoke an immediate weal response in vivo (Fig. 4.3(c) and
Fig. 4.3(d)), despite histological evidence of mast cell degranulation as early as 15 minutes
after injection (Fig. 4.5(d)). Substance P needs to be used across a wider range of
concentrations in vitro, to determine if increased release would be observed with 10"5 M sP,
consistent with the "window" effect seen in vivo (Figure 4.2(a)). Interestingly, there was
evidence that 10"4M sP evoked mediator release in vitro (Table 7.1), despite failing to evoke a
significant weal response in vivo. However, optimal concentrations of secretagogues can only
readily be maintained in vitro, whereas, in vivo, it may be rapidly dispersed or even bound in
the tissues. Based on the above results (Table 7.4), SMCP and HI-SMCP had no obvious
secretagogue activity. Different chymases, like all enzymes, are best compared in terms of
their catalytic activities, but it is interesting to note that the concentration of chymase which
activated rat serosal mast cells was 50|ig/ml (Schick and Austen, 1986) as compared with the
concentration of SMCP at 72pg/ml. Thus, although this concentration evoked an immediate
cutaneous response accompanied by histological evidence of mast cell degranulation in vivo
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(Fig.5.1(a), Fig 5.1(b), Fig 5.1(c), Fig. 5.6(a) and Fig. 5.6(b)) it may not have been sufficient
to activate rOv.IL-3 BMMC in vitro and further dose-response studies will be required.
Theoretically, since both sP and 48/80 appeared to evoke mediator release, if SMCP (as a
basic cationic protein) was working through the same peptidergic pathway (Mousli et al
1994), then mediator release would have been anticipated. Given that cutaneous mast cells
are degranulated as part of the cutaneous response to intradermal injection of SMCP, it can be
speculated that rOv.IL-3 BMMC lack this same mechanism of activation, or alternatively that
ovine cutaneous mast cells could be activated by inflammatory mediators released through the
action of SMCP on native substrates. The possibility of a direct effect of SMCP on vascular
endothelium in the in vivo response has already been alluded to (Chapter 5).
Inconsistent results were obtained when the medium used in the original release study on ovine
CM-BMMC (Tyrodes plus 0.1% gelatin; Huntley et al 1992) was initially used for rOv.IL-3
BMMC. Eaile's medium was a satisfactory replacement, there being no discernible benefit of
the addition of 0.1% gelatin. With this exception, the protocol for mediator release was as for
the original CM-BMMC study (Huntley et al 1992).
A consistent feature in the results outlined above is the relatively high levels of mediator
release apparently due to the effect of diluent alone. This may indicate an actual effect of the
respective diluents or it could reflect a qualitative difference in rOv.IL-3 BMMC between
cultures, with BMMC from certain cultures being more "fragile" and therefore prone to
spontaneous mediator release. Under the experimental conditions outlined, this effect would
be interpreted as attributable to the diluent. An alternative explanation would be that the
apparent spontaneous release could be attributed to cell death. Had time permitted,
measurement of the release of a putative marker for cell death for rOv.IL-3 BMMC (e.g.
(^-glucuronidase) would have been undertaken. The hypothesis of qualitative differences in
rOv.IL-3 BMMC between cultures would be supported by the contention that where there are
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marked differences in diluent-associated mediator release (e.g. A23187 diluent
^-hexosaminidase release; Experiment 1: 25.8%, Experiment 2: 4.7%), there are
proportionate differences in secretagogue-induced mediator release (Experiment 1 [10"4 M]:
49.2%, Experiment 2 [10~4 M]: 23.5%). This would also account for the apparent variability
in values for secretagogue-induced mediator release. However, based on the results presented,
the possibilities that this is a direct effect of diluent or, alternatively, attributable to cell death
cannot be discounted.
One other problem is that the release studies have been undertaken on a non-homogeneous cell
population that contains only 40-50% BMMC. Given that results from Chapter 6 suggested
that SMCP may be a more reliable indicator of rOv.IL-3 BMMC activation than arylsulfatase
or p-hexosaminidase, the possibility that these latter mediators are being produced by other
cell types cannot be eliminated. However, 48/80, sP and A23187 all provoked specific release
of SMCP.
In order to explicitly define ovine mast cell functional heterogeneity, and to confirm that the
sheep holds to the pattern of secretagogue activation seen in other species (Table 1.3(a),
Table 1.4, Table 1.5), both dispersed cutaneous and intestinal mast cells should be challenged
with sP and 48/80. Alternatively, as planned (Chapter 8), mast cell mediators could be
measured in afferent lymph immediately after intradermal challenge with secretagogues.
Either method would help confirm that sP and 48/80 are ovine dermal mast cell secretagogues
(Chapter 4).
These experiments have established that rOv.IL-3 BMMC are responsive to sP, 48/80 and
A23187, but not apparently to SMCP. This contrasts with ovine dermal mast cells, which
appear to be activated by all four secretagogues (Chapters 4 and 5). Phenotypically, rOv.IL-3
BMMC possess both MMC-like (SMCP-containing) and CTMC-like (activation by 48/80)
characteristics. However, rOv.IL-3 BMMC cannot be considered as a suitable in vitro
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analogue of the ovine dermal mast cell, as the latter are overwhelmingly SMCP-negative.
Therefore, further in vitro studies are necessary to generate an ovine BMMC population with





The hypothesis that mast cells participate in cutaneous inflammatory responses is based upon
an expanding body of evidence. For example, certain clinical dermatological disorders are
associated with mast cell hyperplasia (Yamamoto et al 1995), altered levels of IgE (Halliwell
and Longino 1985) or with immediate weal responses (Hawk et al 1980). Additionally,
various mast cell-derived mediators (including arachidonic acid metabolites, proteinases and
cytokines) can evoke vascular or cellular responses when injected into skin in vivo (Colditz
1991b, Colditz and Watson 1992, Walls et al 1994). Finally, and most elegantly, the mast
cell-dependency of certain cutaneous responses has been explicitly defined by use of mast
cell-deficient or locally mast cell-reconstituted W/W mice (reviewed in Galli, Tsai and
Wershil 1993). The main focus of these studies has been the contribution of the mast
cell-derived chymase, SMCP, to mast cell biology of the sheep. The demonstration that ovine
mast cells are heterogeneous with regard to their proteinase content is consistent with findings
in other species and leads to a number of questions. For example, only a small proportion of
ovine dermal mast cells contain SMCP (recently confirmed with a monoclonal anti-SMCP
antibody; J.F.Huntley, personal communication) and yet the intradermal injection of SMCP
evokes a marked cutaneous response. What, therefore, is the proteinase content of the vast
majority of ovine dermal mast cells? Although there is evidence for an additional putative
serine endopeptidase in ovine CM-BMMC (Huntley et al 1992), it is not known if this exists
in ovine dermal mast cells. Additionally, an ovine tryptase has as yet not been isolated,
although SMCP itself possesses "trypsin-like" activity (Pemberton, Huntley and Miller,
submitted). Given that tryptase can evoke marked cutaneous responses in vivo (Walls et al
1994), from a functional standpoint the determination of the presence or absence of tryptase in
ovine dermal mast cells is a major priority. This would also expand knowledge of ovine mast
cell heterogeneity and allow determination of whether chymase (as in rats and mice) or
tryptase (as in the dog and man) is the more abundant ovine proteinase. This is of relevance
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also to pulmonary inflammatory responses and, since the sheep has been advocated as a model
for human asthma (Clark et al 1995) and tryptase is the predominant enzyme in human mast
cells (Walls 1995), the contribution of SMCP relative to tryptase may be of functional
significance. The hypothesis that an undetected ovine mast cell tryptase does exist also allows
speculation regarding an alternative mechanism for the marked neutrophilic dermal infiltrate
that occurs following intradermal injection of SMCP (via hypothetical SMCP-induced mast
cell activation), particularly as neutrophilic infiltrates have not been reported in tissues where
high levels of SMCP release have been detected (e.g. gastrointestinal tract, discussed below).
The demonstration that a small percentage of cutaneous mast cells contained SMCP did,
however, validate its use in intradermal challenge studies, this being one of the first
comprehensive studies where a native proteinase was intradermally injected into the
homologous host. Consistent with studies which have used other chymase preparations in
vivo (Fraki 1977, Walls et al 1994), a prominent neutrophilic infiltrate was detected after the
intradermal injection of SMCP. SMCP evoked a potent weal response (peaking 180 minutes
after injection) and a neutrophil influx (which was still increasing from 180 to 360 minutes
after injection). Indeed, the highest concentration of 36pg (~1.3pM) SMCP was not used in
time course studies because of the severity of response. This apparent potency can be
explained in various ways. Like human chymase (Schechter et al 1989), SMCP is inhibited
relatively slowly (-15 minutes) by its homologous ai-proteinase inhibitor
(kass~ 1.1 xlO3 M'V1; Pemberton, Huntley and Miller, submitted), and, in the absence of any
other inhibitor (apart from a2-macroglobulin), SMCP may be active at some distance from its
point of release (or injection). This could, in part, explain the marked and prolonged
cutaneous response. Furthermore, the potency of SMCP may be altered by the presence of
heparin because the activity of human chymase at pH 7.5 (optimal for interstitial tissues) has
recently been shown to be enhanced by the presence of heparin (McEuen, Sharma and
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Walls, 1995). Also, the intradermal injection of human tryptase in conjunction with heparin
evokes an immediate cutaneous response in ovine skin that is of greater magnitude than that
evoked by tryptase alone (Molinari et al in press). Therefore, if the activity of SMCP was
similarly up regulated by heparin, the in vivo potency of SMCP, when released from mast
cells, may have been underestimated in present studies. However, lack of time precluded the
co-injection of SMCP with heparin in these studies.
The timing of the development of the SMCP-evoked dermal neutrophilic infiltrate is similar to
the timing of ELAM-1 expression that occurs in human skin following mast cell activation
(Klein et al 1989). Indeed, mast cell degranulation occurred within 15 minutes of injecting
SMCP, and the contribution of histamine to the vascular response needs to be elucidated.
Therefore, as discussed in Chapter 5, Hr and H2-receptor antagonists should be used in
combination with SMCP in cutaneous challenge studies in vivo to assess this contribution
(Rubenstein et al 1990, Walls et al 1993). More importantly, the question of whether SMCP
would potentiate a histamine-induced weal response in the sheep (as with chymase in the dog,
Rubenstein et al 1990) needs to be determined. If so, this potentiation by SMCP of a
histamine-induced vascular response would provide a further possible explanation for the
exaggerated cutaneous weal response. One apparent contradiction from these results is the
presence of a marked dermal neutrophilic infiltrate in response to relatively low concentrations
of SMCP whereas, in the gut, it is known that relatively high levels of SMCP are released into
local lymph and blood during the expulsion of nematodes in immune sheep (Huntley et al
1987) in the absence of a neutrophilic infiltrate (indeed neutrophils are not a feature of worm
expulsion in most species; Miller 1993b). One simplistic hypothesis for this contradiction
would be that injected SMCP activates dermal mast cells (the majority of which lack SMCP)
to release additional proteinases which are absent or in low quantities in the overwhelmingly
SMCP-positive mast cells of the gastrointestinal tract, and which recruit neutrophils into the
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dermis. Alternatively, there may be differences in the microenvironment of the skin and the
gastrointestinal tract. For instance, the substrates for SMCP may differ at the two sites, and
peptides released in skin may be chemotactic for neutrophils. The native substrates of SMCP
should, therefore, be characterized. Another possibility, since human chymase can generate
active IL-1 from its precursor by proteolysis (Kupper et al 1990, Mizutani et al 1991) and,
since IL-1 evokes a neutrophilic infiltrate in ovine skin in vivo (Colditz and Watson 1992), is
that SMCP activates a latent cytokine. Whether such a mechanism exists in ovine skin is
unknown. Also, given that bullous lesions were identified on two occasions in SMCP-treated
skin, one possible substrate might be basement membrane proteins. Immunohistochemical or
immunofluorescent studies could therefore be undertaken to identify the localization of SMCP
following intradermal injection, as with human chymase (Sayama et al 1987).
The relative concentrations of proteinase inhibitors at the two sites may be very important.
For example, the local lymph draining from the abomasum in immune animals during
nematode expulsion contains inhibitors (Huntley et al 1987). If the level of inhibitors was
lower in skin than in gut, then SMCP (which is only present in low concentrations in skin)
would be relatively more potent in skin. Further investigations should therefore address the
nature of the inhibitors of SMCP present in ovine skin. This could be achieved fairly readily
by collecting afferent lymph.
Speculatively, SMCP may be able to activate vascular endothelium (or other cell types)
directly via protease-activated receptors (Coughlin 1994, Altieri 1995). Activated
endothelium can also generate pro-inflammatory cytokines (e.g. IL-8, Schall and Bacon
1994), and could contribute to an exaggerated cutaneous response, in contrast to that evoked
by secretagogue-challenge alone.
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Impetus has also been provided for investigation of the possible interaction of SMCP and sP
in neurogenic inflammation. The cutaneous response to sP injection is accompanied by mast
cell degranulation. Given that SMCP cleaves sP in vitro (Pemberton, Huntley and Miller
submitted), then a modulatory role for SMCP in cutaneous responses in vivo can be
envisaged. SP released from nerve endings could activate dermal mast cells, thereby resulting
in mast cell mediator release (including proteinases). Cleavage of sP by proteinases would
remove the initiating stimulus and thus regulate the response. This could be investigated by
injecting affinity purified anti-SMCP antibodies intradermally prior to the injection of sP, and
determining if this prolongs the sP-induced cutaneous response. It is of note that the number
of neutrophils in sP-treated sections fell between 180 and 360 minutes following challenge,
which is at variance with the other agents tested. Whether this curtailment in response is
mediated by an enzymatic effect of SMCP or of another proteinase from dermal mast cells on
sP is speculative, but warrants further investigation. This could, for example, be achieved by
injecting proteinase inhibitors.
A number of questions raised by these studies and discussed above could have been answered
(as originally planned) by further intradermal injections of SMCP and by measuring mediators
entering afferent lymph (Smith, MTntosh and Morris 1970, Hecker 1974). This would have
allowed the monitoring of mast cell mediator release (e.g. histamine and possibly SMCP) into
afferent lymph immediately following cutaneous challenge, thereby allowing more accurate
assessment (in comparison to histological methods) of the effects of putative secretagogues.
Additionally, changes in lymph flow, cell output and phenotypic alterations in cell types
trafficking into skin following mast cell activation can be measured (Yirrell et al 1991). Also,
as in previous studies, the appearance of cytokine activity in afferent lymph draining from the
challenge site can be assessed (Haig et al 1992). This would have provided the ideal system in
the homologous host for dissecting the cutaneous response to intradermal SMCP-challenge.
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Although prefemoral afferent lymphatics in seven sheep were successfully cannulated, lymph
flow stopped in all subjects within three days of cannulation. Therefore, further investigation
of the mechanism of action of SMCP in ovine skin and of the effects of direct mast cell
activation (using the secretagogues identified previously in vivo) on altering inflammatory cell
trafficking through the dermis could not be undertaken. One can speculate that dermal mast
cells, if they are directly activated by SMCP, immediately release TNF-a (Gordon and Galli
1990a) which, in turn, activates vascular endothelium and upregulates the expression of
adhesion molecules, particularly ELAM-1 (Klein et al 1989), thereby initiating the
neutrophilic infiltrate typically associated with the response to TNF-a in ovine skin (Colditz
and Watson 1992). The activation of endothelial cells and other cell types by TNF-a would
subsequently result in the expression of IL-8 and thus augment neutrophil recruitment in ovine
skin (Seow et al 1994). In such an acute response, the expression of ELAM-1 would be
maximal within 4 to 6 hours, and have subsided by 24 hours (Cotran 1987), consistent with
the observed decline in cellular infiltrate from 24 to 72 hours following challenge. Obviously,
other cytokines from a variety of cell types will probably also be involved in both the initiation
(IL-1, IL-6, chemokines) and resolution (IL-3, IL-13, TGF-p) of the inflammatory response.
The cutaneous vascular response to mast cell-derived histamine is likely to include the rapid
appearance of histamine and other mast cell-derived mediators in afferent lymph, and an
increased lymph flow rate from a basal 1.5 to 3.0 ml/hr (containing 75-85% lymphocytes and
500 to 800 cells/mm3; Smith, MTntosh and Morris 1970) peaking 3 hours after injection, the
increased lymph flow subsequently subsiding in association with the declining weal response.
The nature of the likely cellular response is not known but the types of cell present and their
state of activation both require investigation. Flad time allowed, one alternative to lymphatic
cannulation that could have been attempted was to employ microdialysis techniques, where
mediators (e.g. histamine) can be measured in the dialysate draining from activated skin into
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implanted dermal microdialysis fibres following injection of secretagogues
(Petersen et al 1994).
The apparent responsiveness of ovine dermal mast cells to sP and 48/80 suggest that the
functional phenotype of these cells is consistent with that of the CTMC subtype in other
species, although this point was to have been explored further by the cannulation studies
described above. The kinetics of growth and the mediator content of rOv.IL-3 BMMC have
been characterized (Chapter 6), but the conclusions regarding their responses to secretagogues
remains tentative (Chapter 7). Because they contain SMCP, rOv.IL-3 BMMC are MMC-like
(in comparison to in vivo results from ovine skin and gastrointestinal tract) but also have a
CTMC-like characteristic, in view of their response to sP and 48/80. (This is with the proviso
that, as exceptions to the general rule, bovine cutaneous mast cells do not respond to 48/80
(Table 1.3(b); Hunt et al 1991) and rat intestinal mast cells have been shown to respond to sP
(Table 1.4; Befus et al 1986). It is apparent that IL-3 is not the sole factor required for ovine
BMMC development, particularly as ovine CM-BMMC appear structurally more mature and
survive longer in vitro (Huntley et al 1992). Indeed, preliminary studies indicate that
rOv.IL-3 BMMC grown in the presence of recombinant ovine SCF are more developed than
comparable rOv.IL-3 BMMC (J.F.Huntley, personal communication).
Immunohistochemical detection of granule proteinases in rOv.IL-3 BMMC is currently limited
to SMCP. Thus, it is not known if rOv.IL-3 BMMC represent a homogenous population with
respect to proteinase expression (as in rat BMMC; Haig et al 1988a) or whether it is
heterogeneous (as in mouse BMMC; Newlands et al 1991). As rOv.IL-3 BMMC contain low
quantities of SMCP, then this would suggest similarities with mouse, rather than rat, BMMC
populations based on proteinase content. Again, the identification of further ovine mast cell
proteinases would be of importance, as this would greatly help with the further delineation of
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ovine mast cell heterogeneity both in vivo and in vitro. For example, these would help to
detect phenotypic changes in proteinase content that may occur in rOv.IL-3 BMMC due to
SCF addition in vitro.
In summary, these studies have greatly expanded our knowledge of the ovine mast cell and
have defined mast cell heterogeneity in this species. Furthermore, a participating role for mast
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APPENDIX A
Buffers, solutions and fixatives
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Dissolve the above in 1 litre de-ionised, distilled water and adjust pH to 7.2 - 7.3.
A.2. 4% Paraformaldehyde/PBS
8g paraformaldehyde
Dissolve the above in 200ml PBS. Use gentle heat in a fume cupboard and allow the solution
to cool before use.
A.3. 5% Bovine Serum Albumin/PBS
5g BSA
Dissolve the above in 100ml PBS.
A.4. 3,3-diaminobenzidine/PBS Solution
40mg 3,3'-diaminobenzidine tetrahydrochloride
Dissolve the above in 100ml PBS in a fume cupboard. The solution can be divided into 10ml
aliquots and frozen at -70 °C until use. Once thawed, and just prior to use, add 20pl H202
(Hydrogen peroxide solution about 30% (w/v) H202, [100 vols.], BDH, AnalaR Poole, UK,
Cat.No. 10128) to 10ml of solution.
A.5. HBSS/Heparin Tissue Culture Medium
Consists of:-
500ml Hanks' Balanced Salt Solution (Gibco BRL, Life Technologies Ltd., Paisley,
UK, Cat.No. 041-04020M).
10ml Penicillin/Streptomycin solution (Penicillin-Streptomycin solution, 10000 units
penicillin and l OOOOpg streptomycin per ml, Gibco BRL, Life Technologies Ltd., Paisley,
UK, Cat.No. 04305 HOD).
10000 units heparin (Heparin (tissue culture grade 1A), Sigma, Poole, UK, Cat.No.
H3149).
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A.6. IMDM/10% FCS Tissue Culture Medium
Consists of:-
500ml Iscove's Modification ofDulbecco's Medium (Gibco BRL, Life Technologies
Ltd., Paisley, UK, Cat.No. 041-01980M).
50ml Heat-inactivated Foetal Calf Serum (Advanced Protein Products Ltd., Brierly
Hill, UK, Cat.No. AS-302-50; inactivated by heating in a water bath at 56 °C for 30
minutes).
10ml Penicillin/Streptomycin solution (as above).
50|al 2-ME (50mM 2-Mercaptoethanol Gibco BRL, Life Technologies Ltd., Paisley,
UK, Cat.No. 043-01350D).
A.7. Coating Buffer For SMCP ELISA
0.1M NaHC03 (0.84g NaHCCf in 100ml de-ionised, distilled water).
0.1M Na2C03 (l-06g Na2C03 in 100ml de-ionised, distilled water).
The 0.1M NaHC03 is titrated to pH 9.6 with the 0.1M Na2C03. The resulting buffer can be
stored at -20 °C in 10 ml aliquots until use.
A.8. Citrate/Phosphate Buffer For SMCP ELISA
0.1M Citric acid 24.4ml
0.2M Na2HP04 25.6ml
Distilled water 50.0ml
The pH of the buffer should be 5.0.
A.9. Substrate For SMCP ELISA
100ml Citrate/phosphate buffer, pH 0.5 as above.
40mg Orthophenylenediamine (Sigma Chemical Company Ltd., Poole, UK, Cat.No.
P1526)
40pl H202 (Hydrogen peroxide 30% (w/w), [100 vols.], Sigma, Poole, UK, Cat.No.
HI009)
The substrate is made immediately prior to use.
A.10. Substrate For Assay Of Arvlsulfatase Activity
A.10.1. Acetate Buffer




6.255mM p-nitrocatechol sulphate i.e. 9.75mg p-nitrocatechol sulphate (Sigma Chemical
Company Ltd., Poole, UK, Cat.No. N7251) in 5ml of acetate buffer, pH 5.7 (above).
A.ll. B-hexosaminidase Assay Buffers And Substrate




The above is made up to 1 litre with de-ionised, double distilled water.
A.ll.1.2. Solution B
0.1NHCL
Working citrate buffer solution = 67.8ml solution A plus 32.2ml solution B, titrated to pH
4.5.
A.11.2. Substrate
p-nitrophenyl-N-acetyl-P-D-glucosaminide (Sigma Chemical Company Ltd., Poole, UK,
Cat.No. N9376). 5mM substrate solution = 1.7mg substrate per ml of citrate buffer, pH 4.5.




The above is made up to 500ml with de-ionised, double distilled water.
A.ll.3.2. Solution B
0.2N NaOH
Working glycine NaOH solution = 52.8ml solution A plus 47.2ml solution B, titrated to
pH 10.7.
The glycine NaOH solution should be ice-cold when used.
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A.12. Carbol Chromotrope (0.5% Chromotrope In 1% Phenol) Stain
5g Chromotrope (Chromotrope 2R, Gurr® microscopy materials, BDH, Poole, UK,
Cat.No. 34020HP).
lOg Phenol

























Figure B.l. Growth of bone marrow cells shown as total viable cell count (xlO cells/ml)
plotted against time (days) for 10%, 20% and 30% rOv.IL-3 (Mean ± SEM; n=3). # P<0.05
compared with IMDM/10% FCS control and * represents a similar effect at P<0.01.
(N.B. # at day 8 refers to 20% rOv.IL-3, * at day 17 refers to 30% rOv.IL-3).




































Figure B.2. The effect of rOv.IL-3 concentration on the growth of BMMC. The percentage
of SMCP-positive mast cells is plotted against time (days) for 10%, 20% and 30% rOv.IL-3
(Mean ± SEM; n=3). * P<0.01 compared with IMDM/10%FCS control.
The mean peak percentage of SMCP-positive mast cells with 10% rOv.IL-3 was 66.4 ± 3.2%
at day 8. At day 14, when the total viable cell count is also taken into consideration, the
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Ovine mast cell heterogeneity is defined
by the distribution of sheep mast cell proteinase
G.H. Sture a>*, J.F. Huntley b, A. MacKellar b, H.R.P. Miller a
The presence or absence of the granule chymase, sheep mast cell proteinase (SMCP), was
determined in trachea, bronchus, bronchial lymph node, lung, thymus, spleen, liver, flank skin,
abomasum, duodenum, jejunum, ileum, colon and mesenteric lymph node by immunohistochem-
istry and by enzyme-linked immunosorbent assay using a polyclonal, affinity purified anti-SMCP
antibody. Additionally, the presence of putative ovine mast cell subsets was investigated by
comparing the number of mast cells identified histochemically (toluidine blue pH 0.5) with the
number detected by immunostaining. The thymus had the greatest density of mast cells (225.7 ±
23.4 cells mm~2, histochemically) and the highest concentration of SMCP (19.7 ± 9.3 /xg SMCP
g ~1 wet tissue). There was a high degree of correlation between toluidine blue and anti-SMCP
cell counts for all tissues (r2 = 0.96, P < 0.001) with the exception of skin and liver. On the basis
of reactivity to the anti-SMCP antibody, two populations of mast cells were defined, notably those
in gastrointestinal tissues (analogous to the mucosal mast cell subset) and those present in skin
(the putative ovine connective tissue mast cell subset). Ovine mast cell heterogeneity, resulting
from differential expression of SMCP, was thus confirmed.
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proteinase; PBS, phosphate buffered saline; RMCP, rat mast cell proteinase; SMCP,
sheep mast cell proteinase.
2. Introduction
Mast cells in rodents and man are a phenotypically heterogeneous cell population
with respect to tissue site, fixation properties, histochemical staining, biochemistry and
functional activity (reviewed in Galli, 1990). These differences are reflected by their
granule constituents, most notably in their content of intragranule proteinases. Chy-
motrypsin-like mast cell proteinases (chymases) have been isolated from mast cells of
the rat (Lagunoff and Pritzl, 1976, Woodbury et al., 1978), mouse (Newlands et al.,
1987), man (Schechter et al., 1986) and sheep (Huntley et al., 1986). The elucidation of
differences in proteinase expression has led to the identification of mast cell subsets in
the rat (Gibson and Miller, 1986; Gibson et al., 1987; Huntley et al., 1990), mouse
(Miller et al., 1989) and man (Schwartz, 1989). In the rat and mouse, distinct proteinases
are predominantly associated with either the mucosal mast cell (MMC) or connective
tissue mast cell (CTMC) subsets. Thus, rat mast cell proteinase-II (RMCP-II) is chiefly
present in the gastrointestinal MMC subset, whereas rat mast cell proteinase-I (RMCP-I)
is found principally in the CTMC subset. RMCP-I and RMCP-II are the best phenotypic
markers available for rat MMC and CTMC, although they do show some overlap
(Gibson et al., 1987). In the mouse, mouse mast cell proteinase-1 (MMCP-1) is uniquely
present in the MMC subset, whereas mouse mast cell proteinase-4 (MMCP-4) predomi¬
nates in the CTMC subset (Reynolds et al., 1990). In man, mast cells comprise a
population that contains tryptase and chymase (MCtc) and one that contains only
tryptase (MCt). Most anatomical sites are believed to contain a mixture of both of these
types, although MCt prevails in the lung and small intestinal mucosa, whereas MCtc is
chiefly found in skin and small intestinal submucosa (Schwartz, 1989).
Sheep mast cell proteinase (SMCP) has been isolated and characterised as a serine
endopeptidase (Knox and Huntley, 1987) and the mast cell source of this enzyme
confirmed immunohistochemically (Huntley et al., 1986). SMCP is released locally into
lymph and systemically into blood following abomasal challenge with gastric nematodes
in immune sheep (Huntley et al., 1987). Whilst the concentration of SMCP in the
gastrointestinal mucosa is significantly correlated with mast cell counts, the distribution
of SMCP in non-mucosal tissues is unknown. The purpose of this study was, therefore,
to compare the distribution of SMCP and of mast cells in a variety of tissues and organs
with a view to further defining mast cell heterogeneity in the sheep.
3. Materials and methods
3.1. Animals
Four Suffolk-cross lambs, aged 5-12 months, were studied. These had been grazed at
pasture and had not undergone any anthelmintic treatment immediately prior to investi-
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gation. At post-mortem examination, samples from trachea, bronchus, bronchial lymph
node, lung, thymus, spleen, liver, flank skin, abomasum, duodenum, jejunum, ileum,
colon and mesenteric lymph node were taken and processed as described below.
3.2. Preparation of tissue
Tissue for histochemistry and immunohistochemistry was fixed in 4% paraformalde¬
hyde in phosphate buffered saline (PBS) pH 7.4 for 6 h (Newlands et al., 1984). Fixed
samples were then stored in 70% ethanol at 4°C until processing (Miller et al., 1983)
after which they were embedded in paraffin wax.
3.3. Histochemical staining
Serial 4 yu,m sections were stained with toluidine blue pH 0.5 (Enerback, 1966).
3.4. Immunohistochemistry
The standard immunohistochemical technique used was the peroxidase-3,3'-di-
aminobenzidine (DAB) method outlined below, except in heavily pigmented skin. In
order to distinguish immunostaining of SMCP in dermal mast cells from endogenous
melanin, a commercially available avidin/biotin (ABC)-alkaline phosphatase system
utilising a red substrate was used.
3.4.1. Peroxidase-DAB stained tissue sections
Tissue sections, pre-treated with periodic acid and sodium borohydride to block
endogenous peroxidase activity (Heydermann and Neville, 1977), were incubated in 5%
bovine albumin (Sigma, Poole, UK) in PBS for 15 min. Affinity-purified rabbit IgG
anti-SMCP (2.5 p.g ml-1) (Huntley et al., 1986) was added for 1 h, prior to washing
three times in PBS. Goat anti-rabbit IgG-horseradish peroxidase (2.5 /igmP1; Sigma),
cross-adsorbed against sheep IgG, was then added for 1 h; the section was washed three
times in PBS and peroxidase activity was revealed with DAB. As a control, a 1/500
dilution of normal rabbit serum was substituted for antibody.
3.4.2. Vectastain® ABC-alkaline phosphatase (Vector Laboratories, Peterborough,
UK) stained tissue sections
Tissue sections mounted on Vectabond® (Vector Laboratories) prepared slides were
treated with periodic acid and sodium borohydride as described above. Sections were
incubated with normal goat serum for 20 min to reduce background staining. Rabbit
anti-SMCP antibody (2.5 pg ml-1) was added for 30 min, and after washing three times
in PBS a biotinylated goat anti-rabbit secondary antibody was applied. Alkaline phos¬
phatase activity was visualised with a red substrate (Vector®Red; Vector Laboratories)
to which levamisole had been added. Control sections consisted of a 1 /500 dilution of
normal rabbit serum or PBS in place of primary antibody.
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3.5. Cell counts
Tissues were examined using a Leitz Wetzler Dialux 20 EB microscope at X500
magnification. For non-mucosal tissues, graticule counts were started from a known
point of reference so that the same relative area could be counted on both the toluidine
blue and anti-SMCP stained sections. Cells were enumerated in a similar manner in
mucosal tissues, cell counts within the lamina propria being spread between the
basement membrane and epithelium. A minimum of 50 successive fields was counted on
each of two adjacent sections stained with toluidine blue or with anti-SMCP. Four pairs
of sections were examined for each tissue.
3.6. Enzyme-linked immunosorbent assay (ELISA) for SMCP
3.6.1. Sample preparation
Samples were collected on ice, weighed and stored at — 70°C. After thawing, five
volumes of ice cold 20 mM Tris/HCl buffer pH 7.5 containing 1.5 M NaCl were added
per tissue volume and the tissue homogenised using a Silverson heavy duty laboratory
mixer emulsifier. After centrifugation at 800 g, the supernatant fraction was removed
and stored at — 70°C prior to assay.
3.6.2. ELISA method
The double antibody sandwich ELISA for SMCP is fully described elsewhere
(Fluntley et al., 1987).
3.7. Statistical analysis
The mean numbers of toluidine blue and SMCP positive cells in each tissue (n = 4)
were compared using the Student's f-test and for all tissues using linear regression
analysis. The number of SMCP positive cells was compared to respective tissue SMCP
concentrations (pg SMCP g^1 wet tissue) by the use of linear regression analysis.
4. Results
The mean toluidine blue and SMCP mast cell counts, and respective tissue SMCP
concentrations, are given in Table 1. The highest mast cell counts (226 mm-2 with
toluidine blue and 214 mm-2 with anti-SMCP), and the highest concentration of SMCP
(20 pg SMCP g_1 wet tissue) were in the thymus which contained diffusely scattered
focal accumulations of cells, with a predominantly perivascular distribution (Fig. 1). The
gastrointestinal tissues as a group had relatively high cell counts with both techniques
(Fig. 2), and comparatively high tissue SMCP concentrations (Table 1). Despite
appreciable numbers of mast cells determined by both histochemical (Fig. 3) and
immunohistochemical means, SMCP was not detected in tracheal homogenates by
ELISA (Table 1). The cells in this instance were chiefly subepithelial in location.
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Table 1
Tissue cell counts and SMCP concentrations
Tissue n Number of Number of SMCP Tissue SMCP
toluidine blue positive cells per concentration
positive cells per mm2 of tissue ( pg SMCP) per g
mm2 of tissue (mean ± sem) of wet tissue
(mean + sem) (mean ± sem)
Gastrointestinal system
Abomasum 4 81.9 ±47.6 90.5 ±53.6 0.18 ±0.07
Duodenum 3 80.5 ±44.9 83.2 ±34.9 1.3 ±0.7
Jejunum 4 168.1 + 26.4 154.9 ±26.0 1.2 + 0.4
Ileum 4 126.0 ±42.2 128.1 ±43.8 3.3 ±1.6
Colon 4 65.5 ±29.1 55.7 ±23.1 0.6 ±0.2
Respiratory system
Trachea 3 19.7 ± 3.5 22.1 ± 4.6 0.0 ±0.0
Bronchus 3 24.5 ± 3.8 23.8 ± 4.3 0.05 + 0.05
Bronchrial lymph node 4 61.8 ±23.7 60.6 ±20.9 0.12 ±0.05
Lung 4 50.0 + 17.3 51.3 ±18.3 0.11 ±0.03
Other tissues
Thymus 3 225.7 ±23.4 214.4 ± 3.6 19.7 ±9.3
Spleen 4 73.8 ±21.8 57.8 ±13.5 0.07 ±0.02
Liver 4 80.8 ±11.8 13.2 ± 1.5 0.005i ± 0.005
Skin 4 42.2 ± 6.0 0.9+ 0.5 0.02 ±0.01





















Fig. 1. Toluidine blue stained section of ovine thymus. Note large numbers of darkly stained mast cells focally
distributed throughout the section.
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Fig. 2. Toluidine blue stained section of ovine jejunum. Numerous mast cells are present.
There were fewer SMCP positive cells in comparison to toluidine blue positive cells
in both skin (P < 0.01) and liver (P < 0.02). No statistically significant differences
were observed for the other individual tissues examined. The anti-SMCP reactive dermal
cells were morphologically identical to mast cells (well-granulated mononuclear cells).
Dermal basophils were infrequently observed. Their distinct polymorphonuclear appear¬
ance and smaller, finer granules allowed them to be differentiated histologically from
mast cells. In the liver, far fewer cells (16%) reacted with antibody than with toluidine
blue. Morphological examination suggested that these cells were likely to be large
granulated lymphocytes.
Fig. 3. Toluidine blue stained section of ovine trachea. Note predominantly subepithelial location of mast cells.







50 100 150 200 250
No. of Toluidine blue-positive cells per mmz
Fig. 4. Comparison of the number of toluidine blue and SMCP positive mast cells per mm2 in the
gastrointestinal tract (abomasum, duodenum, jejunum, ileum, colon). Each point represents the counts for
sequential sections from an individual tissue (r = 0.98, r2 = 0.96, P < 0.001).
There was a positive correlation between toluidine blue and SMCP mast cell counts
(r2 = 0.96, P < 0.001; Fig. 4) and between SMCP cell counts and tissue SMCP
concentrations (r2 = 0.30, P < 0.02; Fig. 5) from gastrointestinal tissues.
When the number of cells stained by toluidine blue from all tissues except liver and
skin was compared to the number of SMCP stained cells, there was a high degree of
No. SMCP-positive cells per mm2
Fig. 5. Comparison of the number of SMCP positive cells per mm2 versus the concentration (/xg g-1 wet
tissue) of SMCP in the gastrointestinal tract (abomasum, duodenum, jejunum, ileum, colon). Each point
represents an individual tissue sample (r = 0.55, r2 = 0.30, P < 0.02).


















No. of Toluidine blue-positive cells per mm2
Fig. 6. Comparison of the numbers of toluidine blue and SMCP positive mast cells per mm2 for all tissues.
The regression line is calculated including all tissues except liver and skin (r = 0.98, r2 = 0.96, P < 0.001).
Each point represents an individual tissue sample.
correlation (r1 = 0.96, P < 0.001; Fig. 6), in contrast to the finding in skin and liver. A
statistically significant correlation was observed between overall SMCP cell counts and
concentrations of SMCP in all of the tissues (excluding trachea) (r2 = 0.23, P < 0.001).
5. Discussion
Mast cells were detected with the anti-SMCP antibody in virtually all of the tissues
examined, but SMCP positive cells were scarce in skin. This indicates the presence of
two distinct mast cell populations in sheep, this finding being in accordance with
previous studies demonstrating mast cell proteinase heterogeneity in the rat (Gibson and
Miller, 1986) and mouse (Newlands et al., 1993) and in man (Schwartz, 1989), where
two major mast cell subclasses have been identified.
However, a few SMCP positive cells were observed in skin, indicating proteinase
heterogeneity in the dermal mast cell population. This observation may be analogous to
the situation in man, where dermal CTMC can be divided into two subpopulations based
on the presence or absence of a chymase (Schwartz, 1989). On the basis of cellular
morphology, the anti-SMCP antibody did not appear to react with basophils. However,
because of the difficulty in distinguishing basophils and mast cells in tissue sections and
the apparent paucity of the former in tissues, the possibility that antibody to SMCP
cross-reacts with basophils cannot be discounted.
The presence in the liver of a relatively large population of cells putatively identified
as large granular lymphocytes was noted. However, careful examination indicated that
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these cells did not contribute to the toluidine blue positive cell population in other
tissues as stained cells were typically well-granulated and mononuclear, suggesting a
mast cell rather than a basophil or lymphocyte lineage. Moreover, these tissues (with the
exception of skin) had a high correlation between cell numbers detected with toluidine
blue and with antibody to SMCP (r2 = 0.96, P < 0.001).
The presence of high numbers of thymic mast cells has been reported previously
during studies in rats, although their role remains obscure (Huntley et al., 1993).
However, since mast cells produce a wide range of cytokines (Burd et al., 1989; Gordon
and Galli, 1990), it is tempting to speculate that mast cell derived cytokines may
modulate or augment T-cell responses. Certainly, the role and function of ovine thymic
mast cells warrants further study.
Despite there being appreciable numbers of mast cells identified both histochemically
and immunohistochemically in trachea, no SMCP could be detected in tracheal ho-
mogenates. It is possible that this indicates the presence of a distinct proteinase that is
able to cross-react with the anti-SMCP antibody in paraformaldehyde-fixed tissue
sections, but is refractory to detection by the ELISA method. Alternatively, it is known
that both serum and lymph contain 'factors' that may interfere with SMCP-antibody
interactions (Huntley et al., 1987), these possibly being a2-macroglobulin or serpins
(Huntley, 1991). It can be speculated that high inhibitor content in tracheal tissue may
have prevented determination of SMCP by ELISA, although immunohistochemical
identification in fixed tissue was still possible. This interesting anomaly warrants further
investigation.
Previous studies have shown a correlation between the number of gastrointestinal
mast cells detected with anti-SMCP and the tissue content of SMCP (Huntley, 1991). On
the basis of these results, and the finding that this proteinase was released systemically
into blood and lymph following nematode challenge in immune sheep (Huntley et al.,
1987), SMCP was considered an 'MMC' enzyme and analogous to RMCP-II in the rat
(Gibson et al., 1987). The present investigation extends these findings, with significant
correlations (r2 = 0.28, P < 0.001) between SMCP tissue content and mast cell num¬
bers in all tissues and organs except skin and liver.
The results of this study indicate that SMCP is present in all mast cells in most of the
tissues studied, with the exception of skin. These dermal mast cells presumably contain
a proteinase which is antigenically distinct from SMCP and the sheep is, therefore,
similar to other species studied in that there is heterogeneity of granule proteases.
However, there are also species differences which may have important implications in
terms of function and activity of these cells. For instance, in the rat RMCP-I-containing
CTMC predominate in a variety of connective tissues including skin and are widely
distributed throughout these organs. Although RMCP-II-containing MMC are found
principally in the gastrointestinal tract, they are not confined to this tissue, and indeed
can be located in non-mucosal sites (Huntley et al., 1993). The distribution of ovine
mast cell subsets is apparently different to the rat, with clearly defined anatomical
locations for the mast cell proteinase populations. Thus, there exists diversity between
species in mast cell proteinase heterogeneity and expression, and further studies
involving the isolation of ovine dermal mast cell proteinase(s) are required for a full
evaluation of mast cell heterogeneity in the sheep.
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